

**ERIC A. VASILIAUSKAS, M.D.**

**CURRICULUM VITAE**

**BUSINESS ADDRESS:** Inflammatory Bowel Disease Center  
CEDARS-SINAI MEDICAL CENTER  
8730 Alden Drive Suite 2E  
Los Angeles, CA 90048  
Phone: (310)-423-4100  
eFAX: (310)-423-0146  
e-mail: [vasiliauskas@csmc.edu](mailto:vasiliauskas@csmc.edu)

**CITIZENSHIP:** United States

**LANGUAGES SPOKEN:** English, Lithuanian, Spanish

**EDUCATION:**

9/80 - 6/82 College of Du Page, Glen Ellyn, IL  
Associate in Science awarded 3/82  
Associate of Arts awarded 6/82

8/82 - 5/84 University of Illinois, Champaign-Urbana, IL  
Bachelor of Science in Biology awarded 5/84

8/84 - 6/88 University of Illinois College of Medicine, Rockford, IL  
Doctor of Medicine awarded 6/12/88

7/88 - 6/91 Childrens Hospital of Los Angeles, Los Angeles, CA  
Internship and Residency training in General Pediatrics

7/92 - 6/93 Childrens Hospital of Los Angeles & Los Angeles County / University of Southern California Medical Center, Los Angeles, CA  
First year fellowship training in Pediatric Gastroenterology & Nutrition

7/93 - 6/95 Cedars-Sinai Medical Center, Harbor-UCLA Medical Center, & Martin Luther King, Jr. / Charles R. Drew Medical Center, Los Angeles, CA  
Second & third year fellowship training in Pediatric Gastroenterology & Nutrition

7/94 - 6/95 Cedars-Sinai Inflammatory Bowel Disease Center, Cedars-Sinai Medical Center, Los Angeles, CA  
Clinical Research Fellow in Inflammatory Bowel Disease

7/95 - 6/96 Cedars-Sinai Inflammatory Bowel Disease Center, Cedars-Sinai Medical Center, Los Angeles, CA  
Gastroenterology Subspecialty Fellow in Inflammatory Bowel Disease

**LICENSURE:** California Medical License - June 1990 (# G068962)

**CERTIFICATION:** Board Certified in General Pediatrics  
Board Certified in Pediatric Gastroenterology & Nutrition

**PRESENT POSITIONS:**

7/97 - present Associate Clinical Director, Cedars-Sinai Inflammatory Bowel Disease Center, Departments of Medicine and Pediatrics, Divisions of Gastroenterology and Pediatric Gastroenterology and Nutrition, Cedars-Sinai Medical Center, Los Angeles, CA

7/03 - present Associate Clinical Professor of Medicine & Pediatrics, UCLA, Los Angeles, CA

2/14 - present Director, Cedars-Sinai Nutrition & Integrative/Complementary IBD Subspecialty Program

**PREVIOUS POSITIONS / PROFESSIONAL and ACADEMIC EXPERIENCE:**

- 7/88 - 6/91 L.A. County/USC Medical Center, Los Angeles, CA  
Rotations in General Pediatrics, Pediatric ER, Labor and Delivery, & Neonatology
- 2/89 - 3/89 Hospital de Pediatria S.A.M.I.C. "Prof. Dr. Juan P. Garrahan" (The National Pediatric Hospital of Argentina), Buenos Aires, Argentina  
Rotations in Pediatric Infectious Disease and Nephrology
- 2/91 - 2/92 General Pediatrics Private Practice Locums, Los Angeles, CA
- 7/91 - 4/93 Cedars-Sinai Medical Center, Los Angeles, CA  
Medical Staff, Department of Pediatrics, Division of Neonatology - Per Diem coverage - Neonatal Intensive Care Unit
- 7/91 - 10/92 Hollywood Presbyterian / Queen of Angels, Los Angeles, CA  
Per Diem coverage - Neonatal Intensive Care Unit & Labor and Delivery
- 8/91 - 12/91 Childrens Hospital of Los Angeles, Los Angeles, CA  
Medical Staff, Division of Hematology-Oncology, Hematology-Oncology Clinic; Acute Care & Walk-in Visits; Procedure Clinic
- 3/92 - 6/92 The Children's Clinic, Long Beach Memorial Medical Center, Long Beach, CA  
General Pediatrics Attending - Direct patient care & supervision/teaching medical students and residents from the University of California - Irvine
- 7/93 - 6/96 Clinical Instructor of Pediatrics, UCLA School of Medicine, Los Angeles, CA
- 7/96 - 6/97 Acting Clinical Director, Cedars-Sinai Inflammatory Bowel Disease Center, Departments of Medicine and Pediatrics, Divisions of Gastroenterology and Pediatric Gastroenterology and Nutrition, Cedars-Sinai Medical Center, Los Angeles, CA
- 7/97 - 6/03 Assistant Clinical Professor of Medicine & Pediatrics, UCLA, Los Angeles, CA

**PROFESSIONAL ACTIVITIES:**

**COMMITTEE SERVICE:**

**Cedars-Sinai Medical Center:**

- 10/98 - present Cedars-Sinai Medical Center Division of Gastroenterology Pharmacy Consultant  
"Gatekeeper" for Biologic Therapies
- 1/02 - present Member, Institutional Review Board, Cedars-Sinai Medical Center
- 12/05 -12/08 Member, Centricity Electronic Medical Record Attending Physician Advisory  
Committee, Cedars-Sinai Medical Center
- 1/09 – 7/12 Gastroenterology CS-Link Physician & Gastroenterology Content Design Task Forces
- 9/11 - present Vice-Chair, Institutional Review Board-3, Cedars-Sinai Medical Center
- 4/18 - present Member, Rapid Activation IRB, Cedars-Sinai Medical Center

**Other Professional Committee Services:**

- 11/99 - 11/02 Member, Crohn's and Colitis Foundation of America (CCFA) Professional Education  
Committee
- 4/02 - 1/03 Member, Pediatric Working Group of the NIH Workshop "Conduct of Clinical  
Trials in Crohn's disease"
- 3/03 - 12/08 Co-Chairman, Western Regional Pediatric IBD Research Alliance Clinical Trials  
Division
- 9/04 - 9/07 Member, Pediatric IBD Committee of the North American Society for Pediatric  
Gastroenterology, Hepatology and Nutrition (NASPGHAN)
- 10/05 - 11/09 Member, Crohn's and Colitis Foundation of America (CCFA) Patient Education  
Committee
- 12/06 – 7/12 Member, IBD Support Foundation Medical Advisory Board

**PROFESSIONAL ASSOCIATIONS AND SCHOLARLY SOCIETIES:**

- Diplomate of the National Board of Medical Examiners
- Fellow of the American Academy of Pediatrics (AAP)
- North American Society for Pediatric Gastroenterology and Nutrition (NASPGN)
- American Gastroenterological Association (AGA)
- The Crohn's & Colitis Foundation

**EDITORIAL SERVICES TO SCHOLARLY PUBLICATIONS**

Reviewer - *Journal of Pediatric Gastroenterology and Nutrition* (as needed and time permits)

Reviewer - *Inflammatory Bowel Diseases* (as needed and time permits)

Reviewer – *Gastroenterology* (as needed and time permits)

Reviewer - *Clinical Gastroenterology and Hepatology* (as needed and time permits)

Reviewer - *Digestive Diseases and Sciences* (as needed and time permits)

**COMMUNITY SERVICE:**

- 6/02 - present Member, Manhattan Beach Unified School District Medical Advisory Board
- 2010 - 2012 National Federation of the Blind Educational Reform Task Force
- 2010 - 2012 National Federation of the Blind Teachers of Tomorrow Program Parent Mentor
- 10/11 - present Knights of Columbus
- 10/11 - 2104 Member, Manhattan Beach Unified School District Technology Access SubCommittee
- 2/12 – 2104 Member, Manhattan Beach Unified School District Technology Committee
- 1/16 - present Member, National Federation of the Blind Genetic Education Committee
- 2/17 - present Member, NFB Jernigan Institute Research Advisory Council

**COMMUNITY ORGANIZATIONAL AFFILIATIONS:**

- Member, National Federation of the Blind (NFB)
- Member, National Organization of Parents of Blind Children (NOPBC)
- Member, NFB of California
- Member, NFB Sports and Recreation Division
- Member, NFB Deaf-Blind Division
- Member, California Transcribers and Educators for the Blind & Visually Impaired (CTEBVI)

**AWARDS AND HONORS:**

Magnum Cum Laude

Phi Theta Kappa

Dr. Vasiliauskas has been recognized by his peers as one of the "best doctors" in Southern California in his field as listed in [www.superdoctors.com](http://www.superdoctors.com) for 2019, 2018, 2017, 2016, 2013, 2012, 2011, 2010, 2009, & 2008.

**RESEARCH FOCUS AND INTERESTS:****PRINCIPAL INVESTIGATOR:**

1. A Multicenter Study of Anti-TNF Chimeric Monoclonal Antibody (Infliximab) in the Treatment of Pediatric Patients with Active Crohn's Disease (Centocor - Study No. C0168T23).
2. An Open-Label, Stepwise Dose-Escalating Pilot Study to Evaluate the Safety, Tolerance, and Efficacy of Thalidomide in the Treatment of Male Patients with Chronically-Active, Steroid-Dependent Crohn's Disease (Celgene Corp.).
3. Infliximab for the Treatment of Gastrointestinal Behçet's.
4. Thalidomide Extension Study After Four Weeks of CC-1088 Therapy for Steroid-Dependent Crohn's Disease Patients (Celgene Corp). (IRB #3050).
5. A Phase 1 Double-Blind, Placebo Controlled, Stepwise Dose-Escalating Pilot Study to Evaluate the Safety, Tolerance, and Efficacy of CC-1088 in the Treatment of Adult Patients with Moderately Severe, Steroid Dependent Crohn's Disease (Celgene Corp. - Protocol No. CD-001). (IRB #2914).
6. The use of Thioguanine (6-TG) as an Alternate Therapy to 6-Mercaptopurine or Azathioprine for Inflammatory Bowel Disease. (IRB #3082).
7. A Randomized, Double-Blind, Placebo-Controlled, Sequential Dose-Ranging, Multicenter Trial of Azathioprine Delayed-Release Formulation (AZA-DR) in Patients with Active Crohn's Disease (Santarus, Inc.). (IRB #3177).
8. An Open Label Pilot Study to Evaluate the Safety, Tolerance, and Efficacy of Thioguanine (6-TG) as a Steroid Sparing Agent in Patients with Steroid-Dependent Crohn's Disease or Ulcerative Colitis. (IRB #3182).
9. An Open Label Pilot Study to Evaluate the Safety, Tolerance, and Efficacy of Thioguanine (6-TG) in the Treatment of Patients with Moderate Chronically-Active Crohn's Disease or Ulcerative Colitis. (IRB #3183).
10. A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm, Dose Probiotic Therapy for Maintenance or Remission in Clinically Quiescent or Steroid-Dependent Inflammatory Bowel Disease. (IRB #3212).
11. A Phase 2, Double-blind, Placebo Controlled, Dose Escalating, 12-week Pilot Study to Evaluate the Safety, Tolerance, and Efficacy of CC-1088 in the Treatment of Adult Patients with Moderately Severe Crohn's Disease (Celgene Corp.). (IRB #3566).
12. The Efficacy of Lactobacillus GG in Preventing Relapse in [Pediatric] Crohn's disease. (IRB #3747).
13. A Phase II, International, Multicenter, Open Label Study of the Safety, Tolerability and Effectiveness of Three Intravenous Infusions of Antegren™ (Natalizumab) in Adolescents with Moderately to Severely Active Crohn's Disease. (Elan Pharmaceuticals - Protocol No. ELN100226-CD305) (IRB #4026-01).
14. Comparison Study of the Efficacy and Safety of the Oral Formulation of OPC-6535 Tablets in the Treatment of Patients with Mild to Moderate, Active Ulcerative Colitis (Otsuka Pharmaceuticals). (IRB #3282).

15. The Effect of Relationship-Focused Coping on Inflammatory Bowel Disease (IRB #4322).
16. Survey of Vaccination Profile and Risk of Viral Hepatitis in Patients with Inflammatory Bowel Disease (IRB #4467).
17. Evidence for Transplacental Transfer of Maternally Administered Infliximab Monoclonal Therapeutic Antibody to the Newborn: A Case Report (IRB# Pro00008644).
18. Multi-site Trial of Azathioprine Dosing in Crohn's Disease (National Institutes Of Health) (IRB# Pro00008219).
19. Complementary and Alternative Medicine Use in Pediatric Inflammatory Bowel Disease (IRB# Pro00006085).
20. Pneumococcal Vaccination in Patients with Inflammatory Bowel Disease: A Pilot Study to Assess Response in Immune Compromised Patients and Healthy Controls (IRB# Pro00006355).
21. Small Intestinal Bacterial Overgrowth in Ulcerative Colitis (IRB#Pro00013497).
22. A Retrospective Analysis of TPMT-Heterozygotes in Inflammatory Bowel Disease (IRB# Pro00017070).
23. Review of Cedars-Sinai Clinical Experience with Thalidomide for the Treatment of Inflammatory Bowel Disease (IRB# Pro00026489).
24. Vitamin D Repletion and Maintenance in IBD: How much and how often? (IRB# Pro00045446).

**CO/SUB-INVESTIGATOR:**

1. Multicenter Phase I/II Trial of Recombinant Human TNF Receptor (rhu TNFR:Fc) in active Crohn's Disease (Immunex - Protocol No. 16.0005). (PI: Stephan R. Targan, MD)
2. A Randomized Placebo Controlled Study of Prezatide Copper Acetate 0.1% or 1.0% Rectal Solution for the Treatment of Ulcerative Colitis (Procyte - Protocol No. CS-020-94-01). (PI: Stephan R. Targan, MD)
3. Phase II Multi-Center Study of Anti-TNF Chimeric Monoclonal Antibody (cA2) in the Treatment of Patients with Active Crohn's Disease (Centocor - Study No. C0168T11). (PI: Stephan R. Targan, MD)
4. Phase II Multi-Center Study of Anti-TNF Chimeric Monoclonal Antibody (cA2) in the Treatment of Patients with Ulcerative Colitis (Centocor - Study No. C0168T12). (PI: Stephan R. Targan, MD)
5. A Placebo-Controlled, Dose-Ranging Study Followed by a Placebo-Controlled, Repeated-Dose Extension of Anti-TNF Chimeric Monoclonal Antibody (cA2) in the Treatment of Patients with Active Crohn's Disease (Centocor - Protocol No. C0168T16). (PI: Stephan R. Targan, MD)
6. Safety, Tolerance and Activity of Multiple Doses of Subcutaneous rhuIL-10 (SCH 52000) in Patients with Mildly to Moderately Active Crohn's Disease (Phase I/II) (Schering-Plough - Study No. C95-038). (PI: Stephan R. Targan, MD)
7. Safety, Tolerance and Activity of Multiple Doses of Subcutaneous rhuIL-10 (SCH 52000) in Patients with Mildly to Moderately Active Ulcerative Colitis (Phase I/II) (Schering-Plough - Study No. C95-039). (PI: Stephan R. Targan, MD)
8. Safety, Tolerance and Efficacy of Multiple Doses of Subcutaneous rhuIL-10 (SCH 52000) in Patients with Chronic Active Crohn's Disease (Schering-Plough - Study No. C/I95-152). (PI: Stephan R. Targan, MD)
9. Companion Protocol to C/I95-152: Safety and Tolerance of Retreatment with Multiple Doses of Subcutaneous rhuIL-10 (SCH 52000) in Patients with Chronic Active Crohn's Disease (Schering-Plough - Study No. C/I95-171). (PI: Stephan R. Targan, MD)
10. A Placebo-Controlled, Repeated-Dose Study of Anti-TNF Chimeric Monoclonal Antibody (cA2) in the Treatment of Patients with Enterocutaneous Fistulae as a Complication of Crohn's Disease (Centocor). (PI: Stephan R. Targan, MD)
11. A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial of Intravenous Azathioprine Loading to Decrease the Time to Response in Subjects with Steroid-Refractory Crohn's Disease (Galaxo Wellcome - Protocol No. IM1A4001). (PI: Stephan R. Targan, MD)
12. A Phase II Study of the Safety and Efficacy of TAK-603/A-165646 in Patients with Crohn's Disease (Tap Holdings, Inc. - Protocol No. M97-713). (PI: Stephan R. Targan, MD)
13. A Phase II, Multi-National, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Safety and Potential of the Engineered Human Anti-TNF $\alpha$  Antibody, CDP571, to Treat Patients with Moderate to Severe Crohn's Disease Following an Intravenous Dose of 20 or 10mg/kg of CDP571 Followed by 8- or 12- Weekly Dosing with 10mg/kg CDP571 over 24 Weeks (Celltech Therapeutics Limited - Protocol No. CDP571-009). (PI: Stephan R. Targan, MD)



14. A Phase II, Multi-National, Double-Blind, Placebo-Controlled, Parallel Group, 16 Week Study to Assess the Safety and Potential of the Engineered Human Anti-TNF $\alpha$  Antibody, CDP571, to Prevent Disease Flare Whilst Allowing Steroid Withdrawal in Steroid-Dependent Patients with Crohn's Disease Following an Intravenous Dose of 20mg/kg and then, 8 Weeks Later, 10mg/kg of CDP571. (Celltech Therapeutics Limited - Protocol No. CDP571-010). (PI: Stephan R. Targan, MD)
15. Extended Treatment with Anti-TNF Chimeric Antibody (infliximab) for Treatment of Patients with Active Crohn's Disease Previously Enrolled in Centocor Protocols (C0168T08, C0168T11, C0168T16, C0168T20) (Centocor - Protocol No. C0168T24). (PI: Stephan R. Targan, MD)
16. Safety, Tolerance and Efficacy of Treatment with Subcutaneous rHuIL-10 (SCH 52000) in Subjects with Steroid-Dependent Crohn's Disease (Schering-Plough - Study No. C97-455). (PI: Lori Y. Kam, MD)
17. Prospective Study of the Predictive Value of Serological Markers in Pediatric IBD. (Prometheus, CSMC/IBD Center/St. Justine MC). (PI: Marla Dubinsky, MD)
18. A Candidate Gene Approach to Immuno-phenotypic Subgroups of Crohn's Disease (National Institute of Diabetes & Digestive & Kidney Diseases [NIDDK]). (PI: Jerome Rotter) (IRB# 1096)
19. IBD: Genetic and Immunopathologic Mechanisms (National Institutes of Health). (PI: Stephan Targan, MD) (IRB# 1465)
20. IBD: Role Activated Mucosal T Cells in Gut Injury (National Institutes of Health). (PI: Stephan Targan, MD) (IRB# 2448)
21. IBD: TNF-alpha and Crohn's Disease Mucosal Inflammation (National Institutes of Health). (PI: Stephan R. Targan, MD) (IRB# 2673)
22. Biochemical Markers and Genetic TNF Haplotypes as Indicators of Response to anti-TNF Monoclonal Antibody Treatment in Patients with Crohn's Disease. (Prometheus/CSMC/IBD Center). (Lori Y. Kam, MD) (IRB# 2836)
23. An Open-Label, Stepwise Dose-Escalating Pilot Study to Evaluate the Safety and Efficacy of Thalidomide in the Treatment of Male Patients with Active Ulcerative Colitis (Celgene Corp.). (PI: Lori Y. Kam, MD) (IRB# 2861)
24. A Randomized Double-Blind, Placebo-Controlled Multicenter Trial of Oral Tacrolimus (FK506) in the Treatment of Crohn's Disease Complicated by Enterocutaneous Fistulae (Mayo Clinic Laboratories-Fujisawa). (PI: Lori Y. Kam, MD) (IRB# 3049)
25. An Open-Label, Pilot Study of Oral Thalidomide in the Treatment of Recurrent Flare of Active Crohn's Disease after Initial Treatment with Infliximab (Celgene Corp.). (PI: Lori Y. Kam, MD) (IRB# 2954)
26. An Open-Label, Pilot Study of Oral Thalidomide in Active Crohn's Disease Resistant to Infliximab Therapy (Celgene). (PI: Lori Y. Kam, MD, 6/99-Present) (IRB# 2955)
27. Treatment of Hypercalcemic/Hypercalciuric Patients with Chloroquine and Hydroxychloroquine (NIH) (PI: John Adams, MD)
28. A Randomized Double-Blind, Placebo-Controlled Trial of Anti-TNF $\alpha$  Chimeric Monoclonal Antibody (Infliximab, Remicade<sup>TM</sup>) in the Long-Term Treatment of Patients With Moderately to Severely Active Crohn's Disease (ACCENT I) (Centocor - Protocol No. C0168T21). (PI: Stephan R. Targan, MD) (IRB# 2956)

29. Response to Bacterial Antigens and Antibiotic Therapy with Patients with Active Crohn's Disease (NIH-funded). (PI: Stephan R. Targan, MD) (IRB# 3158)
30. Prevention of Chronic Pouchitis Following Ileal Anal Anastomosis (IAPP) with Postoperative Prophylactic Antibiotic Therapy in Ulcerative Colitis (UC) Patients Predetermined to be at High Risk Based on Responses to Bacterial Antigens (NIH-funded). (PI: Stephan R. Targan, MD) (IRB# 3159)
31. Serum Immune Antibody Markers as Predictors of the Development of Pouchitis Following Ileal Pouch Anal Anastomosis (IPAA) in Ulcerative Colitis (UC) (NIH-funded). (PI: Stephan R. Targan, MD) (IRB# 3160)
32. Response to Bacterial Antigens and Antibiotic Therapy in Crohn's Disease Patients who Respond to Infliximab (NIH-funded). (PI: Stephan R. Targan, MD) (IRB# 3161)
33. A Randomized, Double-Masked, Placebo-Controlled Pilot Trial of the Bisphosphonate Risedronate in Inflammatory Bowel Disease Patients Initiating High Dose Steroids for the Prevention of Bone Loss (Proctor & Gamble). (PI: Maria T. Abreu, MD) (IRB# 3171)
34. A Randomized Double-Blind, Placebo-Controlled Trial of Anti-TNF $\alpha$  Chimeric Monoclonal Antibody (Infliximab, Remicade<sup>TM</sup>) in the Long-Term Treatment of Patients With Fistuling Crohn's Disease (ACCENT II) (Centocor - Protocol No. C0168T26). (PI: Stephan R. Targan, MD) (IRB# 3176)
35. The Role of Thymus-Expressed Chemokine (TECK) and Its Receptor CCR9 on Lymphocytes in the Regional Specialization of the Mucosal Immune System and in the Pathogenesis of Crohn's Disease (Eli and Edythe L. Broad Foundation). (PI: Kostas Papadakis, MD) (IRB# 3202)
36. CCFA DNA and Cell Line Bank Patient Acquisition (Crohn's and Colitis Foundation of America) (PI: Andrew Ippoliti, MD) (IRB# 3279)
37. Inflammatory Bowel Disease Center: Clinical Data Repository and Tissue Procurement, Storage, and Utilization. (PI: Stephan Targan, MD) (IRB# 3358)
38. A Phase II, Multi-Center, Open, Mon-Comparative Study to Assess the Safety of a Single Dose of the Engineered Human Anti-TNF $\alpha$  Antibody, CDP571, (10mg/kg) in Patients with Crohn's Disease Who Have Experienced Either an Acute or Delayed Hypersensitivity Reaction to Previous Chimeric Anti-TNF $\alpha$  Antibody Therapy (Infliximab) (Celltech Therapeutics Ltd.). (PI: Lori Y. Kam, MD) (IRB# 3366)
39. A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Dose-Finding, Safety Study of Two Parallel Dose Levels of Subcutaneously Administered Human Monoclonal Antibody to Interleukin-12 (J695) in Patients with Active Crohn's Disease (Genetics Institute / Wyeth-Ayerst Research). (PI: Lori Y. Kam, MD) (IRB# 3369)
40. Testosterone Therapy in Corticosteroid Treated Males with Inflammatory Bowel Disease. (PI: Glenn Braunstein, MD) (IRB# 3374-01A)
41. A Phase II, Randomized, Placebo-Controlled, Double-Blind, Parallel Group, Multicenter Study to Determine the Safety, Pharmacokinetics, and Effectiveness of LDP-02 in Patients with Mildly to Moderately Active Ulcerative Colitis (Millennium Pharmaceuticals). (PI: Maria T. Abreu, MD) (IRB# 3412)
42. A Phase II, Randomized, Placebo-Controlled, Multiple-Dose, Safety, Clinical Activity and Dose-Finding Study of IDEC-131 (Monoclonal Antibody Against CD154) in Patients with Active Crohn's Disease (IDEC Pharmaceuticals). (PI: Stephan R. Targan, MD) (IRB# 3631)

43. The Epidemiology of Pediatric Inflammatory Bowel Disease in the Western Region of North America. (PI: Marla Dubinsky, MD) (IRB# 3766)
44. Metabolic Bone Disease in Inflammatory Bowel Disease. (PI: Maria T. Abreu, MD) (IRB# 3803)
45. A Phase III, International, Multicenter, Double-Blind, Placebo-Controlled Study of the Safety, Efficacy, and Tolerability of Intravenous Antegren™ (Natalizumab) in Subjects with Moderately to Severely Active Crohn's Disease (Elan Pharmaceuticals - Protocol No. AN100226-CD301). (PI: Stephan R. Targan, MD) (IRB# 3813)
46. A Phase I, Dose-Escalation, Pilot Study of Visilizumab in Patients with Severe Ulcerative Colitis that is Refractory to Corticosteroids (Protein Design Labs). (PI: Stephan Targan, MD) (IRB# 3827)
47. A Phase II, Double-Blind, Placebo-Controlled Study to Determine the Safety and Efficacy of a Humanized Anti-Interferon- $\gamma$  Monoclonal Antibody (HuZAF) Administered to Patients with Moderate to Severe Crohn's Disease (Protein Design Labs). (PI: Stephan Targan, MD) (IRB# 3903)
48. A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Human Anti-TNF Monoclonal Antibody Adalimumab for the Maintenance of Clinical Remission in Subjects with Crohn's Disease (Abbott Laboratories - Protocol M02-433). (PI: Stephan Targan, MD) (IRB# 3977)
49. A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Human Anti-TNF Monoclonal Antibody Adalimumab for the Induction of Clinical Remission in Subjects with Crohn's Disease M02-403 (Abbott Laboratories). (PI: Stephan Targan, MD) (IRB# 3978)
50. A Phase III, Multicenter, Open-Label, Long-term Study of the Safety, Tolerability, and Efficacy of Intravenous Antegren™ (Natalizumab) in Crohn's Disease Subjects Who have Previously Participated in Antegren Crohn's Disease Studies. (Elan Pharmaceuticals - Protocol ELN100226-CD351). (PI: Stephan R. Targan, MD) (IRB# 4069)
51. A Randomized, Multicenter, Open-Label Study to Evaluate the Safety and Efficacy of Anti-TNF Alpha Chimeric Monoclonal Antibody (Infliximab, Remicade) in Pediatric Subjects with Moderate to Severe Crohn's Disease (Centocor - REACH Protocol C0168T47) (PI: Marla Dubinsky, MD) (IRB# 4097)
52. A Single-Center, Open-Label Study of the Human Anti-TNF Monoclonal Antibody Adalimumab in Crohn's Disease Patients with Allergic Reactions to Infliximab. (PI: Maria Abreu, MD) (IRB# 4101)
53. A Phase II Randomized, Double-Blind, Placebo-Controlled Multi-Center, Dose-Ranging Study of Intravenous Daclizumab in Patients with Moderate to Severe Ulcerative Colitis. (Protein Design Labs, Inc - Protocol No. DAC-1008). (PI: Stephan Targan, MD) (IRB# 4113)
54. A Multicenter International Observational Study of the Long-term Safety of Infliximab (Remicade) (Centocor, Inc). (PI: Marla Dubinsky, MD) (IRB# 4128)
55. The Role of the Cytokines IL 20, IL 21, IL 22, AND ZSIG81 and Their Receptors in Inflammatory Bowel Disease. (PI: Kostas Papadakis, MD) (IRB# 4199)
56. Phenotypic and Functional Characterization of CCR9+ T Lymphocytes in Small Intestinal (SI) Crohn's Disease (Crohn's and Colitis Foundation of America). (PI: Kostas Papadakis, MD) (IRB# 4254)
57. A Phase I/II, Partially Randomized, Open-Label Study of Visilizumab in Patients With Severe Ulcerative Colitis Refractory to Intravenous Corticosteroids (Protein Design Labs - Protocol 291-408). (PI: Stephan Targan, MD) (IRB# 4288)

58. A Phase III, Multi-National, Multi-Centre, Double-Blind Placebo-Controlled Parallel Group, 26 Week Study to Assess the Safety and Efficacy of the Humanised Anti-TNF PEG Conjugate, CDP870 400 mg sc, (Dosed at Weeks 0, 2, 4 then 4-Weekly to Week 24), in the treatment of Patients with Active Crohn's Disease (Celltech – CDP870-031). (PI: Stephan Targan, MD) (IRB# 4345)
59. A Phase III, Multi-National, Multi-Centre, Open-Label, 52 Week Safety Study to Assess the Safety of Chronic Therapy with the Humanised Anti-TNF PEG Conjugate CDP870 400 mg sc, (Dosed 4-Weekly to Week 48), in the treatment of Patients with Active Crohn's Disease who have Previously Completed Studies CDP870-031 or CDP870-032 (Celltech – CDP870-033). (PI: Stephan Targan, MD) (IRB# 4348)
60. A Phase III, Multi-National, Multi-Centre, Open-Label, 52 Week Safety Study to Assess the Safety of Re-Exposure After a Variable Interval and Subsequent Chronic Therapy with the Humanised Anti-TNF PEG Conjugate CDP870 400 mg sc, (Dosed at Weeks 0, 2, and 4 then 4-Weekly to Week 48), in the treatment of Patients with Active Crohn's Disease who have Previously Withdrawn from Studies CDP870-031 or CDP870-032 Due to Exacerbation of of Crohn's disease (Celltech – CDP870-034). (PI: Stephan Targan, MD) (IRB# 4344)
61. Analysis of the Regulatory Activity of Human Mucosal CD4+CD25 T Cells (Fiterman Foundation). (PI: Kostas Papadakis, MD) (IRB# 4359)
62. A Phase III, Multicenter, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Intravenous Antegren™ (natalizumab) in Subjects with Moderately to Severely Active Crohn's Disease with Elevated C-Reactive Protein (Elan Pharmaceuticals - Protocol ELN100226-CD307). (PI: Stephan R. Targan, MD) (IRB# 4404)
63. A Pilot, Double-Blind, Placebo-Controlled, Parallel Group, Two Stratum Study of the Safety, Tolerability, Immunologic and Clinical Activity, and Population Pharmacokinetics of CCX282-B Administered for Four Weeks in Patients with Moderate to Severe Crohn's Disease (ChemoCentryx – Protocol CL003 282). (PI: Stephan R. Targan, MD) (IRB# Pro00006009)
64. Assessing the Immunomodulatory Effects of Visilizumab (Nuvion) in Crohn's Disease and Ulcerative colitis (Protein Design Labs, Inc). (PI: Kostas Papadakis, MD) (IRB# Pro00006104)
65. The Pediatric Inflammatory Bowel Disease Network for Research and Improvement. (PI: Marla Dubinsky, MD) (IRB# Pro00006132)
66. Intestinal Production of 1-alpha Hydroxylase in Patients with Crohn's Disease. (PI: John Adams/William Brien, MD) (IRB# Pro00006158)
67. A Randomized, Double-blind, Placebo-Controlled, Parallel-Group Study to Investigate the Efficacy and Safety of Nine Weeks' Administration of Three Doses of SB-683699 in Subjects With Moderately-to-Severely Active Crohn's Disease (GlaxoSmithKline – Protocol SB-683699/004). (PI: Stephan R. Targan, MD) (IRB# Pro00006160)
68. A Phase IIa, Open-label Study of Visilizumab in Patients with Moderate-to-Severe Inflammatory, Nonstricturing, Nonpenetrating Forms of Crohn's Disease (Protein Design Labs - Protocol 291-412). (PI: Stephan Targan, MD) (IRB# Pro00006345)
69. Antibodies to the Flagellin, CBir1, Define a Subtype of Crohn's Disease (Crohn's and Colitis Foundation of America). (PI: Stephan Targan, MD) (IRB# Pro00006476)
70. Flagellin Reactivity as a Marker for a Crohn's Subtype (National Institutes of Health). (PI: Stephan Targan, MD) (IRB# Pro00006522)

71. Effect of CCX282 Treatment on the Phenotypic and Functional Characteristics of Peripheral Blood Lymphocytes (PBL) in Patients with Crohn's Disease (ChemoCentryx, Inc). (PI: Kostas Papadakis, MD) (IRB# Pro00006544)
72. Role of Glutathione Peroxidase and Helicobacter spp. in Inflammatory Bowel Disease and Colonic Cancer. (PI: Stephan R. Targan, MD) (IRB# Pro00006790)
73. Determining the Minimally Important Difference for Crohn's Disease: A multiple-anchor prospective estimation of the MID for the Crohn's Disease Activity Index, the Inflammatory Bowel Disease Questionnaire, and the Harvey-Bradshaw Index (Centocor, Inc). (PI: Gil Melmed, MD) (IRB# Pro00007000)
74. A Phase 1, A Multicenter, Dose Escalation, Study of MDX-1100 (anti-CXCL10 Human Monoclonal Antibody) in Patients with Active Ulcerative Colitis (Medarex, Inc). (PI: Kostas Papadakis, MD) (IRB# Pro00007913)
75. The Role of Hepcidin in the Development of Chronic Anemia in Patients with Inflammatory Bowel Disease. (PI: Kostas Papadakis, MD) (IRB# Pro00007920)
76. Exploring the Link Between Serologic Profiles and Subclinical Intestinal Inflammation in Crohn's Disease, a Family Study. (PI: Stephan Targan, MD) (IRB# Pro00008272).
77. Crohn's Disease Survey Project (Elan Pharmaceuticals, Inc). (PI: Stephan R. Targan, MD) (IRB# Pro00008336)
78. A Phase I, Multicenter, Randomized, Placebo-Controlled, Blinded Study of Rituximab in Active Ulcerative Colitis (Genentech - Protocol U2972g). (PI: Stephan R. Targan, MD) (IRB# Pro00006258)
79. A Phase 2/3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Visilizumab in Subjects with Intravenous Steroid Refractory Ulcerative Colitis (Protein Design Labs, Inc) (PI: Andrew Ippoliti, MD) (IRB# Pro00008556)
80. TPMT Enzyme Activity Study. (PI: Kostas Papadakis, MD) (IRB# Pro00008589)
81. Study Using Certain BMS Proprietary Samples from Clinical Trial called "CA184-007: Randomized, Double-Blind, Placebo-Controlled Phase II Study Comparing the Safety of MDX-010 (BMS-734015) Administered With or Without Prophylactic Oral Budesonide (Entocort™ EC) in Patients with Previously Treated Unresectable Stage III or IV Malignant Melanoma" (Bristol-Myers Squibb Company). (PI: Stephan Targan, MD) (IRB# Pro00008583)
82. Can IBD Serologic Testing and Clinical Red Flags Predict Misdiagnosis of Colitis? A Nested Case-Control Study. (PI: Gil Melmed, MD) (IRB# Pro00008690)
83. Do We Have the Correct Diagnosis? Utility of Serologic Testing for Crohn's Disease in Patients with Ulcerative Colitis (Foundation for Clinical Research in IBD). (PI: Andrew Ippoliti, MD) (IRB# Pro00008823)
84. Short and Long-Term Outcomes of Intravenous Cyclosporin A Therapy in Ulcerative Colitis and Crohn's Disease. (PI: Andrew Ippoliti, MD) (IRB# Pro00009053)
85. A Randomized, Double-Blind, Multicenter Study of Visilizumab versus Placebo in Subjects with Intravenous Steroid-Refractory Ulcerative Colitis Previously Responsive in a Visilizumab Study (Protein Design Lab, Inc - Protocol 291-417). (PI: Kostas Papadakis, MD) (IRB# Pro00009927)
86. Determination of True Symptom Criteria for Defining IBS: Development of the LA/IBS Criteria (Seaver Foundation). (PI: Mark Pimentel, MD) (IRB# Pro00010058)

87. The Measurement of Infliximab Levels in Mothers and Newborns. (PI: Marla Dubinsky, MD) (IRB# Pro00010989)
88. An Observational Follow-up Study for Subjects Receiving Salvage Therapy after previous treatment in a Vedolizumab Study for Intravenous Steroid - Refractory Ulcerative Colitis. (PDL BioPharma, Inc.- Protocol 291-420). (PI: Andrew Ippoliti, MD) (IRB# Pro00011025)
89. A Phase III, Multi-Center, Randomized, Placebo-Controlled Study to Evaluate the Clinical Efficacy and Safety of Induction and Maintenance Therapy with Abatacept in Subjects with Active Crohn's Disease (CD) who have had an Inadequate Clinical Response and/or Intolerance to Medical Therapy. (Bristol-Myers Squibb [BMS] - Protocol IM101084). (PI: Gil Melmed, MD) (IRB# Pro00011705)
90. A Phase III, Multi-Center, Randomized, Placebo-Controlled Study to Evaluate the Clinical Efficacy and Safety of Induction and Maintenance Therapy with Abatacept in Subjects with Active Ulcerative Colitis (UC) who have had an Inadequate Clinical Response and/or Intolerance to Medical Therapy. (Bristol-Myers Squibb [BMS] - Protocol IM101108). (PI: Gil Melmed, MD) (IRB# Pro00011861)
91. A 5-Year Registry Study of HUMIRA (Adalimumab) in Subjects with Moderately to Severely Active Crohn's Disease (CD). (Abbott Laboratories - Protocol P06-134). (PI: Gil Melmed, MD) (IRB# Pro00013188)
92. A Multi-center National Prospective Study of Pregnancy and Neonatal Outcomes in Women with Inflammatory Bowel Disease Exposed to Immunomodulators and Biologic Therapy. (Crohn's and Colitis Foundation of America [CCFA]). (PI: Shervin Rabizadeh, MD) (IRB# Pro00013156)
93. Clinical Outcomes of Preferential 6MMP Metabolism in Inflammatory Bowel Disease Patients Treated with Thiopurines. (PI: Guarav Syal, MD) (IRB# Pro00014002)
94. Response to Infliximab for Active Ulcerative Colitis (UC): Repository to Collect Specimens and Clinical Data from UC Patients Receiving Infliximab (REACT Study). (PI: Gil Melmed, MD) (IRB# Pro00014384)
95. Evaluation of Lymphocytic Esophagitis in Inflammatory Bowel Disease (PI: Jeffrey Conklin, MD) (IRB# Pro00016709)
96. Comparison of Two Different Pneumococcal Vaccines in Patients with Crohn's Disease. (PI: Gil Melmed, MD) (IRB# Pro00017984)
97. A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Ustekinumab Therapy in Subjects with Moderately to Severely Active Crohn's Disease Previously Treated with TNF Antagonist Therapy (CERTIFI) (Crohn's Evaluation of Response to Ustekinumab anti-IL12/23 for Induction) (Centocor, Inc - Protocol C0743T26). (PI: Gil Melmed, MD) (IRB# Pro00017306)
98. A Phase 1, Multi-Center, Open-Label, Dose-Escalation Study to Evaluate the Safety of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Adults with Moderate-to Severe Crohn's disease that is Refractory to Oral Corticosteroids and Immune Suppressants. (Celgene Cellular Therapeutics - CCT-PDA001-001). (PI: Gil Melmed, MD) (IRB# Pro00017870)
99. A Phase 3, Randomized, Placebo-Controlled, Blinded, Multicenter Study of the Induction and Maintenance of Clinical Response and Remission by Vedolizumab (MLN0002) in Patients with Moderate to Severe Ulcerative Colitis. (Millennium Pharmaceuticals, Inc. - C13006) (PI: Gil Melmed, MD) (IRB# Pro00019598)

100. A Phase 3, Open-Label Study to Determine the Long-term Safety and Efficacy of Vedolizumab (MLN0002) in Patients with Ulcerative Colitis or Crohn's Disease (Millennium Pharmaceuticals, Inc. - C13008). (PI: Gil Melmed, MD) (IRB# Pro00020157)
101. A Study of Coping Strategies Utilized by Adult Patients with Inflammatory Bowel Disease Protocol. (PI: Gil Melmed, MD) (IRB# Pro00020400)
102. Outcome of Cytomegalovirus Infections in Patients with Inflammatory Bowel Disease. (PI: Gaurav Syal, MD) (IRB# Pro00020558)
103. A Phase 3, Open-Label Study to Determine the Long-term Safety and Efficacy of Vedolizumab (MLN0002) in Patients with Ulcerative Colitis and Crohn's Disease (C13008). (PI: Gil Melmed, MD) (IRB# Pro00020157)
104. Pneumococcal Vaccination for Patients with IBD - Follow-up Study Protocol. (PI: Gil Melmed, MD) (IRB# Pro00021128)
105. Routine Upper Endoscopy in IBD Patients With Colitis: Findings and Clinical Implications. (PI: Gil Melmed, MD) (IRB# Pro00021975)
106. A Phase 2A, Randomized, Double Blind, Placebo Controlled Multi-Center Study to Evaluate the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Adults with Moderate-to-Severe Crohn's Disease. (Celgene Cellular Therapeutics - CCT-PDA001-002). (PI: Gil Melmed, MD) (IRB# Pro00022369)
107. Humoral Immune Response to Pertussis Reactivation Vaccine in Adult Patients with Inflammatory Bowel Disease. (PI: Gil Melmed, MD) (IRB# Pro00022879)
108. Assessment of the viral contribution to exacerbations and the development of IBD. (PI: Dermot McGovern, MD) (IRB# Pro00024187)
109. The Management of Clostridium Difficile Infection in Patients with Inflammatory Bowel Disease. (PI: Gil Melmed, MD) (IRB# Pro00024246)
110. The Role of Fecal Calprotectin in Predicting Outcomes of Ulcerative Colitis. (PI: Gil Melmed, MD) (IRB# Pro00024759)
111. The Influence of Anti-TNF $\alpha$  Therapy on Early Atherosclerosis progression in Crohn's disease. (PI: Marla Dubinsky, MD) (IRB# Pro00025159)
112. Microbiome in IBD: A Request for Transformative, Multidisciplinary Clinical and Translation Research Proposals. (PI: Dermot McGovern, MD) (IRB# Pro00025390)
113. Predictors of Time to Second Surgery in Crohn's Disease. (PI: Dermot McGovern, MD) (IRB# Pro00026241)
114. Intestinal Granulomas in Crohn's Disease: Correlation between Surgical Specimens and Endoscopic Biopsies, and Association with Patient Characteristics, Serologic Markers, and Genetics. (PI: Dermot McGovern, MD) (IRB# Pro00026281)
115. Analysis of the association between vitamin D levels in patients with inflammatory bowel disease and genetic, serologic and clinical phenotype. (PI: Dermot McGovern, MD) (IRB# Pro00026419)
116. Analysis of the association between IBD related genetic and serologic parameters, presence of Human Anti-Chimeric Antibodies (HACAs), and low serum Infliximab levels on disease severity and outcomes. (PI: Dermot McGovern, MD) (IRB# Pro00026575)

117. Systems Biology Analysis of Ulcerative Colitis. (PI: Dermot McGovern, MD) (IRB# Pro00026836)
118. Genetics of Immune Pathways Leading to Severe Forms of IBD. (PI: Dermot McGovern, MD) (IRB# 1096)
119. Patient Reported Outcomes Measurement Information System (PROMIS) Network Study Protocol (Development and Initial Validation of a PROMIS GI Symptoms Item Bank / Evaluation of Psychometric Properties of Item Bank) (National Institutes of Health) (PI: Gil Melmed, MD) (IRB# Pro00027093)
120. A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Safety and Efficacy of Ustekinumab (Stelara) Induction Therapy in Subjects with Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to TNF Antagonist Therapy (UNITI 1) (Janssen Research & Development Protocol CNTO1275CRD3001; Phase 3). (PI: Gil Melmed, MD) (IRB# Pro00027413)
121. A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Safety and Efficacy of Ustekinumab (Stelara) Induction Therapy in Subjects with Moderately to Severely Active Crohn's Disease (Janssen Research & Development Protocol CNTO1275CRD3002; Phase 3). (PI: Gil Melmed, MD) (IRB# Pro00027502)
122. The Role of small bowel ultrasound post Ileocolic resection in Crohn's disease patients. (PI: Namita Singh, MD) (IRB# Pro00027597)
123. A MultiCentre, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of Oral CP-690,550 (Tofacitinib) as an Induction Therapy in Subjects with Moderate to Severe Ulcerative Colitis (Pfizer A3921094; Phase 3). (PI: Gil Melmed, MD) (IRB# Pro00028764)
124. A MultiCentre, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of Oral CP-690,550 (Tofacitinib) as a Maintenance Therapy in Subjects with Ulcerative Colitis (Pfizer A3921096). (PI: Gil Melmed, MD) (IRB# Pro00028783)
125. A Multi-Center, Open-Label Study of CP-690,550 (Tofacitinib) in Subjects with Moderate to Severe Ulcerative Colitis (Pfizer A3921139; Phase 3). (PI: Gil Melmed, MD) (IRB# Pro00028814)
126. Anti-Fungal Immunity in Ulcerative Colitis. (PI: David Underhill) (IRB# Pro00029429)
127. Genetic, serologic, and clinical associations among patients with Helicobacter pylori (H. pylori) and inflammatory bowel disease (IBD). (PI: David Shih, MD) (IRB# Pro00029771)
128. Inflammatory Bowel Disease - Outcomes, Preferences, Education, Resource Utilization, Assessment Database. (IBD-OPERA Database - UC). (PI: Gil Melmed, MD) (IRB# Pro00030780)
129. A Randomized, Double-Blind, Placebo-Controlled Dose-Escalation Study to Determine the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Crohn's Disease. (Celgene Cellular Therapeutics CCT-PDA001-CD-003). (PI: Gil Melmed, MD) (IRB# Pro00030938)
130. Inflammatory Bowel Disease - Outcomes, Preferences, Education, Resource Utilization, Assessment. Database. (IBD-OPERA Database - CD). (PI: Gil Melmed, MD) (IRB# Pro00031099)



131. Prospective analysis on the effect of anti-TNF $\alpha$  medication (infliximab, adalimumab, and certolizumab) on thiopurine metabolites. (PI: Gaurav Syal, MD) (IRB# Pro00032043)
132. Clostridium Difficile Infection (CDI) in Patients with Inflammatory Bowel Disease (IBD): Association with Patient Characteristics and Genetics. (PI: Dermot McGovern, MD) (IRB# Pro00033588)
133. Clinical, genetic, and serologic characteristics of patients with inflammatory bowel disease and psoriasis. (PI: Dermot McGovern, MD) (IRB# Pro00038081)
134. A Genetic Model of Inflammatory Bowel Disease using Human Intestinal Organoids (3358 Analysis). (PI: Stephan Targan, MD) (IRB# Pro00038299)
135. Factors predicting a response of anti-TNF agents for the patients with IBD. (PI: Gil Melmed, MD) (IRB# Pro00038598)
136. Navigating Use of Biologics in IBD: Development of A Novel Patient Decision Aid Using Conjoint Analysis and Social Media Insights. (PI: Brennan Spiegel, MD) (IRB# Pro00039038)
137. Genetic and Serologic Predictors of Fibrostenosing Crohn's Disease. (PI: David Shih, MD) (IRB# Pro00045274)

**INVITED LECTURES / PRESENTATIONS:**

1. Therapies in Inflammatory Bowel Disease; Family Practice Housestaff, California Medical Hospital, LA 9/21/1995
2. Inflammatory Bowel Disease Update: Pathogenesis & Treatment; Medicine Grand Rounds, Kaiser Permanente Hospital, LA 4/1/1997
3. Novel Therapies of IBD: anti-TNF, IL-10, and IV Imuran; “Turning Corners: Pharmaceutical, Therapeutic, & Surgical Advances in Inflammatory Bowel Disease” - CCFA Physician-Patient Conference, LA, CA 6/28/1997
4. Serum Immune Markers in Inflammatory Bowel Disease; Pediatric Gastroenterology Grand Rounds, North Shore Hospital, NY 9/16/1997
5. Inflammatory Bowel Disease: Reestablishing the Delicate Balance; “Creating a Delicate Balance” - CCFA Patient Seminar, Woodland Hills, CA 11/15/1997
6. Prospects for Genotype-Phenotype Correlations; CCFA/IOIBD Crohn’s Disease Clinical Phenotyping Workshop, New York, NY 1/9/1998
7. Serum Immune Markers (ANCA & ASCA) in Inflammatory Bowel Disease: Clinical Correlates and Implications for Therapy; Army Tacoma, WA 3/13/1998
8. Serum Immune Markers in IBD: Clinical Correlates and Therapeutic Implications for the Pediatrician; Pediatric Grand Rounds, Swedish-American Hospital/University of Illinois College of Medicine, Rockford, IL 8/13/1998
9. Inflammatory Bowel Disease & Therapeutics in Pediatrics; Pediatric Grand Rounds, Children’s Hospital of Orange County, Orange, CA 9/2/1998
10. Monoclonal Antibody Therapy; “Inflammatory Bowel Diseases” - 2<sup>nd</sup> Nestlé Nutrition Workshop, International Seminar, Pasadena, CA 11/11/1998
11. Thalidomide in Crohn’s Disease; “Thalidomide: Impact on the Practitioner” (Seminar), University of Utah and the Utah Department of Health, The University of Utah Health Sciences Center, Salt Lake City, Utah 1/30/1999
12. Thalidomide Therapy in Crohn's Disease – An Overview; “Thalidomide Update Meeting”, Medical Education Collaborative, Irving, TX 6/19/1999
13. Inflammatory Bowel Disease: New Approaches to Treatment; 12<sup>th</sup> Annual Nutrition Support Symposium, Southern California Chapter of the American Society of Parenteral and Enteral Nutrition (ASPEN), Long beach, CA 9/18/1999
14. Recent Approaches to the Medical Management of Crohn’s Disease; “Colon and Rectal Surgery: The Third Millennium” – University of Southern California School of Medicine, Pasadena, CA 2/4/2000
15. “Genetic, Serologic, & Biochemical Profiles: Unlocking the Doors to ‘Reagent Grade’ Intervention” and “Inflammatory Bowel Disease: New & Emerging Treatment Options”; Inflammatory Bowel Disease Symposium, Idaho GUT Club, Sun Valley, ID 3/10-11/2000
16. Thalidomide Therapy in Inflammatory Bowel Disease – An Overview; Gastroenterology Grand Rounds, University of Southern California School of Medicine, LA, CA 3/24/2000
17. Innovations in the Management of Inflammatory Bowel Disease – Medical Grand Rounds, St. Jude Medical Center, Fullerton, CA 8/29/2000

18. Evolving Concepts and Therapeutic Approaches in Pediatric IBD; Children's Hospital and Regional Medical Center and University of Washington School of Medicine, Seattle, WA 11/10/2000 New Concepts and Therapies in Pediatric IBD; Pediatric IBD Patient and Parent Support Group Education Seminar; Children's Hospital and Regional Medical Center, Seattle, WA 11/11/2000
20. Children with IBD and Their Families; "Everything you ever wanted to know about IBD series" - CCFA Patient Seminar, Greater Los Angeles Chapter, CA 6/30/2001
21. Infliximab in Pediatric IBD: Evolving Concepts & Therapeutic Approaches; Pediatric Gastroenterology Grand Rounds, Children's Hospital of Los Angeles, LA, CA 8/10/2001
22. Evolving Concepts & Therapeutic Approaches; Medicine Grand Rounds, Tripler Army Medical Center, Honolulu, HI, 8/23/2001
23. Advances in the Management of Inflammatory Bowel Diseases, Maui GI Conference, Maui HI, 8/25/2001
24. Optimizing Current Therapies in IBD; San Diego GI Society, La Jolla, CA 9/25/2001
25. The Clinical Implications of Emerging Diagnostic, Translational, and Therapeutic Strategies - Update on Management and Treatment of Inflammatory Bowel Disease; Children's Hospital and Louisiana Chapter of CCFA, New Orleans, LA 1/12/2002
26. Meeting the Challenge of Crohn's Disease & Ulcerative Colitis: Public Education Symposium; Children's Hospital and Louisiana Chapter of CCFA, New Orleans, LA 1/12/2002
27. Recent Advances in the Diagnosis and Treatment of Crohn's Disease; Orange County GI Society, Irvine, CA 2/12/2001
28. A Clinical Update in Inflammatory Bowel Disease; Kaiser Permanente Pediatric Gastroenterologist update, LA, CA 2/27/2002 Recent Advances in the Diagnosis & Treatment of Inflammatory Bowel Diseases; Medicine Grand Rounds, St. John's Regional Medical Center, Oxnard, CA 3/19/2002 New Diagnostic and Treatment Considerations in Pediatric IBD; Pediatric Gastroenterology Grand Rounds, Valley Children's Hospital, Fresno, CA, 3/21/2002
31. Recent Advances in the Diagnosis and Treatment of IBD, Fresno GI Society, Fresno 3/21/2002
32. Advances in the Treatment of Crohn's disease; Medicine Grand Rounds, St. Joseph Hospital, Orange, CA 4/12/2002
33. An Update on Medical Therapies for Children with IBD – An Update on the Diagnosis and Management of Pediatric Inflammatory Bowel Disease; Cedars-Sinai Medical Center and the CCFA Greater Los Angeles Chapter, LA, CA 4/13/2002
34. FAQ's: Frequently Asked Questions in the Management of Pediatric IBD: A Parent Education Symposium; Cedars-Sinai Medical Center and the CCFA Greater Los Angeles Chapter, LA, CA 4/13/2002
35. New Guidelines for Inflammatory Bowel Disease; Medicine Grand Rounds, John F Kennedy Memorial Hospital, Indio, CA 6/5/2002
36. Important Management Considerations in the Refractory Pediatric IBD Patient – a Case-Based Review; Pediatric Gastroenterology Grand Rounds, Children's Hospital Boston, Boston, MA 7/17/2002

37. Crohn's Disease and Surgery; Cedars-Sinai Medical Center Gastroenterology Symposium; Santa Barbara, CA 11/4-6/2002
38. New Diagnostic and Therapeutic Options in the Management of Pediatric Inflammatory Bowel disease. Bay Area Stanford/UCSF Pediatric GUT Club, San Francisco, CA 10/15/2002
39. Clinical Implications of IBD Serology and Metabolite Monitoring in the Management of Inflammatory Bowel Disease; GI Conference, Kaiser Permanente, LA, CA 11/21/2002
40. Infliximab in Pediatric IBD – Advances in the Inflammatory Bowel Diseases Symposium; CCFA, NY, NY 12/6-7/2002
41. The Paradigm Shift: A New Approach to the Diagnosis, Classification, & Treatment of Inflammatory Bowel Diseases; Gastroenterology Grand Rounds & Pediatric Grand Rounds, William Beaumont Hospital, Royal Oak, MI 4/29/2003
42. New Developments in the Diagnosis, Stratification & Treatment of Inflammatory Bowel Diseases; Medicine Grand Rounds, Santa Barbara Cottage Hospital, Santa Barbara, CA 11/20/2003
43. Treatment Options in Pediatric IBD; CCFA Teen/Parent Support Group Meeting, Greater Los Angeles Chapter, CA 12/9/2003
44. Stepping up therapy: The Role of Immunomodulators; Western Research Pediatric IBD Research Alliance Meeting, Seattle, WA 4/4/2004
45. What are Crohn's Disease, Ulcerative Colitis, & Indeterminate Colitis? - *What are the Options?*; Pediatric IBD Patient and Parent Support Group Education Seminar; Children's Hospital and Regional Medical Center, Seattle, WA 4/3/2004
46. Optimizing Therapies in Pediatric IBD; CCFA Teen/Parent Support Group Meeting, Greater Los Angeles Chapter, CA 4/20/2004
47. Serological Markers in Inflammatory Bowel Diseases & Celiac Disease; Pediatric Grand Rounds, New York Medical College, Valhalla, NY 6/2/2004
48. New Trends in the Treatment of Inflammatory Bowel Disease; Medicine Grand Rounds, Santa Monica, CA 2/3/2005
49. Optimizing Therapies and Individualizing Treatment Strategies in Inflammatory Bowel Disease (IBD); Medi-Cal Pharmacists Educational Program, LA, CA 10/20/2005
50. New Approaches to Diagnosing & Managing Inflammatory Bowel Disease; Medicine Grand Rounds, Encino-Tarzana Regional Medical, Tarzana, CA 1/26/2006
51. Evolving Paradigms in the Diagnosis & Management of Inflammatory Bowel Disease; Osteopathic Physicians & Surgeons of California 45th Annual Convention & Exposition, Palm Springs, CA, 2/15/2006
52. Balancing Eastern and Western Medicine; CCFA Greater Los Angeles Chapter Patient and Family Education Conference: "A Patient's Perspective of IBD", Long Beach, CA, 4/1/2006
53. Advances in Pediatric Inflammatory Bowel Disease; Fresno-Madera Medical Society's 56th Annual Yosemite Postgraduate Institute, Yosemite, CA 3/31/2007
54. "Fine-Tuning" Your IBD Patient's Treatment Regimen; Gastroenterology GUT Club Presentation, Honolulu, HI 5/1/2007

55. Pro: Post-op Prevention for Crohn's Disease; CCFA Greater Los Angeles Chapter Physician Education Conference: "IBD Hot Topics 2008", Los Angeles, CA, 3/29/2008
56. Complementary Alternative Therapies: What Works and Why; CCFA Greater Los Angeles Chapter Patient and Family Education Conference: "IBD Hot Topics 2008", Los Angeles, CA, 3/29/2008
57. New Treatment Options for Crohn's Disease; North Orange County Gut Club, Anaheim, CA 10/29/2008
58. Selecting Biologic Treatments for Crohn's Disease; Orange County Gut Club, Newport Beach, CA, 2/19/2009
59. Alternative Therapies for IBD; IBD Support Foundation's Pediatric IBD Support Group Meeting, Universal City, CA 1/27/2009
60. "Why We Do What We Do?"; Greater Los Angeles/Orange County Chapters Physician Education Conference: "2009 Back to IBD Basics" Los Angeles, CA 3/28/2009
61. "Basic Principles of IBD Surgery - Optimizing Pre-op Work-up and Post-op Outcomes" – A Point-Counter-Point Discussion; Greater Los Angeles/Orange County Chapters Physician Education Conference: "2009 Back to IBD Basics" Los Angeles, CA 3/28/2009
62. "IBD Treatment Philosophy: "What is It?"; CCFA Greater Los Angeles/Orange County Chapters Patient and Family Education Conference: "2009 Back to IBD Basics" Los Angeles, CA 3/28/2009
63. Serologic Markers in IBD: Clinically Useful or Purely a Research Tool? - Simposio Latinoamericano de Enfermedad Inflamatoria Intestinal; Santiago, Chile 4/9/2010
64. The Dawn of a New Era: The 21st Century Pharmacogenetic-Based Approach to Thiopurine Therapy in IBD. - Simposio Latinoamericano de Enfermedad Inflamatoria Intestinal; Santiago, Chile 4/9/2010
65. Post-Operative Prevention in Crohn's Disease: Pros & Cons... What is in the Patient's Best Interest? - Simposio Latinoamericano de Enfermedad Inflamatoria Intestinal; Santiago, Chile 4/9/2010
66. Treatment Options in Refractory Ulcerative Colitis. - Simposio Latinoamericano de Enfermedad Inflamatoria Intestinal; Santiago, Chile 4/10/2010
67. "Fine-Tuning" IBD Therapy to Wellness: A Cased-Based Overview. - Simposio Latinoamericano de Enfermedad Inflamatoria Intestinal; Santiago, Chile 4/10/2010
68. Alternative Therapies in IBD; IBD Support Foundation's Life & IBD Education Symposium, Los Angeles, 11/13/ 2011
69. Alternative Therapies in IBD: An Integrative Approach to Wellness; CCFA Los Angeles Chapter Spring Family and Patient Education Conference Los Angeles, CA 4/20/2013
70. The Latest Advances in Crohn's Diseases & Ulcerative Colitides. Health Concerns Symposium 2014: Healing Digestive Disorders. San Francisco, CA 9/14/2014
71. Diet's Impact on IBD: Time for a Paradigm Shift?; CCFA Los Angeles Chapter Patient and Family Education Conference Los Angeles, CA 10/25/2015
72. Nutrition and Integrative Treatments for IBD; CCFA Los Angeles Chapter Educational Program for Patients, Families, and Caregivers Living with Crohn's Disease and Ulcerative Colitis, Santa Barbara, CA 9/10/2016

73. Therapeutic Nutrition in IBD; 40th Annual Seminar for GI Nurses and Associates, Los Angeles, CA 9/24/2016
74. Intro to Nutritional & Integrative Therapies in IBD; CCFA Los Angeles Patient and Family Education Conference, Los Angeles, CA 10/9/2016
75. Journey to Wellness with IBD: Integrating Nutrition & other Complementary Strategies with a Special Focus on the Specific Carbohydrate Diet (SCD); CCFA Los Angeles Chapter Educational Program for Patients, Families, and Caregivers Living with Crohn's Disease and Ulcerative Colitis, Santa Ana, CA 4/2/2017
76. IBD Doctors Panel Q&A; Crohn's & Colitis Foundation's Patient & Family Education Conference, Los Angeles, CA 9/24/2107
77. Integrating Complementary Strategies to Enhance Wellness in IBD; Crohn's & Colitis Foundation's Patient & Family Education Conference, Los Angeles, CA 9/24/2107
78. Diet & Nutrition Panel Q&A; Crohn's & Colitis Foundation's Patient & Family Education Conference, Los Angeles, CA 11/10/2108
79. Herbs & GUT Microbial Manipulation in IBD: What We Know & What We Don't Know; Crohn's & Colitis Foundation's Patient & Family Education Conference, Los Angeles, CA 11/10/2108

**CSMC/UCLA MEDICAL AND GRADUATE STUDENT & FELLOWS LECTURES:**

1. The Bleeding Infant, Child, & Adolescent - Differential Diagnosis & Therapy; Pediatric Housestaff, Cedars-Sinai Medical Center, LA 12/18/1995
2. New Stratification Strategies in Inflammatory Bowel Disease; Seminar in Inflammatory Bowel Disease; Cedars-Sinai Medical Center, LA 3/22/1996
3. Miliary Crohn's Disease; Pediatric Case Conference, Cedars-Sinai Medical Center, LA 1/14/1997
4. Inflammatory Bowel Disease: A New Era for Treatment of Crohn's Disease & Ulcerative Colitis; Patient-Education Seminar; Cedars-Sinai Medical Center, LA 3/1/1997
5. Inflammatory Bowel Disease Overview; UCLA Medical Student Lecture; Cedars-Sinai Medical Center, LA 3/31/1997
6. Serum Immune Markers in IBD: Clinical Correlates and Implications for the Future; Gastroenterology Grand Rounds, Cedars-Sinai Medical Center, LA, CA 10/30/1997
7. Serum Immune Markers in IBD - Considerations for the Pediatrician; Pediatric Housestaff, Cedars-Sinai Medical Center, LA 3/9/1998
8. An Overview of Inflammatory Bowel Disease; UCLA Medical Student Lecture; Cedars-Sinai Medical Center, LA 3/30/1998
9. Cytokine-Directed Therapies in Inflammatory Bowel Disease; Gastroenterology Grand Rounds, Cedars-Sinai Medical Center, LA, CA 6/25/1998
10. Monoclonal Antibody Therapy in IBD; "New Innovations in Nutritional Therapy for Inflammatory Bowel Disease" - UCLA Center for Human Nutrition Seminar, LA, CA 11/11/1998
11. Anti-TNF Monoclonal Antibody Therapy in IBD; Colorectal Surgery Grand Rounds, UCSD Thornton Hospital, La Jolla, CA 1/7/1999
12. An Overview of Inflammatory Bowel Disease; UCLA Medical Student Lecture; Cedars-Sinai Medical Center, LA 3/29/1999
13. Oral Anti-TNF Therapies in Inflammatory Bowel Disease; Gastroenterology Grand Rounds, Cedars-Sinai Medical Center, LA, CA 4/8/1999
14. Pediatric IBD: Advances in Diagnosis and Treatment; Pediatric Grand Rounds, Cedars-Sinai Medical Center, LA, CA 10/14/1999
15. Through the Colitiscope: Advances in Pediatric Inflammatory Bowel Disease; "Through the Colitiscope: A View of Inflammatory Bowel Disease for in the Next Millennium..." - Cedars-Sinai Medical Center and University of California San Francisco Educational Seminar, San Francisco, CA 2/4-5/2000
16. An Overview of Inflammatory Bowel Disease; UCLA Medical Student Lecture; Cedars-Sinai Medical Center, LA 3/24/2000
17. Medicine Chief's Rounds; Internal Medicine Housestaff; Cedars-Sinai Medical Center, LA 7/26/2000
18. New Developments in Diagnosis and Treatment of Pediatric IBD; Pediatric Clinical Case Conference; Cedars-Sinai Medical Center, LA 9/12/2000
19. An Overview of Serum Immune Markers in Inflammatory Bowel Disease; Internal Medicine Housestaff; Cedars-Sinai Medical Center, LA 11/14/2000

20. Gastrointestinal Bleeding: A Case Based Overview; UCLA Medical Student Lecture; Cedars-Sinai Medical Center, LA 12/11/2000
21. Medicine Chief's Rounds; Internal Medicine Housestaff; Cedars-Sinai Medical Center, LA 1/24/2001
22. Pediatric IBD: New Diagnostic and Therapeutic Strategies; Pediatric Grand Rounds, Cedars-Sinai Medical Center, LA, CA 2/26/2001
23. Medical Management of Complicated Crohn's Disease - Integrating Recent Advances into Clinical Practice; Cedars-Sinai Medical Center Gastroenterology Symposium; Napa, CA 11/2-4/2001
24. Medical Management of Crohn's Disease; UCLA GI Fellow's Conference, LA 3/8/2002
25. Clinical Implications of Recent Advances in the Diagnosis & Treatment of Inflammatory Bowel Diseases; Medicine Grand Rounds, VA Sepulveda-UCLA, LA, CA 9/26/2002
26. A Paradigm Shift: Clinical Implications of Recent Advances in the Diagnosis & Treatment of Inflammatory Bowel Diseases; UCLA GI Fellow's Conference, LA 3/14/2003
27. When Do You Operate on Crohn's? Special Issues in Pediatric IBD - Annual Update in Gastroenterology: A Symposium for Gastroenterologists and Internists; Cedars-Sinai Medical Center Gastroenterology Symposium; Napa Valley, CA 9/12-14/2003
28. New Developments in the Diagnosis & Treatment of Inflammatory Bowel Diseases; Medicine Grand Rounds, Harbor UCLA Medical Center, Torrance, CA 9/16/2003
29. Diagnostic Dilemma: Is it UC or "UC-like" CD? Does it Really Matter? (Yes!); Gastroenterology Grand Rounds, Cedars-Sinai Medical Center, LA, CA 10/6/2003
30. Novel Diagnostic Testing in IBD: From Antibodies to Capsule Endoscopy - Annual Update in Gastroenterology: A Symposium for Gastroenterologists and Internists; Cedars-Sinai Medical Center Gastroenterology Symposium, Monterey, CA 10/15-17/2004
31. Medical Therapy of Crohn's Disease; UCLA GI Fellow's Conference, LA 1/28/2005
32. Management of Inflammatory Bowel Disease; Medicine Grand Rounds, Martin Luther King, Jr. / Charles R. Drew Medical Center, Los Angeles, CA 3/29/2005
33. GI Bleeding: UCLA Medical Student III Gastroenterology Block Case-Based Seminars, 8/22/2005
34. IBD: Evolving Diagnostic & Management Paradigms; GI Nurse and Endoscopy Staff Education Rounds, Cedars-Sinai Medical Center, LA, CA 8/31/2005
35. The Genetics of IBD: Does It Help Us Clinically? - Annual Update in Gastroenterology: A Symposium for Gastroenterologists and Internists; Cedars-Sinai Medical Center Gastroenterology Symposium, La Jolla, CA 10/21-23/2005
36. Management of IBD: A Case History Approach; A CME Accredited Program co-sponsored by The Institute for Medical Education<sup>SM</sup> and the Cedars-Sinai IBD Center, Redondo Beach, CA, 12/1/2005
37. "Fine-Tuning" Your IBD Patient's Therapy: A Case-Based Discussion; Gastroenterology Grand Rounds, Cedars-Sinai Medical Center, LA, CA 3/2/2006
38. New Approaches to Diagnosing & Managing Pediatric Inflammatory Bowel Disease; Pediatric Grand Rounds, Cedars-Sinai Medical Center, LA, CA 3/30/2006



39. Management of Crohn's Disease: A Case History Approach; Harbor UCLA GI Fellow's Conference, Harbor UCLA Medical Center, Torrance, CA 4/25/2006
40. New Approaches to Diagnosing, Classifying, & Managing Inflammatory Bowel Disease; Medicine Grand Rounds, Harbor UCLA Medical Center, Torrance, CA 4/25/2006
41. "Fine-Tuning" Your IBD Patient's Treatment Regimen - Annual Update in Gastroenterology: A Symposium for Gastroenterologists, Internists and Surgeons; Cedars-Sinai Medical Center Gastroenterology Symposium, Napa, CA 9/15/2006
42. GI Bleeding: UCLA Medical Student III Gastroenterology Block Case-Based Seminars, 6/25/2007
43. Immunotherapy for Crohn's – What's New and What Have We Learned? – 8<sup>th</sup> Annual Update in Gastroenterology: A Symposium for Gastroenterologists, Internists and Surgeons; Cedars-Sinai Medical Center Gastroenterology Symposium, La Quinta, CA 10/26/2007
44. GI Bleeding: UCLA Medical Student III Gastroenterology Block Case-Based Seminars, 6/23/2008
45. Titrating the IBD Patient – 9<sup>th</sup> Annual Update in Gastroenterology: A Symposium for Gastroenterologists, Internists and Surgeons; Cedars-Sinai Medical Center Gastroenterology Symposium, Lake Tahoe, CA 9/20/2008
46. Refractory Colitis – 9<sup>th</sup> Annual Update in Gastroenterology: A Symposium for Gastroenterologists, Internists and Surgeons; Cedars-Sinai Medical Center Gastroenterology Symposium, Lake Tahoe, CA 9/20/2008
47. Diarrhea: UCLA Medical Student III Gastroenterology Block Case-Based Seminars, 10/13/2008
48. Introduction to IBD Therapeutics: PhD Graduate Program Lecture Series, 1/16/2009
49. GI Bleeding: UCLA Medical Student III Gastroenterology Block Case-Based Seminars, 4/27/2009
50. Diarrhea: UCLA Medical Student III Gastroenterology Block Case-Based Seminars, 6/22/2009
51. Treatment Options in Refractory Ulcerative Colitis – 10<sup>th</sup> Annual Educational Meeting in Gastroenterology: A Symposium for Gastroenterologists, Internists and Surgeons; Cedars-Sinai Medical Center Gastroenterology Symposium, Santa Monica, CA 10/9/2009
52. Challenging Cases in IBD, A Panel Discussion – 10<sup>th</sup> Annual Educational Meeting in Gastroenterology: A Symposium for Gastroenterologists, Internists and Surgeons; Cedars-Sinai Medical Center Gastroenterology Symposium, Santa Monica, CA 10/9/2009
53. Diarrhea: UCLA Medical Student III Gastroenterology Block Case-Based Seminars, 10/12/2009
54. GI Bleeding: UCLA Medical Student III Gastroenterology Block Case-Based Seminars, 12/7/2009
55. GI Bleeding: UCLA Medical Student III Gastroenterology Block Case-Based Seminars, 6/21/2010
56. Diarrhea: UCLA Medical Student III Gastroenterology Block Case-Based Seminars, 12/6/2010
57. Combination Therapy in IBD: Who and When; 11<sup>th</sup> Annual Educational Meeting in Gastroenterology: A Symposium for Gastroenterologists, Internists and Surgeons; Cedars-Sinai Medical Center Gastroenterology Symposium, Los Angeles, CA 3/19/2011
58. Challenging Cases in IBD, A Panel Discussion; 11<sup>th</sup> Annual Educational Meeting in Gastroenterology: A Symposium for Gastroenterologists, Internists and Surgeons; Cedars-Sinai Medical Center Gastroenterology Symposium, Los Angeles, CA 3/19/2011

59. GI Bleeding: UCLA Medical Student III Gastroenterology Block Case-Based Seminars, 6/20/2011
60. Overview of IBD: IBD and GI Fellows & Residents Lecture, 7/7/2011
61. Medical Treatment Strategies in IBD: IBD and GI Fellows & Residents Lecture, 7/14/2011
62. Surgical & Post-operative Management Issues in IBD: IBD and GI Fellows & Residents Lecture, 8/4/2011
63. Diarrhea: UCLA Medical Student III Gastroenterology Block Case-Based Seminars, 10/17/2011
64. Therapeutic Options in IBD: GI Fellows, Residents, & Medical Student Lecture, 11/10/2011
65. Management of a Patient on Immunomodulators and Biologics; 12<sup>th</sup> Annual Educational Meeting in Gastroenterology: A Symposium for Gastroenterologists, Internists and Surgeons; Cedars-Sinai Medical Center Gastroenterology Symposium, Los Angeles, CA 3/9/2012
66. GI Bleeding: UCLA Medical Student III Gastroenterology Block Case-Based Seminars, 6/25/2012
67. Diarrhea: UCLA Medical Student III Gastroenterology Block Case-Based Seminars, 10/15/2012
68. Is There a Role for Immunomodulator Therapy in the Biologic Era? - 13<sup>th</sup> Annual Educational Meeting in Gastroenterology; Cedars-Sinai Medical Center Gastroenterology Symposium, Los Angeles, CA 3/2/2013
69. GI Bleeding: UCLA Medical Student III Gastroenterology Block Case-Based Seminars, 6/24/2013
70. Diarrhea: UCLA Medical Student III Gastroenterology Block Case-Based Seminars, 10/14/2013
71. IBD Potpourri: Genetics, Environment, Bugs, Diet, Antibiotics, Vitamin D, etc; 14<sup>th</sup> Annual Educational Meeting in Gastroenterology: A Symposium for Gastroenterologists, Internists and Surgeons; Cedars-Sinai Medical Center Gastroenterology Symposium, Los Angeles, CA 3/1/2014
72. GI Bleeding: UCLA Medical Student III Gastroenterology Block Case-Based Seminars, 6/23/2014
73. A Case Based Discussion on the Impact of Stress on Compliance in IBD: IBD Monthly Psycho-Social Seminar, 8/20/2014
74. Diarrhea: UCLA Medical Student III Gastroenterology Block Case-Based Seminars, 10/13/2014
75. A Case Based Discussion on the Impact of Stress on Compliance in IBD: IBD Monthly Psycho-Social Seminar, 8/20/2014
76. A Case Based Discussion on Stress in IBD: IBD Monthly Psycho-Social Seminar, 11/19/2014
77. Managing Difficult Psychosocial Issues in IBD; 15<sup>th</sup> Annual Educational Meeting in Gastroenterology: A Symposium for Gastroenterologists, Internists and Surgeons; Cedars-Sinai Medical Center Gastroenterology Symposium, Los Angeles, CA 3/6/2015
78. GI Bleeding: UCLA Medical Student III Gastroenterology Block Case-Based Seminars, 6/22/2015
79. Diet's Impact on IBD: The Beginning of a Paradigm Shift?; Gastroenterology Grand Rounds, Cedars-Sinai Medical Center, LA, CA 10/15/2015
80. Complementary and Alternative Medicine in Inflammatory Bowel Disease; 16<sup>th</sup> Annual Educational Meeting in Gastroenterology; Cedars-Sinai Medical Center Gastroenterology Symposium, Los Angeles, CA 3/4/2016
81. Counter-Transference: Is it a Problem or an Opportunity? A Case Based Discussion: IBD Monthly Psycho-Social Seminar, 4/20/2016

82. Therapeutic Nutrition in IBD; 17<sup>th</sup> Annual Educational Meeting in Gastroenterology; Cedars-Sinai Medical Center Gastroenterology Symposium, Los Angeles, CA 3/3/2017
83. GI Bleeding: UCLA Medical Student III Gastroenterology Block Case-Based Seminars, 4/24/2017
84. Microbiomes: Potential Healthcare Decisions and Practices Customized Just for You: 19<sup>th</sup> Annual Board of Governors HealthCare College Keynote Panel Presentation at Cedars-Sinai, Los Angeles, 5/9/2017
85. Quality of Life: Just what do we mean? A Case Based Discussion: IBD Monthly Psycho-Social Seminar, 5/17/2017
86. GI Bleeding: UCLA Medical Student III Gastroenterology Block Case-Based Seminars, 7/3/2017
87. Positioning & Optimizing "Traditional" Non-Biologic Medications in IBD: "Why We Do What We Do?"; CSMC IBD Fellows & Staff Core Lectures Series, Los Angeles, CA 9/21/2017
88. Beyond the Textbooks: Integrating, Positioning & Optimizing Non-Traditional "CAM" Strategies in IBD; CSMC IBD Fellows & Staff Core Lectures Series, Los Angeles, CA 11/30/2017
89. Diarrhea: UCLA Medical Student III Gastroenterology Block Case-Based Seminars, 1/8/2018
90. Diarrhea: UCLA Medical Student III Gastroenterology Block Case-Based Seminars, 2/26/2018
91. "Side Effects May Include... IBD Medication Risk Counseling"; 18<sup>th</sup> Annual Educational Meeting in Gastroenterology; Cedars-Sinai Medical Center Gastroenterology Symposium, Los Angeles, CA 3/2/2018
92. Beyond the Textbooks: Positioning & Optimizing 5ASAs & Thiopurines in 2018; CSMC IBD Fellows & Staff Core Lectures Series, Los Angeles, CA 9/20/2018
93. Methotrexate, Thalidomide, & Cyclosporine in IBD: Important Considerations & Practical Pearls; CSMC IBD Fellows & Staff Core Lectures Series, Los Angeles, CA 10/18/2018
94. Diarrhea: UCLA Medical Student III Gastroenterology Block Case-Based Seminars, 10/29/2018

**VISITING PROFESSOR FOR USC IBD CASE-BASED FELLOW'S CONFERENCE**

1. Traditional, Novel, Experimental, and Alternative Approaches to Managing IBD; University of Southern California (USC) GI Fellow's IBD Conference, LA, CA 10/18/2005
2. IBD Management: A Case History Approach; University of Southern California GI Fellow's Conference, LAC-USC Medical Center, Los Angeles, CA 10/16/2007
3. IBD Management: A Case History Approach; University of Southern California GI Fellow's Conference, LAC-USC Medical Center, Los Angeles, CA 4/15/2008
4. IBD Management: A Case History Approach; University of Southern California GI Fellow's Conference, LAC-USC Medical Center, Los Angeles, CA 10/21/2008
5. IBD Management: A Case History Approach; University of Southern California GI Fellow's Conference, LAC-USC Medical Center, Los Angeles, CA 4/21/2009
6. IBD Management: A Case History Approach; University of Southern California GI Fellow's Conference, LAC-USC Medical Center, Los Angeles, CA 12/15/2009
7. IBD Management: A Case History Approach; University of Southern California GI Fellow's Conference, LAC-USC Medical Center, Los Angeles, CA 6/15/2010
8. IBD Management: A Case History Approach; University of Southern California GI Fellow's Conference, LAC-USC Medical Center, Los Angeles, CA 10/19/2010
9. IBD Management: A Case History Approach; University of Southern California GI Fellow's Conference, LAC-USC Medical Center, Los Angeles, CA 8/23/2011
10. IBD Management: A Case History Approach; University of Southern California GI Fellow's Conference, LAC-USC Medical Center, Los Angeles, CA 4/21/2015
11. IBD Management: A Case History Approach; University of Southern California GI Fellow's Conference, LAC-USC Medical Center, Los Angeles, CA 10/8/2015
12. IBD Management: A Case History Approach; University of Southern California GI Fellow's Conference, LAC-USC Medical Center, Los Angeles, CA 3/20/2017

**INVITED COMMUNITY SERVICE-DIRECTED LECTURES / PRESENTATIONS:**

1. **"Setting the Foundations for Successful Mainstreaming"**; workshop presentation at the California Transcribers and Educators of the Visually Handicapped (CTEVH) 45th Annual Conference entitled "Going Strong at 45, Keeping Literacy Alive"; Los Angeles, CA 3/12/04
2. **"The Gift of Braille Literacy: A Gift that Truly Keeps on Giving"**; presentation at the National Federation of the Blind of California (NFBC) Braille symposium entitled "Braille: Transitioning Into a New Millennium"; Burbank, CA 10/1/04
3. **"You Can't Win the Game if you Don't Know the Rules"**; workshop presentation with Judith Lesner at the California Transcribers and Educators of the Visually Handicapped (CTEVH) 46th Annual Conference entitled "THE VIEW FROM HERE: Learning from the Past...Planning for the Future"; Burlingame, CA 3/5/05
4. **"An 'Access-It-Yourself' Resource Guide for Parents and Educators of Blind Children"**; workshop presentation at the California Transcribers and Educators of the Visually Handicapped (CTEVH) 46th Annual Conference entitled "THE VIEW FROM HERE: Learning from the Past...Planning for the Future"; Burlingame, CA 3/5/05
5. **"Creating Opportunities for Your Child to Learn About Their World via Tactual & Kinesthetic Experiences: a Parent's Perspective"**; A parent panelist presentation as part of the National Federation of the Blind of California (NFBC)-sponsored workshop panel presentation entitled "The Importance of Tactile Exploration by Blind and Visually Impaired Students" (Co-panelists: Nancy Burns & Dr. Stuart Wittenstein) at the California Transcribers and Educators of the Visually Handicapped (CTEVH) 46th Annual Conference entitled "The View for Here: Learning from the Past... Planning for the Future"; Burlingame, CA 3/5/05
6. **"Braille Literacy – It's a Family Value"**; presentation at the National Federation of the Blind of Louisiana (NFBL) & Louisiana Center for the Blind Educational Conference for Professionals & Parents of Blind Children entitled "From Cradle to Career - The ABCs of Blindness"; Metairie, LA 3/18/05
7. **"Braille Literacy: It's a Family Value – A Parent's Perspective on Early Braille Immersion with Concrete Suggestions for Providing a Braille-Rich Environment"**; presentation at the National Federation of the Blind of California (NFBC) Braille and the Braille Institute of America's symposium entitled "Braille: Progress, Play and Empowerment: A Hands-On Workshop for Educators and Parents of Blind and Visually Impaired Children" Los Angeles, CA; 11/4/05
8. **"More Than Six Dots & a Cell: A Parents Perspective on Foreign Language Braille, Expectations, Teamwork, & Parental Support"**; A parent panelist presentation as part of the panel presentation entitled "More Than Six Dots and a Cell: Forging the Teacher/Parent Partnership to Support Braille Literacy" (Co-panelists: Keith Christian & Annee Hartzell) at the National Federation of the Blind of California (NFBC) Braille and the Braille Institute of America's symposium entitled "Braille: Progress, Play and Empowerment: A Hands-On Workshop for Educators and Parents of Blind and Visually Impaired Children" Los Angeles, CA; 11/5/05
9. **"Technology: It's in Our Elementary Schools and It's Here to Stay"**; workshop presentation with co-presenter Vejas Vasiliauskas (3<sup>rd</sup>-grader) at the California Transcribers and Educators of the Visually Handicapped (CTEVH) 47th Annual Conference entitled "Focus on the Future: Preparing for Life"; Anaheim, CA 3/11/06

10. **"Braille Literacy – It's a Family Value: Concrete & Practical Suggestions for Providing a Braille-Rich Environment "**; presentation at the National Federation of the Blind of Louisiana (NFBL) & Louisiana Center for the Blind Educational Conference for Professionals & Parents of Blind Children entitled "Cradle to Career - The ABCs of Blindness"; Ruston, LA 4/7/06
11. **"Life as a Blind Third Grader"**; invited classroom presentation with co-presenter Vejas Vasiliauskas (3<sup>rd</sup>-grader) at St. Martin of Tours Elementary School, Los Angeles, CA 5/8/06
12. **"The Power of Knowledge"**; presentation at the National Federation of the Blind 2006 National Convention's National Organization of Parents of Blind Children (NOPBC)–sponsored symposium entitled "The Equation for Success 2006 Seminar for Parents and Teachers"; Dallas, TX 7/1/06
13. **"Braille Literacy: It's a Family Value Workshop"**; workshop presentation at the National Federation of the Blind 2006 National Convention's National Organization of Parents of Blind Children (NOPBC)–sponsored symposium entitled "The Equation for Success 2006 Seminar for Parents and Teachers"; Dallas, TX 7/1/06
14. **"An 'Access-It-Yourself' Resource Workshop for Parents & Educators of Blind Children"**; presentation at the National Federation of the Blind National Convention 2006; Dallas, TX 7/4/06
15. **"A Family Approach to Achieving Independence & Success: Living An "ICDX" (I Can Do It) Philosophy"**; Keynote speaker presentation at the California School for the Blind; Fremont, CA 8/28/06
16. **"We Can Play, Too!: Sports and Recreation for Blind Kids"**; panel presentation at the National Federation of the Blind of California State Convention 2006 "The Road to Independence: The Journey Continues"; Irvine, CA 10/14/06
17. **"Equal Expectations: A Belief Paradigm or Politically-Correct, Feel-Good Phrase?"**; Keynote speaker presentation at the California Transcribers and Educators of the Visually Handicapped (CTEVH) 48th Annual Conference entitled "Check Your Resources"; Santa Clara, CA 3/2/07
18. **"Letting Your Child's Wild Side Out"**; workshop presentation with Grace Tiscareno-Sato at the California Transcribers and Educators of the Visually Handicapped (CTEVH) 48th Annual Conference entitled "Check Your Resources"; Santa Clara, CA 3/3/07
19. **"Braille and Blindness Skills"**; Co-presentation with Vejas Vasiliauskas; Lions Clubs International District 4-L3 Membership Meeting Presentation.; Culver City, CA 3/17/2007
20. **"Sports, Fitness, & Recreation: A Father & Son Perspective"**; Co-presentation with Vejas Vasiliauskas at the Sports & Recreation Division Meeting entitled "Sports and Recreation: A Lifestyle": NFB National Convention; Atlanta, GA 7/2/2007
21. **"Letting Your Child's Wild Side Out"**; workshop presentation with Grace Tiscareno-Sato at the California Transcribers and Educators of the Visually Handicapped (CTEVH) 49th Annual Conference entitled "Ready to Go!"; Los Angeles, CA 3/1/08
22. **"Letting Your Child's Wild Side Out"**; workshop presentation with Grace Tiscareno-Sato at the National Federation of the Blind National Convention 2006; Dallas, TX 7/2/08
23. **"Braille Reading Rates"**; workshop presentation with Jerry Whittle at the National Federation of the Blind National Convention 2010; Dallas, TX 7/3/10.

24. **“The Failure of the Educational System In Meeting the Needs of the Blind”**; General Session panel presentation with Sheila Amato, Noreen Grice, and Laura Webber at the National Federation of the Blind National Convention 2010; Dallas, TX 7/7/10.
25. **“Integrating Digital Education & Traditional Braille Instruction: Addressing the Spectrum of Challenges”**; keynote presentation at the California Transcribers and Educators for the Blind and Visually Impaired (CTEBVI) 53rd Annual Conference entitled "Bridging the Gap"; Los Angeles, CA 3/16/12
26. **“Wake Up Call: The Era of Digital Education Has Arrived and is Coming to Your District Soon”**; workshop presentation at the California Transcribers and Educators for the Blind and Visually Impaired (CTEBVI) 53rd Annual Conference entitled "Bridging the Gap"; Los Angeles, CA 3/17/12
27. **“Tech Skills: The New Developmental Milestone of the 21<sup>st</sup> Century: Early Intervention Includes Fostering Little Techies”**; keynote presentation at the Lowenfeld-Akeson Early Years Symposium" entitled “Tech & Tablets: Tools for Tackling Tomorrow”; California School for the Blind in Fremont, CA 2/9/13
28. **“Encouraging Sports, Fitness, Recreation, & a Healthy Lifestyle: Beyond the Textbooks: A Father’s & Pediatrician’s Perspective”**; workshop presentation at the California Transcribers and Educators for the Blind and Visually Impaired (CTEBVI) 59th Annual Conference entitled "Developing Professionals"; Los Angeles, CA 3/13/18

**BIBLIOGRAPHY:****RESEARCH PAPERS - PEER REVIEWED**

1. Rosenthal P, Podesta L, Grier R, Said J, Sher L, Cocjin J, Watanabe F, Vasiliauskas E, Van de Velde R, Makowka L. Failure of liver transplantation to diminish cardiac deposits of amylopectin and leukocyte inclusions in type IV glycogen storage disease. **Liver Transplantation and Surgery** 1995, **1(6):373-376**.
2. Vasiliauskas EA, Plevy SE, Landers CJ, Binder SW, Ferguson DM, Yang HY, Rotter JI, Vidrich A, Targan SR. Perinuclear antineutrophil cytoplasmic antibodies (pANCA) in patients with Crohn's disease (CD) define a clinical subgroup. **Gastroenterology** 1996, **110(6):1810-1819**.
3. Uc A, Vasiliauskas E, Piccoli DA, Flores AF, Di Lorenzo C, Hyman PE. Chronic intestinal pseudoobstruction associated with fetal alcohol syndrome. **Dig Dis Sci** 1997, **42(6):1163-1167**.
4. Facklis K, Plevy SE, Vasiliauskas EA, Kam L, Taylor K, Targan SR, Fleshner PR. Crohn's disease-associated genetic marker is seen in medically unresponsive ulcerative colitis patients and may be associated with pouch-specific complications. **Dis Colon Rectum** 1999, **42(5):601-606**.
5. Rutgeerts P, D'Haens G, Targan S, Vasiliauskas E, Hanauer SB, Present DH, Mayer L, van Hogezaand RA, Braakman T, DeWoody KL, Schaible TF, van Deventer SJH. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. **Gastroenterology** 1999, **117(4):761-769**.
6. Vasiliauskas EA, Kam LY, Abreu-Martin MT, Hassard PV, Papadakis KA, Yang HY, Zeldis JB, Targan SR. An open-label pilot study of low-dose thalidomide in chronically-active, steroid-dependent Crohn's disease. **Gastroenterology** 1999, **117(6):1278-1287**.
7. Hassard PV, Vasiliauskas EA, Kam LY, Targan SR, Abreu-Martin MT. Efficacy of mycophenolate mofetil in patients failing 6-mercaptopurine or azathioprine therapy for Crohn's disease. **Inflamm Bowel Dis** 2000, **6(1):16-20**.
8. Rowe FA, Walker JH, Karp LC, Vasiliauskas EA, Plevy SE, Targan SR. Factors predictive of response to cyclosporin treatment for severe, steroid-resistant ulcerative colitis. **Am J Gastroenterol** 2000, **95(8):2000-2008**.
9. Vasiliauskas EA, Kam LY, Karp LC, Gaiennie J, Yang HY, Targan SR. Marker antibody expression stratifies Crohn's disease into immunologically homogeneous subgroups with distinct clinical characteristics. **Gut** 2000, **47(4):487-496**.
10. Hassard PV, Binder SW, Nelson V, Vasiliauskas EA. Anti-tumor necrosis factor monoclonal antibody therapy for gastrointestinal Behçet's disease: a case report. **Gastroenterology** 2001, **120(4):995-999**.
11. Papadakis KA, Tung JK, Binder SW, Kam LY, Abreu MT, Targan SR, Vasiliauskas EA. Outcome of cytomegalovirus (CMV) infections in patients with inflammatory bowel disease. **Am J Gastroenterol** 2001, **96(7):2137-2142**.
12. Dubinsky MC, Hassard PV, Seidman EG, Kam LY, Abreu MT, Targan SR, Vasiliauskas EA. An open-label pilot study using thioguanine as a therapeutic alternative in Crohn's disease patients resistant to 6-mercaptopurine therapy. **Inflamm Bowel Dis** 2001, **7(3):181-189**.



13. Fleshner PR, Vasiliauskas EA, Kam LY, Fleshner NE, Gaiennie J, Abreu-Martin MT, Targan SR. High level perinuclear antineutrophil cytoplasmic antibody (pANCA) in ulcerative colitis patients before colectomy predicts the development of chronic pouchitis after ileal pouch-anal anastomosis. **Gut** 2001, **49(5):671-677**.
14. Dubinsky MC, Yang HY, Hassard PV, Seidman EG, Kam LY, Abreu MT, Targan SR, Vasiliauskas EA. 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. **Gastroenterology** 2002, **122(4):904-915**.
15. Abreu MT, Taylor KD, Lin YC, Hang T, Gaiennie J, Landers CJ, Vasiliauskas EA, Kam LY, Rojany M, Papadakis KA, Rotter JI, Targan SR, Yang HY. Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn's disease. **Gastroenterology** 2002, **123(3): 679-688**.
16. Dubinsky MC, Feldman EJ, Abreu MT, Targan SR, Vasiliauskas EA. Thioguanine: a potential alternate thiopurine for IBD patients allergic to 6-mercaptopurine or azathioprine. **Am J Gastroenterol** 2003, **98(5):1058-63**.
17. Dubinsky MC, Vasiliauskas EA, Singh H, Abreu MT, Papadakis K, Tran T, Martin P, Vierling JM, Geller SA, Targan SR, Poordad FF. 6-thioguanine can cause serious liver injury in inflammatory bowel disease patients. **Gastroenterol** 2003, **125(2):298-303**.
18. Papadakis KA, Treyzon L, Abreu MT, Fleshner PR, Targan SR, Vasiliauskas EA. Infliximab in the treatment of medically refractory indeterminate colitis. **Aliment Pharmacol Ther** 2003, **18(7):741-747**.
19. Shastri S, Dubinsky MC, Poordad FF, Vasiliauskas EA, Geller SA. Early nodular hyperplasia of the liver occurring with inflammatory bowel diseases in association with thioguanine therapy. **Archs Pathol Lab Med** 2004, **128(1):49-53**.
20. Mow WS, Lo SK, Targan SR, Dubinsky MC, Treyzon L, Abreu-Martin MT, Papadakis KA, Vasiliauskas EA. Initial experience with wireless capsule enteroscopy in the diagnosis and management of inflammatory bowel disease. **Clin Gastroenterol Hepatol** 2004, **2(1):31-40**.
21. Mow WS, Vasiliauskas EA, Lin YC, Fleshner PR, Papadakis KA, Taylor KD, Landers CJ, Abreu-Martin MT, Rotter JI, Yang HY, Targan SR. Association of antibody responses to microbial antigens and complications of small bowel Crohn's disease. **Gastroenterol** 2004, **126(2):414-24**.
22. Mow WS, Abreu-Martin MT, Papadakis KA, Pitchon HE, Targan SR, Vasiliauskas EA. High incidence of anergy in inflammatory bowel disease patients limits the usefulness of PPD screening before infliximab therapy. **Clin Gastroenterol Hepatol** 2004, **2(4):309-13**.
23. Geller SA, Dubinsky MC, Poordad, FF, Vasiliauskas EA, Cohen AH, Abreu MT, Tran T, Martin P, Vierling JM, Targan SR. Early hepatic nodular hyperplasia and submicroscopic fibrosis associated with 6-thioguanine therapy in inflammatory bowel disease. **Am J Surg Pathol** 2004, **28(9):1204-1211**.
24. Youdim A, Vasiliauskas EA, Targan SR, Papadakis KA, Ippoliti A, Dubinsky MC, Lechago J, Paavola J, Loane J, Lee SK, Gaiennie J, Smith K, Do J, Abreu MT. Pilot study of adalimumab in infliximab-allergic patients. **Inflamm Bowel Dis** 2004, **10(4):333-338**.
25. Matuk R, Crawford J, Abreu MT, Targan SR, Vasiliauskas EA, Papadakis KA. The spectrum of gastrointestinal toxicity and effect on disease activity of selective cyclooxygenase-2 inhibitors in patients with inflammatory bowel disease. **Inflamm Bowel Dis** 2004, **10(4):352-356**.

26. Abreu MT, Kantorovich V, Vasiliauskas EA, Gruntmanis U, Matuk R, Daigle K, Chen S, Zehnder D, Lin YC, Yang HY, Hewison M, Adams JS. Measurement of vitamin D levels in inflammatory bowel disease patients reveals a subset of Crohn's disease patients with elevated 1,25-dihydroxyvitamin D and low bone mineral density. **GUT** 2004, **53(8):1129-1133**.
27. Papadakis KA, Shaye OA, Vasiliauskas EA, Ippoliti A, Dubinsky MC, Birt J, Paavola J, Lee SK, Price J, Targan SR, Abreu MT. Safety and efficacy of adalimumab (D2E7) in Crohn's disease patients with an attenuated response to infliximab. **Am J Gastroenterol** 2005, **100(1):75-79**.
28. Hui T, Landers C, Vasiliauskas E, Abreu-Martin M, Dubinsky M, Papadakis KA, Gaiennie J, Lin YC, Huiying Y, Targan S, Fleshner P. Serologic responses in indeterminate colitis patients before ileal pouch-anal anastomosis may determine those at risk for continuous pouch inflammation. **Dis Colon Rectum** 2005, **48(6):1254-62**.
29. Targan SR, Landers CJ, Yang H, Lodes MJ, Cong Y, Papadakis KA, Vasiliauskas E, Elson CO, Hershberg RM. Antibodies to CBir1 flagellin define a unique response that is associated independently with complicated Crohn's disease. **Gastroenterol** 2005, **128(7):2020-8**.
30. Abreu MT, Geller JL, Vasiliauskas EA, Kam LY, Vora P, Martyak LA, Yang H, Hu B, Lin YC, Keenan G, Price J, Landers CJ, Adams JS, Targan SR. Treatment with infliximab is associated with increased markers of bone formation in patients with Crohn's disease. **J Clin Gastroenterol** 2006, **40(1):55-63**.
31. Okon A, Dubinsky M, Vasiliauskas EA, Papadakis KA, Ippoliti A, Targan SR, Fleshner PR. Elevated platelet count before ileal pouch-anal anastomosis for ulcerative colitis is associated with the development of chronic pouchitis. **Am Surg** 2005, **71(10):821-6**.
32. Dubinsky MC, Lin Y-C, Dutridge D, Picornell Y, Landers CJ, Farrior S, Wrobel I, Antonio Quiros A, Vasiliauskas EA, Grill B, Israel D, Bahar R, Christie D, Wahbeh G, Silber G, Dallazadeh S, Shah P, Thomas D, Kelts D, Hershberg RM, Elson CO, Targan SR, Taylor KD, Rotter JI, Yang HY and the Western Regional Pediatric IBD Research Alliance. Serum immune responses predict rapid disease progression among children with Crohn's disease: immune responses predict disease progression. **Am J Gastroenterol** 2006, **101(2):360-7**.
33. Mei L, Targan SR, Landers CJ, Dutridge D, Ippoliti A, Vasiliauskas EA, Papadakis KA, Fleshner PR, Rotter JI, Yang H. Familial expression of anti-Escherichia coli outer membrane porin C in relatives of patients with Crohn's disease. **Gastroenterol** 2006, **130(4):1078-85**.
34. Melmed GY, Ippoliti AF, Papadakis KA, Tran TT, Birt JL, Lee SK, Frenck RW, Targan SR, Vasiliauskas EA. Patients with inflammatory bowel disease are at risk for vaccine-preventable illnesses. **Am J Gastroenterol** 2006, **101(8):1834-40**.
35. Vasiliauskas EA, Church JA, Silverman N, Barry M, Targan SR, Dubinsky MC. Case report: evidence for transplacental transfer of maternally administered infliximab to the newborn. **Clin Gastroenterol Hepatol** 2006, **4(10):1255-8**.
36. Spivak J, Landers CJ, Vasiliauskas EA, Abreu MT, Dubinsky MC, Papadakis KA, Ippoliti A, Targan SR, Fleshner PR. Antibodies to i2 predict clinical response to fecal diversion in Crohn's disease. **Inflamm Bowel Dis** 2006, **12(12):1122-30**.
37. Devlin SM, Yang H, Ippoliti A, Taylor KD, Landers CJ, Su X, Abreu MT, Papadakis KA, Vasiliauskas EA, Melmed GY, Fleshner PR, Mei L, Rotter JI, Targan SR. NOD2 variants and antibody response to microbial antigens in Crohn's disease patients and their unaffected relatives. **Gastroenterology** 2007, **132(2):576-86**.

38. Melmed GY, Elashoff R, Chen GC, Nastaskin I, Papadakis KA, Vasiliauskas EA, Liu W, Landers C, Ippoliti AF, Targan SR. Predicting a change in diagnosis from ulcerative colitis to Crohn's disease: a nested, case-control study. **Clin Gastroenterol Hepatol** 2007, **5(5):602-8**.
39. Papadakis KA, Yang H, Ippoliti A, Mei L, Elson CO, Hershberg RM, Vasiliauskas EA, Fleshner PR, Abreu MT, Taylor K, Landers CJ, Rotter JI, Targan SR. Anti-flagellin (CBir1) phenotypic and genetic Crohn's disease associations. **Inflamm Bowel Dis** 2007, **13(5):524-30**.
40. Shaye OA, Yadegari M, Abreu MT, Poordad F, Simon K, Martin P, Papadakis KA, Ippoliti A, Vasiliauskas E, Tran TT. Hepatotoxicity of 6-mercaptopurine (6-MP) and azathioprine (AZA) in adult IBD patients. **Am J Gastroenterol** 2007, **102:2488-94**.
41. Fleshner P, Ippoliti A, Dubinsky M, Ognibene S, Vasiliauskas E, Chelly M, Mei L, Papadakis KA, Landers C, Targan S. A prospective multivariate analysis of clinical factors associated with pouchitis after ileal pouch-anal anastomosis. **Clin Gastroenterol Hepatol** 2007, **5(8):952-8**.
42. Schluender SJ, Ippoliti A, Dubinsky M, Vasiliauskas EA, Papadakis KA, Mei L, Targan SR, Fleshner PR. Does infliximab influence surgical morbidity of ileal pouch-anal anastomosis in patients with ulcerative colitis? **Dis Colon Rectum** 2007, **50(11):1747-53**. (<http://springerlink.com/content/k535858366pk6303/fulltext.pdf>)
43. Mehdizadeh S, Chen G, Enayati PJ, Cheng DW, Han NJ, Shaye OA, Ippoliti A, Vasiliauskas EA, Lo SK, Papadakis KA. Diagnostic yield of capsule endoscopy in ulcerative colitis and inflammatory bowel disease of unclassified type (IBDU). **Endoscopy** 2008, **40(1):30-5**.
44. Melmed G, Fleshner PR, Bardakcioglu O, Ippoliti A, Vasiliauskas EA, Papadakis KA, Dubinsky M, Rotter J, Landers C, Targan SR. Family history and serology predict Crohn's disease after ileal pouch-anal anastomosis for ulcerative colitis. **Dis Colon Rectum** 2008, **51:100-8**. (<http://springerlink.com/content/m77518083u277743/fulltext.pdf>).
45. Fleshner P, Ippoliti A, Dubinsky M, Vasiliauskas E, Mei L, Papadakis KA, Rotter JI, Landers C, Targan S. Both Preoperative perinuclear antineutrophil cytoplasmic antibody and anti-CBir1 expression in ulcerative colitis patients influence pouchitis development after ileal pouch-anal anastomosis. **Clin Gastroenterol Hepatol** 2008, **6(5):561-8**.
46. Dubinsky MC, Kugathasan S, Mei L, Picornell Y, Nebel J, Wrobel I, Quiros A, Silber G, Wahbeh G, Katzir L, Vasiliauskas E, Bahar R, Otley A, Mack D, Evans J, Rosh J, Hemker MO, Leleiko N, Crandall W, Langton C, Landers C, Taylor KD, Targan SR, Rotter JI, Markowitz J, Hyams J; Western Regional Pediatric IBD Research Alliance, Pediatric IBD Collaborative Research Group, and The Wisconsin Pediatric IBD Alliance. Increased immune reactivity predicts aggressive complicating Crohn's disease in children. **Clin Gastroenterol Hepatol** 2008, **6(10):1105-11**.
47. Markowitz J, Kugathasan S, Dubinsky M, Mei L, Crandall W, Leleiko N, Oliva-Hemker M, Rosh J, Evans J, Mack D, Otley A, Pfefferkorn M, Bahar R, Vasiliauskas E, Wahbeh G, Silber G, Quiros JA, Wrobel I, Nebel J, Landers C, Picornell Y, Targan S, Lerer T, Hyams J. Age of diagnosis influences serologic responses in children with Crohn's disease: A possible clue to etiology? **Inflamm Bowel Dis** 2008, **15(5):714-19**. Published online 23 December 2008. ([www3.interscience.wiley.com/cgi-bin/fulltext/121582809/PDFSTART](http://www3.interscience.wiley.com/cgi-bin/fulltext/121582809/PDFSTART)).
48. McGovern DPB, Taylor KD, Landers C, Derkowski C, Dutridge D, Dubinsky M, Ippoliti A, Vasiliauskas E, Mei L, Mengesha E, King L, Pressman S, Targan SR, Rotter JI. MAGI2 genetic variation and inflammatory bowel disease. **Inflamm Bowel Dis** 2009, **15(1):75-83**. Published online August 21, 2008. ([www3.interscience.wiley.com/cgi-bin/fulltext/121384774/PDFSTART](http://www3.interscience.wiley.com/cgi-bin/fulltext/121384774/PDFSTART)).

49. Takedatsu H, Taylor KD, Mei L, McGovern DPB, Landers CJ, Gonsky R, Cong Y, Vasiliauskas EA, Ippoliti A, Elson CO, Rotter JI, Targan SR. Linkage of CD-related serological phenotypes: NFKB1 haplotypes are associated with anti-CBir1 & ASCA, and show reduced NF-kB activation. **GUT** 2009, **58(1):60-7**. Published online October 2, 2008. (<http://gut.bmj.com/cgi/rapidpdf/gut.2008.156422v1>).
50. Pimentel M, Hwang L, Melmed GY, Low K, Vasiliauskas E, Ippoliti A, Yang J, Lezcano S, Conklin JL, Sahakian A. New clinical method for distinguishing D-IBS from other gastrointestinal conditions causing diarrhea: the LA/IBS diagnostic strategy. New clinical method for distinguishing D-IBS from other gastrointestinal conditions causing diarrhea: the LA/IBS diagnostic strategy. **Dig Dis Sci** 2010, **55(1):145-9**. Published online January 24, 2009. ([www.springerlink.com/content/528q47hgk44741r1/fulltext.pdf](http://www.springerlink.com/content/528q47hgk44741r1/fulltext.pdf)).
51. Murrell ZA, Melmed GY, Ippoliti A, Vasiliauskas EA, Dubinsky M, Targan SR, Fleshner PR. A prospective evaluation of the long-term outcome of ileal pouch-anal anastomosis in patients with inflammatory bowel disease-unclassified and indeterminate colitis. **Dis Colon Rectum** 2009, **52(5):872-8**.
52. McGovern DP, Rotter JI, Mei L, Haritunians T, Landers C, Derkowski C, Dutridge D, Dubinsky M, Ippoliti A, Vasiliauskas E, Mengesha E, King L, Pressman S, Targan SR, Taylor KD. Genetic epistasis of IL23/IL17 pathway genes in Crohn's disease. **Inflamm Bowel Dis** 2009, **15(6):883-9**. Published online 23 February 2009. ([www3.interscience.wiley.com/cgi-bin/fulltext/122212937/PDFSTART](http://www3.interscience.wiley.com/cgi-bin/fulltext/122212937/PDFSTART)).
53. Markowitz J, Kugathasan S, Dubinsky M, Mei L, Crandall W, LeLeiko N, Oliva-Hemker M, Rosh J, Evans J, Mack D, Otley A, Pfefferkorn M, Bahar R, Vasiliauskas E, Wahbeh G, Silber G, Quiros JA, Wrobel I, Nebel J, Landers C, Picornell Y, Targan S, Lerer T, Hyams J. Age of diagnosis influences serologic responses in children with Crohn's disease: a possible clue to etiology? **Inflamm Bowel Dis** 2009, **15(5):714-9**. Published online December 23 2008 ([www3.interscience.wiley.com/cgi-bin/fulltext/121582809/PDFSTART](http://www3.interscience.wiley.com/cgi-bin/fulltext/121582809/PDFSTART)).
54. Ippoliti A, Devlin S, Mei L, Yang H, Papadakis KA, Vasiliauskas EA, McGovern DP, Abreu MT, Melmed G, Shaye O, Enayati P, Chen G, Choi J, Taylor K, Landers CJ, Rotter JI, Targan SR. Combination of innate and adaptive immune alterations increased the likelihood of fibrostenosis in Crohn's disease. **Inflamm Bowel Dis** 2010 Aug;**16(8):1279-85**. Published online December 21 2009. ([www3.interscience.wiley.com/cgi-bin/fulltext/123221621/PDFSTART](http://www3.interscience.wiley.com/cgi-bin/fulltext/123221621/PDFSTART))
55. Melmed GY, Agarwal N, Frenck RW, Ippoliti AF, Ibanez P, Papadakis KA, Simpson P, Barolet-Garcia C, Ward J, Targan SR, Vasiliauskas EA. Immunosuppression impairs response to pneumococcal polysaccharide vaccination in patients with inflammatory bowel disease. **Am J Gastroenterol** 2010, **105:148-54**. Published online September 15 2009. ([www.nature.com/ajg/journal/vaop/ncurrent/pdf/ajg2009523a.pdf](http://www.nature.com/ajg/journal/vaop/ncurrent/pdf/ajg2009523a.pdf)).
56. Murrell Z, Vasiliauskas E, Melmed G, Lo S, Targan S, Fleshner P. Preoperative wireless capsule endoscopy does not predict outcome after ileal pouch-anal anastomosis. **Dis Colon Rectum**, 2010 **53(3):293-300**.
57. Mehdizadeh S, Chen GC, Barkodar L, Enayati PJ, Pirouz S, Yadegari M, Ippoliti A, Vasiliauskas EA, Lo SK, Papadakis KA. Capsule endoscopy in patients with Crohn's disease: diagnostic yield and safety. **Gastrointest Endosc** 2010 **71(1):121-7**. Published online October 27 2009.

58. McGovern DP, Gardet A, Törkvist L, Goyette P, Essers J, Taylor KD, Neale BM, Ong RT, Lagacé C, Li C, Green T, Stevens CR, Beauchamp C, Fleshner PR, Carlson M, D'Amato M, Halfvarson J, Hibberd ML, Lördal M, Padyukov L, Andriulli A, Colombo E, Latiano A, Palmieri O, Bernard EJ, Deslandres C, Hommes DW, de Jong DJ, Stokkers PC, Weersma RK; NIDDK IBD Genetics Consortium, Sharma Y, Silverberg MS, Cho JH, Wu J, Roeder K, Brant SR, Schumm LP, Duerr RH, Dubinsky MC, Glazer NL, Haritunians T, Ippoliti A, Melmed GY, Siscovick DS, Vasiliauskas EA, Targan SR, Annese V, Wijmenga C, Pettersson S, Rotter JI, Xavier RJ, Daly MJ, Rioux JD, Seielstad M. Genome-wide association identifies multiple ulcerative colitis susceptibility loci. **Nat Genet** 2010 42(4):332-7. Published online Mar 14 2010. ([www.nature.com/ng/journal/v42/n4/pdf/ng.549.pdf](http://www.nature.com/ng/journal/v42/n4/pdf/ng.549.pdf)).
59. McGovern DPB, Jones MR, Taylor KD, Marcianti K, Yan X, Dubinsky M, Ippoliti A, Vasiliauskas E, Berel D, Derkowski C, Dutridge D, International IBD Genetics Consortium, Fleshner P, Shih DQ, Melmed G, Mengesha E, King L, Pressman S, Haritunians T, Guo X, Targan SR, Rotter JI. Fucosyltransferase 2 (FUT2) non-secretor status is associated with Crohn's disease. **Hum Mol Genet** 2010 19(17):3468-76. Published online June 22 2010. (<http://hmg.oxfordjournals.org/content/19/17/3468.full.pdf>).
60. Haritunians T, Taylor KD, Targan SR, Dubinsky M, Ippoliti A, Kwon S, Guo X, Melmed GY, Berel D, Mengesha E, Psaty BM, Glazer NL, Vasiliauskas EA, Rotter JI, Fleshner PR, McGovern DPB. Genetic predictors of medically refractory ulcerative colitis. **Inflamm Bowel Dis** 2010 16(11):1830-40. Published online May 18 2010. (<http://onlinelibrary.wiley.com/doi/10.1002/ibd.21293/pdf>).
61. White E, Melmed GY, Vasiliauskas EA, Dubinsky M, Berel D, Targan SR, Fleshner PR. A prospective analysis of clinical variables, serologic factors, and outcome of ileal pouch-anal anastomosis in patients with backwash ileitis. **Dis Colon Rectum** 2010 53(7):987-94.
62. Basseri RJ, Basseri B, Vassilaki ME, Melmed GY, Ippoliti A, Vasiliauskas EA, Fleshner PR, Lechago J, Hu B, Berel D, Targan SR, Papadakis KA. Colorectal cancer screening and surveillance in Crohn's colitis. **J Crohns Colitis** 2012 6(8):824-9. Published online Feb 5 2012.
63. White EC, Melmed GY, Vasiliauskas E, Dubinsky M, Ippoliti A, McGovern D, Targan S, Fleshner P. Does preoperative immunosuppression influence unplanned hospital readmission after surgery in patients with Crohn's disease? **Dis Colon Rectum** 2012 55(5):563-8. Published online March 29 2012.
64. Le Q, Melmed G, Dubinsky M, McGovern D, Vasiliauskas EA, Murrell Z, Ippoliti A, Shih D, Kaur M, Targan S, Fleshner P. Surgical outcome of ileal pouch-anal anastomosis when used intentionally for well-defined Crohn's disease. **Inflamm Bowel Dis** 2013 19(1):30-6. Published online Mar 29 2012.
65. Shih DQ, Nguyen M, Zheng L, Ibanez P, Mei L, Kwan LY, Bradford K, Ting C, Targan SR, Vasiliauskas EA. Split-dose administration of thiopurine drugs: a novel and effective strategy for managing preferential 6-MMP metabolism. **Aliment Pharmacol Ther** 2012 36(5):449-5. Published online July 11 2012.
66. Surti B, Spiegel B, Ippoliti A, Vasiliauskas EA, Simpson P, Shih DQ, Targan SR, McGovern DP, Melmed GY. Assessing Health Status in Inflammatory Bowel Disease Using a Novel Single-Item Numeric Rating Scale. **Dig Dis Sci** 2012. Published online Dec 19 2012.

67. Dubinsky MC, Kugathasan S, Kwon S, Haritunians T, Wrobel I, Wahbeh G, Quiros A, Bahar R, Silber G, Fariior S, Stephens M, Teleten N, Panikkath D, Ippoliti A, Vasiliauskas E, Fleshner P, Williams C, Landers C, Rotter JI, Targan SR, Taylor KD, McGovern DP. Multidimensional prognostic risk assessment identifies association between IL12B variation and surgery in Crohn's disease. **Inflamm Bowel Dis** 2013 Jul;**19(8):1662-70.**
68. Basseri B, Vasiliauskas EA, Chan O, Wang HL, Basseri RJ, Pimentel M, Soffer E, Conklin JL. Evaluation of peripapillary lymphocytosis and lymphocytic esophagitis in adult inflammatory bowel disease. **Gastroenterol Hepatol** 2013 Aug;**9(8):505-11.** ([www.ncbi.nlm.nih.gov/pmc/articles/PMC3980993/pdf/GH-09-505.pdf](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3980993/pdf/GH-09-505.pdf))
69. Weizman A, Huang H, Berel D, Targan SR, Dubinsky M, Fleshner P, Ippoliti A, Kaur M, Panikkath D, Brant SR, Oikonomou I, Duerr R, Rioux J, Silverberg M, Rotter JI, Vasiliauskas E, Haritunians T, Shih D, Li D, Melmed GY, McGovern. Clinical, serologic, and genetic factors associated with pyoderma gangrenosum and erythema nodosum in inflammatory bowel disease patients. **Inflamm Bowel Dis** 2014 Mar;**20(3):525-33.**
70. Horton HA, Dezfoli S, Berel D, J Hirsch J, Ippoliti A, McGovern D, Kaur M, Shih D, Dubinsky M, Targan SR, Fleshner P, Vasiliauskas EA, Grein J, Murthy R, Melmed GY. Antibiotics for the Treatment of Clostridium difficile Infection in Hospitalized Patients with Inflammatory Bowel Disease. **Antimicrob Agents Chemother** 2014 Sep;**58(9):5054-59.** Published online Jun 9, 2014. ([www.ncbi.nlm.nih.gov/pmc/articles/PMC4135854/pdf/zac5054.pdf](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4135854/pdf/zac5054.pdf))
71. Lau C, Dubinsky M, Melmed G, Vasiliauskas EA, Berel D, McGovern D, Ippoliti A, Shih D, Targan S, Fleshner P. The Impact of Preoperative Serum Anti-TNF $\alpha$  Therapy Levels on Early Postoperative Outcomes in Inflammatory Bowel Disease Surgery. **Ann Surg** 2014 Jun **19.** [Epub ahead of print]
72. Weizman AV, Huang B, Targan S, Dubinsky M, Fleshner P, Kaur M, Ippoliti A, Panikkath D, Vasiliauskas E, Shih D, McGovern DP, Melmed GY. Pyoderma Gangrenosum among Patients with Inflammatory Bowel Disease: A Descriptive Cohort Study. **J Cutan Med Surg** 2014 Oct;**18(5):361.**
73. Gerich ME, Yoon JL, Targan SR, Ippoliti AF, Vasiliauskas EA. Long-Term Outcomes of Thalidomide in Refractory Crohn's Disease. **Aliment Pharmacol Ther** 2015 Mar;**41(5):429-37.** Published online Dec 15, 2014. (<http://onlinelibrary.wiley.com/doi/10.1111/apt.13057/pdf>)
74. Dezfoli S, Henry HA, Thepyasuwan N, Berel D, Targan SR, Vasiliauskas EA, Dubinsky M, Shih DQ, McGovern DP, Ippoliti A, Feldman EJ, Melmed GY. Combined Immunosuppression Impairs Immunogenicity To Tetanus and Pertussis Vaccination Among Patients with Inflammatory Bowel Disease. **Inflamm Bowel Dis** 2015 Aug;**21(8):1754-60.** ([www.ncbi.nlm.nih.gov/pubmed/25985242](http://www.ncbi.nlm.nih.gov/pubmed/25985242))
75. Taleban S, Li D, Targan SR, Ippoliti A, Brant SR, Cho JH, Duerr RH, Rioux JD, Silverberg MS, Vasiliauskas EA, Rotter JI, Haritunians T, Shih DQ, Dubinsky M, Melmed GY, McGovern DP. Ocular Manifestations in Inflammatory Bowel Disease Are Associated with Other Extra-intestinal Manifestations, Gender, and Genes Implicated in Other Immune-related Traits. **J Crohns Colitis.** 2016 Jan;**10(1):43-9.**
76. Taleban S, Van Oijen MG, Vasiliauskas EA, Fleshner PR, Shen B, Ippoliti AF, Targan SR, Melmed GY. Colectomy with Permanent End Ileostomy Is More Cost-Effective than Ileal Pouch-Anal Anastomosis for Crohn's Colitis. **Dig Dis Sci.** 2016 Feb;**61(2):550-9.**

77. Ahmed S, Melmed G, McGovern D, Robbins LA, Shih D, Vasiliauskas E, Singh N, Rabidzadeh S, Ippoliti A, Targan S, Fleshner P. Nonbloody Diarrhea but Not Significant Weight Loss at Diagnosis Is Associated with the Development of Denovo Crohn's Disease After Ileal Pouch-anal Anastomosis for Ulcerative Colitis. **Inflamm Bowel Dis.** 2016 Mar;**22(3):654-61.**
78. Kaur M, Panikkath D, Yan X, Liu Z, Berel D, Li D, Vasiliauskas EA, Ippoliti A, Dubinsky M, Shih DQ, Melmed GY, Haritunians T, Fleshner P, Targan SR, McGovern DP. Perianal Crohn's Disease is Associated with Distal Colonic Disease, Strictureing Disease Behavior, IBD-Associated Serologies and Genetic Variation in the JAK-STAT Pathway. **Inflamm Bowel Dis.** 2016 Apr;**22(4):862-9.**
79. Robbins L, Zaghiyan K, Melmed G, Vasiliauskas E, Ahmed S, McGovern D, Rabizadeh S, Singh N, Landers C, Ippoliti A, Shih D, Targan S, Fleshner P. Outcomes with Anti-Tumor Necrosis Factor-Alpha Therapy and Serology in Patients with denovo Crohn's Disease after Ileal Pouch Anal Anastomosis. **J Crohns Colitis.** 2016 Jul 27. pii: jjw134. [Epub ahead of print]
80. Yoon SM, Haritunians T, Chhina S, Liu Z, Yang S, Landers C, Li D, Ye BD, Shih S, Vasiliauskas EA, Ippoliti A, Rabizadeh S, Targan S, Melmed GY, McGovern DPB. Colonic Phenotypes Are Associated with Poorer Response to Anti-TNF Therapies in Patients with IBD. **Inflamm Bowel Dis** 2017 Aug;**23(8):1382-1393.**
81. Gu P, Kapur A, Li D, Haritunians T, Vasiliauskas E, Shih DQ, Targan SR, Spiegel BM, McGovern DP, Black JT, Melmed GY. Serological, genetic and clinical associations with increased health-care resource utilization in inflammatory bowel disease. **J Dig Dis.** 2018 Jan;**19(1):15-23.**
82. Momozawa Y, Dmitrieva J, Théâtre E, Deffontaine V, Rahmouni S, Charlotiaux B, Crins F, Docampo E, Elansary M, Gori AS, Lecut C, Mariman R, Mni M, Oury C, Altukhov I, Alexeev D, Aulchenko Y, Amininejad L, Bouma G, Hoentjen F, Löwenberg M, Oldenburg B, Pierik MJ, Vander Meulen-de Jong AE, Janneke van der Woude C, Visschedijk MC; International IBD Genetics Consortium, Lathrop M, Hugot JP, Weersma RK, De Vos M, Franchimont D, Vermeire S, Kubo M, Louis E, Georges M. Collaborators (160): Abraham C, Achkar JP, Ahmad T, Ananthakrishnan AN, Andersen V, Anderson CA, Andrews JM, Annese V, Aumais G, Baidoo L, Baldassano RN, Bampton PA, Barclay M, Barrett JC, Bayless TM, Bethge J, Bitton A, Boucher G, Brand S, Brandt B, Brant SR, Büning C, Chew A, Cho JH, Cleynen I, Cohain A, Croft A, Daly MJ, D'Amato M, Danese S, Jong D, Denapiene G, Denson LA, Devaney KL, Dewit O, D'Inca R, Dubinsky M, Duerr RH, Edwards C, Ellinghaus D, Essers J, Ferguson LR, Festen EA, Fleshner P, Florin T, Franke A, Fransen K, Gearry R, Gieger C, Glas J, Goyette P, Green T, Griffiths AM, Guthery SL, Hakonarson H, Halfvarson J, Hanigan K, Haritunians T, Hart A, Hawkey C, Hayward NK, Hedl M, Henderson P, Hu X, Huang H, Hui KY, Imielinski M, Ippoliti A, Jonaitis L, Jostins L, Karlsten TH, Kennedy NA, Khan MA, Kiudelis G, Krishnaprasad K, Kugathasan S, Kupcinskas L, Latiano A, Laukens D, Lawrance IC, Lee JC, Lees CW, Leja M, Limbergen JV, Lionetti P, Liu JZ, Mahy G, Mansfield J, Massey D, Mathew CG, McGovern DPB, Milgrom R, Mitrovic M, Montgomery GW, Mowat C, Newman W, Ng A, Ng SC, Ng SME, Nikolaus S, Ning K, Nöthen M, Oikonomou I, Palmieri O, Parkes M, Phillips A, Ponsioen CY, Potocnik U, Prescott NJ, Proctor DD, Radford-Smith G, Rahier JF, Raychaudhuri S, Regueiro M, Rieder F, Rioux JD, Ripke S, Roberts R, Russell RK, Sanderson JD, Sans M, Satsangi J, Schadt EE, Schreiber S, Schulte D, Schumm LP, Scott R, Seielstad M, Sharma Y, Silverberg MS, Simms LA, Skieceviciene J, Spain SL, Steinhart AH, Stempak JM, Stronati L, Sventoraityte J, Targan SR, Taylor KM, Ter Velde A, Torkvist L, Tremelling M, Sommeren SV, Vasiliauskas E, Verspaget HW, Walters T, Wang K, Wang MH, Wei Z, Whiteman D, Wijmenga C, Wilson DC, Winkelmann J, Xavier RJ, Zhang B, Zhang CK, Zhang H, Zhang W, Zhao H, Zhao ZZ. IBD risk loci are enriched in multigenic

regulatory modules encompassing putative causative genes. **Nat Commun.** 2018 Jun 21;9(1):2427. Published online 2018 Jun 21.

83. Lee CK, Melmed GY, Mann A, Danovitch I, Hedrick R, McGovern DPB, Targan S, Shih D, Vasiliauskas E, IsHak WW, Feldman E. A Multidisciplinary Approach to Biopsychosocial Care for Adults With Inflammatory Bowel Disease: A Pilot Study. **Inflamm Bowel Dis.** 2018 Jun 15. [Epub ahead of print]



**BOOK CHAPTERS**

1. Di Lorenzo C and Vasiliauskas E. Gastrointestinal bleeding. In: Berkowitz CD, ed. Pediatrics-a primary care approach. Philadelphia, PA: WB Saunders, 1996:339-344.
2. Di Lorenzo C and Vasiliauskas E. Gastrointestinal bleeding. In: Berkowitz CD, ed. Pediatrics-a primary care approach. 2<sup>nd</sup> edition. Philadelphia, PA: WB Saunders, 2000:400-405.
3. Kam LY and Vasiliauskas E. New diagnostic approaches in inflammatory bowel disease. In: Targan SR, Shanahan F, Karp LC, eds. Inflammatory bowel disease: from bench to bedside. 2<sup>nd</sup> edition. Great Britain: Kluwer Academic Publishers, 2003:409-429.
4. Vasiliauskas E and Dubinsky M. Laboratory Testing in Inflammatory Bowel Disease. In: Oliva-Hemker M, Ziring D, Bousvaros, eds. A Your Child with Inflammatory Bowel Disease: A Family Guide for Caregiving. The NASPGHAN IBD Book for Families. 1<sup>st</sup> edition. Baltimore, MD. The Johns Hopkins University Press, 2010.
5. Vasiliauskas E. Gastrointestinal Behçet's Disease. In: Bayless TM, Hanauer SB, eds. Advanced Therapy in Inflammatory Bowel Disease. 3<sup>rd</sup> edition, Volume II: IBD and Crohn's Disease. Shelton, CT: People's Medical Publishing House-USA, 2011:1009-1020.
6. Vasiliauskas E. Complementary and Alternative Therapies. In: Oliva-Hemker M, Ziring D, Saeed S, Bousvaros A, eds. Your Child with Inflammatory Bowel Disease: A Family Guide for Caregiving. The NASPGHAN IBD Book for Families. 2<sup>nd</sup> edition. Baltimore, MD. The Johns Hopkins University Press, 2017.

**LETTERS TO THE EDITOR**

1. Vasiliauskas EA, Targan SR. Do pANCA define a clinical subgroup in patients with Crohn's disease? **Gastroenterology** 1997, **112**:316-317.
2. Dubinsky MC, Vasiliauskas EA, Targan SR, Poordad FF. Reply to Klaus R. Herrlinger, Matthias Schwab, Klaus Fellermann, Eduard F. Stange. 6-Thioguanine-Buried Alive? **Gastroenterol** 2004, **126**(3):940-42.
3. Papadakis KA, Matuk R, Abreu MT, Vasiliauskas EA, Fleshner PR, Lechago J, Tran T, Poordad FF, Martin P, Vierling J, Targan SR. Crohn's ileitis after liver transplantation from a living related donor with Crohn's disease. **GUT** 2004, **53**(9):1389-1390.
4. Gerich M, Yoon J, Vasiliauskas E. Reply to Authors' reply to Editorial: is thalidomide a good option for patients with refractory Crohn's disease? **Aliment Pharmacol Ther** 2015 Apr;**41**(8):786.

**INVITED REVIEWS**

1. Vasiliauskas EA. Monoclonal antibody therapy in inflammatory bowel disease. In: Bistran BR and Walker-Smith JA, eds. "Inflammatory Bowel Diseases": Nestlé Nutrition Workshop Series Clinical & Performance Programme; Nestec Ltd., Vevey/S. Karger AG Basel, 1999;2;237-255.
2. Vasiliauskas EA. Pediatric inflammatory bowel disease. **Curr Treat Options Gastroenterol 2000, 3(5):403-425.**
3. Hassard PV and Vasiliauskas EA. "Infliximab-dependent" Crohn's disease. **Clinical Lessons in the Diagnosis & Management of Inflammatory Bowel Disease 2000, 1(1):6-9.**
4. Abreu MT, Vasiliauskas EA, Kam LY, Dubinsky MC. Use of serologic tests in Crohn's Disease. **Clin Perspectives in Gastroenterology 2001:155-164.**
5. Vasiliauskas EA. Use of antibody expression for stratification of IBD. **Innovations: Tackling IBD in the 21<sup>st</sup> Century 2000:29-31.**
6. Vasiliauskas EA. Recent advances in classification and diagnosis of IBD. **Current Gastroenterology Reports 2003, 5(6):493-500.**

**OTHER PUBLICATIONS**

1. Vasiliauskas E and Rosenthal P. Is acute fatty liver of pregnancy a metabolic defect? **Am J Gastroenterol 1994, 89(10):1908-1910.**
2. Vasiliauskas E. Serum immune markers in inflammatory bowel disease. **Gastroenterology & Endoscopy News 1997, October:35-37.**
3. Vasiliauskas E. Serologic testing in inflammatory bowel disease. **Gastroenterology & Hepatology 2005, September, 1(2):84-93.**
4. Vasiliauskas EA. Immunization Issues in Patients with IBD. **Advances in Digestive Disorders 2008, September.**
5. Shih DQ, Nguyen M, Vasiliauskas EA. Split-Dose of 6MP/Azathioprine to Manage IBD Patients with Preferential 6MMP Metabolism. **Advances in Digestive Disorders 2010, January.**

**COMMUNITY-FOCUSED PUBLICATIONS:**

1. Vasiliauskas E. **Braille Literacy -- It's A Family Value.** Web-published in the *Voice of the Nation's Blind*, the internet journal of the National Federation of the Blind (NFB); December 2005 ([www.nfb.org/nfb/NewsBot.asp?MODE=VIEW&ID=61&SnID=44365653](http://www.nfb.org/nfb/NewsBot.asp?MODE=VIEW&ID=61&SnID=44365653)).
2. Vasiliauskas E. **Educating the World, One Reporter at a Time.** *Braille Monitor* 2006, February, Volume 49, No. 2: 95-100 ([www.nfb.org/Images/nfb/Publications/bm/bm06/bm0602/bm060205.htm](http://www.nfb.org/Images/nfb/Publications/bm/bm06/bm0602/bm060205.htm)).
3. Vasiliauskas E. **Braille Literacy -- It's A Family Value.** *NFBC Journal* (National Federation of the Blind of California) 2005, Fall/Winter: 5-11.
4. Vasiliauskas E. **Braille Literacy -- It's A Family Value.** *CTEVH JOURNAL* (California Transcribers and Educators of the Visually Handicapped), Winter 2005-06, Volume XLVIII, No. 4: 13-23 ([www.ctevh.org/journals/CTEVH%20winter%2005-06.pdf](http://www.ctevh.org/journals/CTEVH%20winter%2005-06.pdf)).
5. Vasiliauskas E. **Power of Knowledge.** *Future Reflections* 2007, Volume 25, No. 4: 26-30. ([www.nfb.org/Images/nfb/Publications/fr/fr24/fr06win10.htm](http://www.nfb.org/Images/nfb/Publications/fr/fr24/fr06win10.htm)); Editor's introduction page 4. ([www.nfb.org/Images/nfb/Publications/fr/fr24/fr06win03.htm](http://www.nfb.org/Images/nfb/Publications/fr/fr24/fr06win03.htm)).
6. Vasiliauskas E. **Power of Knowledge.** *Braille Monitor* 2007 March Volume 50, No. 3: 186-193. ([www.nfb.org/Images/nfb/Publications/bm/bm07/bm0703/bm070310.htm](http://www.nfb.org/Images/nfb/Publications/bm/bm07/bm0703/bm070310.htm)); (MP3: [www.nfb.org/images/nfb/Audio/Braille\\_Monitor/2007/March/The\\_Power\\_of\\_Knowledge.mp3](http://www.nfb.org/images/nfb/Audio/Braille_Monitor/2007/March/The_Power_of_Knowledge.mp3)).
7. Cheadle B. and Vasiliauskas E. **Forging Trust and Effective Parent Partnerships: Vital Ingredients for the Success of Blind Children.** D.V.I. Quarterly (Division on Visual Impairments: a division of the Council for Exceptional Children [CEC]) Spring 2007 "Special Issue: Partnering with Parents", Volume 52, No. 3: 25-28. ([www.cecdvi.org/DVIOQ/Full%20Issues/DVIOQ\\_Spring\\_2007\\_\(1\).pdf](http://www.cecdvi.org/DVIOQ/Full%20Issues/DVIOQ_Spring_2007_(1).pdf))
8. Vasiliauskas E. **So Dad, When Can I Go Surfing?** *Future Reflections* 2007 "Special Issue: Sports, Fitness, and Blindness", Volume 26, No. 2: 2-6. ([www.nfb.org/images/nfb/Publications/fr/fr26/Issue2/fr07sum02.htm](http://www.nfb.org/images/nfb/Publications/fr/fr26/Issue2/fr07sum02.htm)).
9. Vasiliauskas E. **Equal Expectations: A Belief Paradigm or Politically-Correct, Feel-Good Phrase?** *Future Reflections* 2008, Volume 27, No. 1: 22-35. ([www.nfb.org/images/nfb/Publications/fr/fr27/1/fr270107.htm](http://www.nfb.org/images/nfb/Publications/fr/fr27/1/fr270107.htm)).
10. Vasiliauskas E. **Enriching Your Blind Child's Life via Foreign Language Braille: Practical Suggestions for Families and Educators Seeking Out Foreign Language Braille and Other Foreign Language Resources with a Special Focus on Spanish.** *Google Knol web-publication* 2009 (<http://knol.google.com/k/eric-vasiliauskas-md-drv/enriching-your-blind-childs-life-via/2fo8us37li3cv/1#>).
11. Vasiliauskas E. **Enriching Your Child's Life with Foreign Language Braille: Practical Suggestions for Families and Educators, with a Special Focus on Spanish.** *Future Reflections* 2009, Volume 28, No. 2: 26-30. ([www.nfb.org/images/nfb/Publications/fr/fr28/fr2/fr280207.htm](http://www.nfb.org/images/nfb/Publications/fr/fr28/fr2/fr280207.htm)).
12. Amato S, Grice N, Webber L, Vasiliauskas E. **The Failure of the Educational System In Meeting the Needs of the Blind.** *Braille Monitor* 2010, Volume 53, No. 9 26-30. ([www.nfb.org/images/nfb/Publications/bm/bm10/bm1009/bm100902.htm](http://www.nfb.org/images/nfb/Publications/bm/bm10/bm1009/bm100902.htm)).
13. Vasiliauskas E. **Equal and Appropriate Expectations: Challenges in Education.** *Future Reflections* 2011, Volume 30, No. 1: 22-35. ([www.nfb.org/images/nfb/Publications/fr/fr30/1/fr300101.htm](http://www.nfb.org/images/nfb/Publications/fr/fr30/1/fr300101.htm)).

14. Vasiliauskas E. **Tandem Surfboarding Brothers.** *Braille Monitor* 2011, Volume 54, No. 11 26-30 ([www.nfb.org/images/nfb/Publications/bm/bm11/bm1111/bm111108.htm](http://www.nfb.org/images/nfb/Publications/bm/bm11/bm1111/bm111108.htm)).
15. Vasiliauskas E. **Ensuring that Blind Children Can Swim in the Mainstream Demands Concerted Action.** *Braille Monitor* 2012, Volume 55, No. 2 22-35. ([www.nfb.org/images/nfb/Publications/bm/bm12/bm1202/bm120206.htm](http://www.nfb.org/images/nfb/Publications/bm/bm12/bm1202/bm120206.htm)).
16. Vasiliauskas E. **Lithuanian Braille: Connecting the Dots with Our Heritage.** Lithuanian Foundation 50th Anniversary Contest “LIETUVA, AŠ TURIU TAVE – LITHUANIA, YOU ARE MINE!” 1<sup>st</sup> Place Winner. ([www.lithuanianfoundation.org/lithuanian-foundation-50th-anniversary-contest](http://www.lithuanianfoundation.org/lithuanian-foundation-50th-anniversary-contest) & [www.draugas.org/legacy/Lithuanian\\_Braille\\_Vasiliauskas\\_2011.pdf](http://www.draugas.org/legacy/Lithuanian_Braille_Vasiliauskas_2011.pdf)).
17. Vasiliauskas E. **Lithuanian Braille: Connecting the Dots with Our Heritage.** *Bridges: Lithuanian American News Journal* 2012, July/August 10-16. ([www.lithuanian-american.org/m/wp-content/uploads/pubs-bridges/publications-bridges-201207.pdf](http://www.lithuanian-american.org/m/wp-content/uploads/pubs-bridges/publications-bridges-201207.pdf)).
18. Vasiliauskas E. **Lietuviškas Brailio raštas: taškėliai, jungiantys vaikus su jų istorija.** *Draugas, The Lithuanian World-Wide Daily Newspaper* July 14, 2012. ([www.draugas.org/legacy/07-14-12vasiliauskas.lietuviskasbrailiorastas.html](http://www.draugas.org/legacy/07-14-12vasiliauskas.lietuviskasbrailiorastas.html))
19. Vasiliauskas E. **Here Today, Gone Tomorrow: The Day the Lights Went Out.** In: Maneki S ed. *Integrating Print and Braille: A Recipe for Literacy.* Baltimore, MD: National Federation of the Blind, 2012: in book conclusion. (<https://nfb.org/images/nfb/publications/books/integrating-print-braille/integratingprintandbrailleconclusion.html> & [http://nfb.org/images/nfb/documents/epub/final\\_integrating\\_print\\_and\\_braille.epub](http://nfb.org/images/nfb/documents/epub/final_integrating_print_and_braille.epub)).
20. Vasiliauskas E. **A Parents Perspective in the chapter "Let's Hear from the Experts" In: *iOS Success: Making the iPad Accessible: A Guide for Teachers and Parents*, by Larry L. Lewis National Braille Press Inc. (2013)**
21. Vasiliauskas E. **Integrating Digital Education and Traditional Braille Instruction: Addressing the Spectrum of Challenges (Epilogue) *CTEBVI JOURNAL*** (California Transcribers and Educators of the Blind & Visually Impaired), Spring 2013, Volume LV, No. 1: 27-28 ([www.ctebvi.org/journals/Spring2013.doc](http://www.ctebvi.org/journals/Spring2013.doc))

**ABSTRACTS PRESENTED**

1. Vasiliauskas E, Piccoli DA, Flores AF, Di Lorenzo C, Hyman PE. Chronic intestinal pseudo-obstruction in fetal alcohol syndrome. Poster presentation at the North American Society for Pediatric Gastroenterology and Nutrition, 1993.
2. Vasiliauskas E, Piccoli DA, Flores AF, Di Lorenzo C, Hyman PE. Chronic intestinal pseudo-obstruction in fetal alcohol syndrome. **Gastroenterology 1994;106(4):A637**. Poster presentation at the American Gastroenterological Association, 1994.
3. Vasiliauskas EA, Vanderhal AL, Rosenthal P. Transcutaneous bilirubinometry affords a non-invasive longitudinal measure of serum bilirubin in cholestatic infants. **Pediatr Res 1995;37(4):242A(#1439)**. Poster presentation at the American Pediatric Society - Society for Pediatric Research, 1995.
4. Vasiliauskas EA, Plevy SE, Ferguson DM, Vidrich A, Landers C, Targan SR. Perinuclear antineutrophil cytoplasmic antibodies (pANCA) in patients with Crohn's disease (CD) define a clinical subgroup. **Gastroenterology 1995;108(4):A935**. Oral presentation at the American Gastroenterological Association, 1995.
5. Vasiliauskas EA, Cobb L, Vidrich A, Targan SR, Rosenthal P. Biliary atresia - an autoimmune disorder? **J Pediatr Gastroenterol Nutr 1995;21(3):327(A#14)**. Poster presentation at the North American Society for Pediatric Gastroenterology and Nutrition, 1995.
6. Vasiliauskas EA, Targan SR, Cobb L, Vidrich A, Rosenthal P. Biliary atresia - an autoimmune mediated disorder? **Hepatology 1995;22(4):128A(A#87)**. Poster presentation at the American Association for the Study of Liver Diseases, 1995.
7. Abreu-Martin MT, Vasiliauskas EA, Gaiennie J, Voigt B, Targan SR. Continuous infusion cyclosporine (CSA) is effective for severe acute Crohn's disease (CD)...but for how long? **Gastroenterology 1996;110(4):A851**. Poster presentation at the American Gastroenterological Association, 1996.
8. Yang H, Plevy SE, Landers CJ, Vasiliauskas EA, Beaudet A, Rotter JI, Targan SR. The R241 allele of ICAM-1 is associated with a distinct clinical subgroup of Crohn's disease (CD) characterized by *perinuclear* ANCA (pANCA) production. **Gastroenterology 1996;110(4):A1049**. Oral presentation at the American Gastroenterological Association, 1996.
9. Plevy SE, Landers CJ, Vasiliauskas EA, Targan SR, Vidrich A. Alterations in serum immunoglobulin (Ig) G subclasses provide evidence for distinct immune responses in pANCA positive Crohn's disease patients. **Gastroenterology 1996;110(4):A993**. Poster presentation at the American Gastroenterological Association, 1996.
10. Vasiliauskas EA, Plevy SE, Targan SR. Stratification of Crohn's disease by antineutrophil cytoplasmic antibodies (ANCA) & anti-*Saccharomyces cerevisiae* antibody (ASCA) distinguishes phenotypic subgroups. **Gastroenterology 1997;112(4):A1112**. President's Plenary Poster presentation at the American Gastroenterological Association, 1997.
11. Plevy SE, Vasiliauskas EA, Taylor K, Gaiennie J, Kramer R, Fleshner PR, Yang H, Rotter JI, Targan SR. The Crohn's disease associated tumor necrosis factor (TNF) microsatellite a2b1c2d4e1 haplotype and anti-*Saccharomyces cerevisiae* antibody (ASCA) define medically resistant forms of ulcerative colitis. **Gastroenterology 1997;112(4):A1062**. Oral presentation at the American Gastroenterological Association, 1997.

12. Rowe FA, Vasiliauskas EA, Plevy SE, Targan SR. Admit clinical and laboratory parameters are associated with clinical outcome in steroid resistant chronic ulcerative colitis (CUC) requiring cyclosporine-A (CSA). **Gastroenterology** 1997;**112(4):A1077**. Poster presentation at the American Gastroenterological Association, 1997.
13. Facklis K, Plevy SE, Vasiliauskas EA, Taylor K, Targan SR, Fleshner PR. A Crohn's disease associated genetic marker is seen in medically unresponsive ulcerative colitis and may be associated with pouch-specific complications. **Dis Colon Rectum** 1997;**40(6):A15(#41)**. Oral presentation at the American Society of Colon and Rectal Surgeons, 1997.
14. EA Vasiliauskas, L Kam, J Gaiennie, SR Targan. Early onset Crohn's Disease (CD) differs from late adult onset CD - Immunologic evidence. **J Pediatr Gastroenterol Nutr** 1998;**27(4):471(A#33)**. Poster presentation at the North American Society for Pediatric Gastroenterology and Nutrition, 1998.
15. Vasiliauskas EA, Kam LY, Abreu-Martin MT, Papadakis KA, Zeldis JB, Targan SR. An open-label, stepwise dose-escalating pilot study to evaluate the safety, tolerance, & efficacy of low-dose thalidomide in the treatment of chronically-active, steroid-dependent Crohn's disease (CD). **Gastroenterology** 1999;**116(4):A837(#G3637)**. Oral presentation at the American Gastroenterological Association, 1999.
16. Vasiliauskas EA, Thomas DW, Schaffer S, Marshall WF Jr, Targan SR. Collaborative experience of open-label anti-TNF $\alpha$  chimeric monoclonal antibody, Remicade<sup>TM</sup>, in pediatric patients with refractory Crohn's Disease. **Gastroenterology** 1999;**116(4):A584(#G2559)**. Oral presentation at the American Gastroenterological Association, 1999.
17. Baldassano R, Vasiliauskas EA, Braegger C, Sinaasappel M, Escher J, Wagner C, DeWoody K, Livingston R, Ferry G, Kirshner B, Keller K, Turck D, Hadigan C, Winter H. A multicenter study of anti-TNF $\alpha$  chimeric monoclonal antibody (infliximab) in the treatment of pediatric patients with active Crohn's disease. **Gastroenterology** 1999;**116(4):A665(#G2903)**. Oral presentation at the American Gastroenterological Association, 1999.
18. Kam L, Vasiliauskas EA, Landers CJ, Targan SR. Magnitude of response to Remicade<sup>TM</sup> correlates with marker antibody expression. **Gastroenterology** 1999;**116(4):A744(#G3232)**. Poster presentation at the American Gastroenterological Association, 1999.
19. Vasiliauskas E, Targan S, Sands B, Hanauer S, Mayer L, Present D, Braakman T, DeWoody K, Schaible T, Rutgeerts P, van Deventer S. Consistency of treatment benefit with Infliximab in patients with moderate-to-severe active Crohn's disease. **Gastroenterology** 1999;**116(4):A837(#G3636)**. Poster presentation at the American Gastroenterological Association, 1999.
20. Fleshner PR, Vasiliauskas EA, Kam L, Abreu M, Targan SR. High level perinuclear antineutrophil cytoplasmic antibody (pANCA) in ulcerative colitis patients before colectomy predicts the development of chronic pouchitis after ileal pouch anal anastomosis. **Gastroenterology** 1999;**116(4):A716(#G3107)**. Oral presentation at the American Gastroenterological Association, 1999.
21. Hassard P, Vasiliauskas EA, Kam LY, Targan SR, Abreu-Martin MT. Limited benefit of mycophenolate mofetil (MMF) for the treatment of severe refractory Crohn's disease (CD). **Gastroenterology** 1999;**116(4):A733(#G3183)**. Poster presentation at the American Gastroenterological Association, 1999.

22. Pimentel M, Tabibzadeh S, Morgan MA, Vasiliauskas E, Lin HC. Selective inhibition of enteric organisms by mesalamine. **Gastroenterology** 1999;116(4):A796(#G3452). Poster presentation at the American Gastroenterological Association, 1999.
23. Pimentel M, Tabibzadeh S, Kirit-Kiriak V, Papadakis K, Vasiliauskas E, Kam L, Targan S, Lin HC. Prolonged prodrome of gastrointestinal symptoms is associated with Crohn's disease but not ulcerative colitis. **Gastroenterology** 1999;116(4):A796(#G3453).
24. Dubinsky M, Hassard P, Yang HY, Kam L, Abreu M, Seidman EG, Targan SR, Vasiliauskas EA. 6-MP metabolite levels correlate with clinical response and drug toxicity in adult IBD. **Am J Gastroenterol** 1999;94(9):2641(#A258). Oral presentation at the American College of Gastroenterology, 1999.
25. Dubinsky M, Hassard P, Seidman EG, Targan SR, Vasiliauskas EA. Serial 6-MP metabolite measurements identify 6-MP resistant IBD patients. **Am J Gastroenterol** 1999;94(9):2641(#A259).
26. Hadigan C, Baldassano R, Braegger CP, Vasiliauskas E, Escher JC, Sinaasappel M, Ferry GD, Kirschner B, Wagner C, Livingston R, DeWoody K, Winter HS. Pharmacokinetics of infliximab (anti-TNF $\alpha$ ) in children with Crohn's disease: a multicenter trial. **J Pediatr Gastroenterol Nutr** 1999;29(4):525(#A143). Oral/Plenary Session presentation at the North American Society for Pediatric Gastroenterology and Nutrition, 1999.
27. Vasiliauskas EA, Thomas DW, Schaffer S, C Dezenberg, J Noel, Marshall WF Jr, Targan SR. Collaborative experience of open-label infliximab, in refractory pediatric Crohn's disease. **J Pediatr Gastroenterol Nutr** 1999;29(4):525(#A144). Oral/Plenary Session presentation at the North American Society for Pediatric Gastroenterology and Nutrition, 1999.
28. Kam LY, Vasiliauskas EA, Abreu MT, Hassard PV, Zeldis JB, Targan SR. Open labeled pilot study of thalidomide (thal) as a novel therapy for medically resistant ulcerative colitis (UC). **Gastroenterology** 2000;118(4):A582(#3028). Poster presentation at the American Gastroenterological Association, 2000.
29. Landers CJ, Yang H, Lin YC, Vasiliauskas EA, Braun J, Targan SR. IgA serum antibody reactivity with I2, a novel Crohn's disease marker: anti-I2 level is independent from ASCA and ANCA levels, even though IgA ASCA positivity is correlated with anti-I2 positivity. **Gastroenterology** 2000;118(4):A348(#1871). Poster presentation at the American Gastroenterological Association, 2000.
30. Fleshner PR, Taylor KD, Yang H, Lin YC, Vasiliauskas EA, Targan SR, Rotter JI. Chronic pouchitis after ileal pouch-anal anastomosis for ulcerative colitis (UC) is associated with the interferon- $\gamma$  receptor- $\alpha$  (IFN $\gamma$ R $\alpha$ ) gene independent of perinuclear antineutrophil cytoplasmic antibody (pANCA) level. **Gastroenterology** 2000;118(4):A338(#1827). Poster presentation at the American Gastroenterological Association, 2000.
31. Taylor KD, Vasiliauskas EA, Kam LY, Lin YC, Targan SR, Rotter JI, Yang H. Specific clinical and immunological features in Crohn's disease patients are associated with the MHC Class III marker notch4. **Gastroenterology** 2000;118(4):A869(#4830). Oral presentation at the American Gastroenterological Association, 2000.
32. Kam LY, Vasiliauskas EA, Abreu MT, Hassard PV, Kalenich A, Gaiennie J, Record L, Schaible TF, Targan SR. Attenuation of response to multiple retreatment infliximab infusions for active Crohn's disease (CD): potential factors that minimize decreased response. **Gastroenterology** 2000;118(4):A655(#3597). Oral presentation at the American Gastroenterological Association, 2000.

33. Vasiliauskas EA, Schaffer S, Dezenberg CV, Baron HI, Noel JM, Nanjundiah P, Khosoo V, Marshall WF Jr., Thomas DW. Collaborative experience of open-label infliximab, in refractory pediatric Crohn's disease. **Gastroenterology** 2000;**118(4):A178(#1009)**. Oral presentation at the American Gastroenterological Association, 2000.
34. Dubinsky MC, Hassard PV, Abreu MT, Kam L, Seidman EG, Targan SR, Vasiliauskas EA. Thioguanine (6-TG): a therapeutic alternative in a subgroup of IBD patients failing 6-mercaptopurine (6-MP). **Gastroenterology** 2000;**118(4):A891(#4929)**. Oral presentation at the American Gastroenterological Association, 2000.
35. Dubinsky MC, Hassard PV, Kam L, Abreu MT, Seidman EG, Targan SR, Vasiliauskas EA. Serial 6-mercaptopurine (6-MP) metabolite measurements in combination with dose escalation unmasks an important biochemical explanation for "6-MP resistance". **Gastroenterology** 2000;**118(4):A890(#4926)**. Oral presentation at the American Gastroenterological Association, 2000.
36. Vasiliauskas EA, Schaffer S, Dezenberg CV, Baron HI, Noel JM, Nanjundiah P, Khosoo V, Marshall WF Jr., Thomas DW. Collaborative experience of open-label infliximab, in refractory pediatric Crohn's disease. **J Pediatr Gastroenterol Nutr** 2000;**31(2):S227(#889)**. Poster presentation at the North American Society for Pediatric Gastroenterology and Nutrition, 2000.
37. Kantorovich V, Adams JS, Targan SR, Hassard PV, Vasiliauskas EA. Endogenous Overproduction of 1,25-dihydroxyvitamin D in patients with Crohn's disease. **Journal of Bone and Mineral Research** 2000;**15(1):#576(#M509)**. Poster presentation at the American Society for Bone and Mineral Research, 2000.
38. Dubinsky MC, Hassard PV, Kam L, Abreu MT, Seidman EG, Targan SR, Vasiliauskas EA. An open label pilot study evaluating the safety, tolerance and efficacy of thioguanine (6-TG) as an alternate therapy in patients failing 6-mercaptopurine (6-MP). **Am J Gastroenterol** 2000;**95(9):2532(#A414)**. Oral presentation at the American College of Gastroenterology, 2000.
39. Dubinsky MC, Feldman E, Abreu MT; Seidman EG; Baroni D, Tripler AMC; Kornbluth A, Targan SR, Vasiliauskas EA. Idiosyncratic adverse reactions to 6-mercaptopurine (6-MP) and azathioprine (AZA) can be averted by switching to thioguanine (6-TG) in patients with IBD. **Gastroenterology** 2001;**120(5)Suppl(1):A-12(#56)**. Oral presentation at the American Gastroenterological Association, 2001.
40. Sachmechian A, Vasiliauskas EA, Abreu MT, Binder S, Papadakis K, Schaible T, Targan SR, Kam LY. Malignancy following Remicade™ therapy: incidence and characteristics. **Gastroenterology** 2001;**120(5)Suppl(1):A-619(#3144)**. Poster presentation at the American Gastroenterological Association, 2001.
41. Papadakis KA, Abreu MT, Targan SR, Vasiliauskas EA. Is infliximab effective for the treatment of indeterminate colitis? **Gastroenterology** 2002;**122(4):A-616(#W1356)**. Poster presentation at American Gastroenterological Association Meeting, 2002.
42. Mow WS, Abreu MT, Papadakis KA, Targan SR, Vasiliauskas EA. High incidence of anergy limits the usefulness of PPD screening for tuberculosis (TB) prior to Remicade® in inflammatory bowel disease (IBD). **Gastroenterology** 2002;**122(4):A-100(#774)**. Oral presentation at American Gastroenterological Association Meeting, 2002.
43. Mow WS, Lo SK, Abreu MT, Targan SR, Papadakis KA, Vasiliauskas EA. Video capsule enteroscopy can be useful in the diagnosis and management of inflammatory bowel disease (IBD). **Gastroenterology** 2002;**122(4):A-218(#S1385)**. Poster presentation at American Gastroenterological Association Meeting, 2002.



44. Abreu MT, Taylor KD, Lin YC, Hang T, Gaiennie J, Vasiliauskas EA, Kam LY, Rojany M, Papadakis KA, Rotter JI, Targan SR, Yang HY. Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn's disease (CD). **Gastroenterology** 2002;122(4):A-29(#246). Oral presentation at American Gastroenterological Association Meeting, 2002.
45. Abreu MT, Kantorovich V, Vasiliauskas E, Matuk R, Chen S, Lin Y-C, Gruntmanis U, Zehnder D, Yang HY, Hewison M, Adams J. Inappropriately high 1,25-dihydroxyvitamin D expression: a marker for Crohn's disease and low bone mineral density. **Gastroenterology** 2002;122(4):A-78(#649). Oral presentation at American Gastroenterological Association Meeting, 2002.
46. Poordad FF, Vasiliauskas EA, Abreu MT, Tran T, Martin P, Vierling JM, Targan SR, Geller SA, Dubinsky MC. Nodular regenerative hyperplasia (NRH) of the liver associated with 6-thioguanine (6-TG) therapy in inflammatory bowel disease (IBD). **Hepatology** 2002;36(4):333A(#680). Poster presentation at American Association for the Study of Liver Diseases Meeting 2002.
47. Abreu MT, Kam LY, Vasiliauskas EA, Vora P, Yang HY, Lin YC, Gaiennie J, Landers CJ, Salas C, Targan SR, Every R, Adams J, Keenan G. Treatment with infliximab is associated with increased markers of bone synthesis in patients with Crohn's disease. **Am J Gastroenterol** 2002;97(9)Suppl:S269(#819). Oral presentation at American College of Gastroenterology Meeting 2002.
48. Shastri S, Dubinsky M, Poordad F, Vasiliauskas E, Geller SA. Nodular hyperplasia of the liver (Sabourin lesion) occurring with inflammatory bowel diseases in association with 6-thioguanine therapy. **Am J Clin Pathol** 2002;118(4):631(#42). Presentation at American Society of Clinical Pathologists Meeting 2002.
49. Mow W, Vasiliauskas EA, Lin Y-C, Fleshner PR, Papadakis K, Taylor KD, Landers CJ, Rotter JI, Abreu MT, Yang HY, Targan SR. Antibodies Against the Crohn's disease (CD)-Associated Bacterial Sequence I2 (anti-I2) are an Independent Marker of Fibrostenosing CD. **Gastroenterology** 2003;124(4)Suppl(1):A-2(#26). Oral presentation at American Gastroenterological Association Meeting, 2003.
50. Dubinsky M, Vasiliauskas E, Singh H, Tran T, Papadakis K, Abreu M, Martin P, Vierling J, Geller S, Targan S, Poordad F. 6-Thioguanine (6-TG) May Cause Serious Liver Injury in Inflammatory Bowel Disease (IBD) Patients. **Gastroenterology** 2003;124(4)Suppl(1):A-8(#67). Oral presentation at American Gastroenterological Association Meeting, 2003.
51. Hui T, Fleshner PR, Landers CJ, Gaiennie J, Abreu M, Vasiliauskas E, Papadakis KA, Lin C-Y, Yang HY, Targan SR. The Presence or Absence of Serologic Responses in Indeterminate Colitis (IC) Patients Before Ileal Pouch-Anal Anastomosis (IPAA) May Determine Those at Risk for Persistent Pouch Inflammation. **Gastroenterology** 2003Suppl(1);124(4):A-192(#S1308). Poster presentation at American Gastroenterological Association Meeting, 2003.
52. Lo SK, Zaidel O, Tabibzadeh S, Papadakis KA, Treyzon L, Kimble J, Vasiliauskas EA. Utility of Wireless Capsule Enteroscopy (WCE) and IBD Serology in Reclassifying Indeterminate Colitis (IC). **Gastroenterology** 2003;124(4)Suppl(1):A-192(#S1310). Poster presentation at American Gastroenterological Association Meeting, 2003.
53. Dubinsky MC, Lee-Uy N, Lin Y-C, Dutridge D, Vasiliauskas EA, Landers CJ, Targan SR, Roundtree B, Thomas D, Davis J, Dallalzadeh S, Bahar R, Taylor KD, Rotter JI, Yang HY. Synergism of NOD2 and ASCA (Anti-Saccharomyces Cerevisiae Antibodies) Contributes to Disease Behavior in Pediatric Crohn's disease (CD). **Gastroenterology** 2003;124(4)Suppl(1):A-372 (#M1556). Poster presentation at American Gastroenterological Association Meeting, 2003.

54. Tabibzadeh S, Zaidel O, Papadakis K, Vasiliauskas E, Kimble J, Treyzon L, Lo SK. Utility of Wireless Capsule Enteroscopy (WCE) versus Serology in the Evaluation of Small Bowel Crohn's Disease. **Gastroenterology 2003;124(4)Suppl(1):A-170(#M1889)**. Poster presentation at American Gastroenterological Association Meeting, 2003.
55. Tabibzadeh S, Kimble J, Zaidel O, Papadakis KA, Vasiliauskas EA, Treyzon L, Lo SK. Distribution of Small Bowel Erosions or Ulcerations in Patient Presenting for Wireless Capsule Enteroscopy (WCE). **Gastroenterology 2003;124(4)Suppl(1):A-170(#M1890)**. Poster presentation at American Gastroenterological Association Meeting, 2003.
56. Spivak J, Targan SR, Vasiliauskas EA, Abreu MT, Papadakis KA, Landers CJ, Fleshner P. Antibodies to I2 Predict Clinical Response to Fecal Diversion in Crohn's Disease. **Gastroenterology 2004;126(4)Suppl(2):A-69(#527)**. Poster presentation at American Gastroenterological Association Meeting, 2004.
57. Ippoliti A, Abreu M, Fleshner P, Papadakis K, Targan S, Vasiliauskas E. Cyclosporine in Crohn's and Indeterminate Colitis – a Five Year Experience at Cedars-Sinai Medical Center, Los Angeles. **Gastroenterology 2004;126(4)Suppl(2):A-630(#W1406)**. Poster presentation at American Gastroenterological Association Meeting, 2004.
58. Papadakis K, Yang H, Elson CO, Hershberg R, Vasiliauskas E, Fleshner P, Ippoliti A, Abreu MT, Taylor KD, Rotter J, Landers CJ, Targan SR. Anti-Flagellin (anti-CBir) Phenotypic and Genetic Crohn's Disease (CD) Associations. **Gastroenterology 2005;128(4)Suppl(2):A-1(#7)**. Oral presentation at American Gastroenterological Association Meeting, 2005.
59. Dubinsky MC, Lin Y-C, Dutridge D, Farrior S, Picornell Y, Landers CJ, Vasiliauskas EA, Wrobel I, Quiros A, Grill B, Israel D, Bahar R, Christie D, Silber G, Dallazadeh S, Thomas DW, Shah P, Targan SR, Kelts D, Taylor KD, Rotter JI, Yang HY. Serum Immune Responses Predict Rapid Disease Progression Among Children with Crohn's disease. **Gastroenterology 2005;128(4)Suppl(2):A-1(#11)**. Oral presentation at American Gastroenterological Association Meeting, 2005.
60. Mei L, Landers C, Dutridge D, Ippoliti A, Vasiliauskas EA, Papadakis KA, Fleshner P, Targan SR, Rotter JI, Yang H. Familial Expression of Anti-Escherichia Coli Outer Membrane Porin C (OmpC) in Relatives of Patients with Crohn's Disease. **Gastroenterology 2005;128(4)Suppl(2):A-2(#12)**. Oral presentation at American Gastroenterological Association Meeting, 2005.
61. Vasiliauskas E, Dubinsky M, Barry M, Targan S. High Serum Levels of Infliximab Detected in the Newborn of a Mother Receiving Infliximab during Pregnancy. **Gastroenterology 2005;128(4)Suppl(2):A-26(#148)**. Oral presentation at American Gastroenterological Association Meeting, 2005.
62. Picornell Y, Abreu MT, Ippoliti A, Landers C, Mei L, Papadakis KA, Vasiliauskas EA, Fleshner P, Dutridge D, Rotter JI, Targan SR, Yang H. CARD8 Variant and the Expression of Anti-OmpC are Synergistically Associated with Internal Penetrating Crohn's Disease. **Gastroenterology 2005;128(4)Suppl(2):A-113(#730)**. Oral presentation at American Gastroenterological Association Meeting, 2005.
63. Rosenstrauch P, Vasiliauskas EA, Targan SR, Papadakis KA, Ippoliti A, Loane J, Lee S, Chavira CM, Nicassio P, Abreu MT. Couple-Based Coping Strategy is Associated with Quality of Life and Marital Satisfaction in Patients with Inflammatory Bowel Disease (IBD). **Gastroenterology 2005;128(4)Suppl(2):A-325-326(#M1181)**. Poster presentation at American Gastroenterological Association Meeting, 2005.

64. Shaye O, Yang J, Mehdibzadeh S, Ognibene S, Fleshner P, Vasiliauskas E, Papadakis K, Targan SR, Ippoliti A. Efficacy of Cyclosporin A in Severe Ulcerative Colitis – a 9-Year Experience. **Gastroenterology 2005;128(4)Suppl(2):A-578(#W1024)**. Poster presentation at American Gastroenterological Association Meeting, 2005.
65. Ognibene S, , Vasiliauskas E, Dubinsky M, Ippoliti A, Papadakis K, Shaye O, Mehdibzadeh S, Targan S, Fleshner P. Long Term Morbidity of Cyclosporin A Treated Patients with Ulcerative Colitis: A Word of Caution. **Gastroenterology 2005;128(4)Suppl(2):A-584(#W1051)**. Poster presentation at American Gastroenterological Association Meeting, 2005.
66. Dubinsky M, Mei L, Landers C, Katzir L, Farrior S, Wrobel I, Quiros A, Bahar R, Whabeh G, Grill B, Silber G, Kelts D, Pietzak M, Dallalzadeh S, Vasiliauskas E, Nelson C, Hershberg R, Yang H, Rotter J, Targan S, and the Western Regional Pediatric IBD Research Alliance. Antibodies to a Novel Flagellin (CBIR1) Adds Clinical Utility to the Diagnosis and Differentiation of Pediatric IBD. **J Pediatr Gastroenterol Nutr 2005;41(4):539(#149)**. Presentation at the North American Society for Pediatric Gastroenterology and Nutrition, 2005.
67. Dubinsky M, Mei L, Landers C, Katzir L, Farrior S, Wrobel I, Quiros A, Bahar R, Whabeh G, Grill B, Silber G, Pietzak M, Vasiliauskas E, Dallalzadeh S, Kelts D, Elson C, Hershberg R, Yang H, Targan S, Rotter J, and the Western Regional Pediatric IBD Research Alliance. Familial Expression of Serological Immune Responses in Pediatric IBD. **J Pediatr Gastroenterol Nutr 2005;41(4):539(#150)**. Presentation at the North American Society for Pediatric Gastroenterology and Nutrition, 2005.
68. Melmed GY, Ippoliti AF, Papadakis K, Targan SR, Vasiliauskas EA. Patients with Inflammatory Bowel Disease are at Risk for Vaccine-Preventable Illnesses. **Am J Gastroenterol 2005;100(9)Suppl:S301(#815)**. Poster presentation at American College of Gastroenterology Meeting 2002.
69. Ippoliti AF, Devlin S, Yang H, Mei L, Papadakis K, Vasiliauskas E, Melmed G, Shaye O, Enyati P, Chen G, Choi J, Nastaskin I, Patel Y, Mehdikhani E, Taylor KD, Landers C, Rotter JI, Targan S. The Relationship Between Abnormal Innate and Adaptive Immune Function and Fibrostenosis in Crohn's Disease Patients. **Gastroenterology 2006;130(4)Suppl(2):A-24(#127)**. Oral presentation at American Gastroenterological Association Meeting, 2006.
70. Fleshner P, Vasiliauskas E, Dubinsky M, Mei L, Landers C, Ippoliti A, Papadakis K, Targan S. Both Preoperative pANCA and CBir1 Flagellin Expression in Ulcerative Colitis (UC) Patients Influence Pouchitis Development after Ileal Pouch-Anal Anastomosis (IPAA). **Gastroenterology 2006;130(4)Suppl(2):A-25(#130)**. Oral presentation at American Gastroenterological Association Meeting, 2006.
71. Rotter JI, Taylor KD, Yang H, Mei L, Picornell Y, Hawn TR, Abreu MT, Aderem A, Papadakis KA, Vasiliauskas EA, Ippoliti A, Targan SR. TLR5 Polymorphisms are Associated with OmpC and CBIR1 Expression and with Severity of Crohn's Disease in Ashkenazi Jews. **Gastroenterology 2006;130(4)Suppl(2):A-53 (#348)**. Oral presentation at American Gastroenterological Association Meeting, 2006.
72. Devlin SM, Ippoliti A, Yang H, Papadakis K, Vasiliauskas E, Abreu MT, Melmed GY, Fleshner P, Taylor KD, Mei L, Landers CJ, Rotter JI, Targan SR. NOD2 Variants are Significantly Associated with Sero-Reactivity to Microbial Antigens in Crohn's Disease (CD). **Gastroenterology 2006;130(4)Suppl(2):A-64 (#442)**. Oral presentation at American Gastroenterological Association Meeting, 2006.

73. Taylor KD, Yang H, Mei L, Landers CJ, Cong Y, Papadakis KA, Vasiliauskas EA, Ippoliti A, Elson CO, Rotter JI, Targan SR. Genes Regulating the Expression of Antibody to CBIR1 Flagellin In Humans Are Located Within a Syntenic Region To The Major Mouse Colitogenic Locus *Cdcs1*. **Gastroenterology** 2006;130(4)Suppl(2):A-64 (#444). Oral presentation at American Gastroenterological Association Meeting, 2006.
74. Schluender SJ, Mehdibzadeh S, Vasiliauskas EA, Dubinsky M, Papadakis KA, Ippoliti A, Lo S, Targan S, Fleshner P. Does Preoperative Wireless Endoscopic Capsule Predict Long-Term Outcome After Ileal Pouch-Anal Anastomosis (IPAA)? **Gastroenterology** 2006;130(4)Suppl(2):A-214 (#S1378). Poster presentation at American Gastroenterological Association Meeting, 2006.
75. Dubinsky M, Katzir L, Wrobel I, Quiros A, Mei L, Picornell Y, Su X, Wahbeh G, Silber G, Bahar R, Grill B, Vasiliauskas E, Taylor KD, Targan SR, Yang H, Rotter JI. CARD8: A Novel Association with Childhood-Onset Ulcerative Colitis (UC). **Gastroenterology** 2006;130(4)Suppl(2):A-587 (#T1983). Poster presentation at American Gastroenterological Association Meeting, 2006.
76. Schluender SJ, Vasiliauskas EA, Dubinsky M, Papadakis KA, Ippoliti A, Targan S, Fleshner P. Does Infliximab Influence Surgical Morbidity or Long-Term Outcome of Ileal Pouch-Anal Anastomosis in Patients with Ulcerative Colitis? **Gastroenterology** 2006;130(4)Suppl(2):A-647-8 (#W1158). Poster presentation at American Gastroenterological Association Meeting, 2006. <http://ddw2006.abstractcentral.com/planner>
77. Melmed GY, Ippoliti AF, Chen GC, Nastaskin I, Vasiliauskas EA, Papadakis KA, Landers CJ, Elashoff EM, Targan SR. Can Clinical 'Red Flags' at the Time of Presentation with Ulcerative Colitis Predict Which Patients Will Subsequently Undergo a Change in Diagnosis to Crohn's Disease? **Gastroenterology** 2006;130(4)Suppl(2):A-654 (#W1188). Poster presentation at American Gastroenterological Association Meeting, 2006.
78. Shaye OS, Yadegari M, Ippoliti A, Vasiliauskas EA, Dubinsky M, Papadakis KA, Targan S, Fleshner P. Is Preoperative Gastritis Associated with Long-Term Outcome After Ileal Pouch-Anal Anastomosis (IPAA)? **Am J Gastroenterol** 2006, 101(9)Suppl:S465(#1195).
79. Dubinsky MC, Kugathan S, Mei L, Picornell Y, Nebel J, Wrobel IT, Quiros JA, Silber G, Wahbeh G, Vasiliauskas E, Bahar RJ, Otley A, Mack DR, Evans JS, Rosh JR, Oliva Hemker M, Leleiko NS, Crandall WV, Langton C, Taylor KD, Targan SR, Rotter JI, Markowitz JF, Hyams JS. Increased Immune Reactivity Predicts Aggressive Complicating Crohn's disease in Children. **Gastroenterology** 2007;132(4)Suppl(2):A-17 (#82). Oral presentation at American Gastroenterological Association Meeting, 2007.
80. Melmed GY, Ippoliti AF, Vasiliauskas E, Dubinsky MC, Papadakis KA, Rotter, JI, Targan SR, Fleshner P. A Prospective Analysis of Predictive Factors for the Diagnosis of Crohn's Disease After Ileal Pouch-Anal Anastomosis for Ulcerative Colitis. **Gastroenterology** 2007;132(4)Suppl(2):A-511-2 (#T1303). Poster presentation at American Gastroenterological Association Meeting, 2007.
81. Mahadevan U, Terdiman JP, Church J, Vasiliauskas E, Gitis A, Dubinsky MC. Infliximab Levels in Infants Born to Women with Inflammatory Bowel Disease. **Gastroenterology** 2007;132(4)Suppl(2):A-144 (#959). Oral presentation at American Gastroenterological Association Meeting, 2007.

82. Murrell ZA, Vasiliauskas EA, Dubinsky MC, Ippoliti A, Melmed GY, McGovern DP, Targan SR, Fleshner P. Preoperative Wireless Capsule Endoscopy Does Not Predict Long-Term Outcome After Ileal Pouch-Anal Anastomosis. **Gastroenterology 2008;134(4)Suppl(1):A-15 (#89)**. Oral presentation at American Gastroenterological Association Meeting, 2008.
83. Markowitz J, Kugathasan S, Dubinsky MC, Ling M, Crandall W, LeLeiko NS, Oliva-Hemker M, Rosh JR, Evans J, Mack DR, Otley AR, Pfefferkorn MD, Bahar RJ, Vasiliauskas EA, Wahbeh G, Silber G, Quiros JA, Wrobel IT, Nebel J, Landers CJ, Picornell Y, Taylor KD, Rotter JI, Targan SR, Hyams JS. Age of Diagnosis Influences Serologic Responses in Children with Crohn Disease: a Possible Clue to Etiology? **Gastroenterology 2008;134(4)Suppl(1):A-54 (#394)**. Oral presentation at American Gastroenterological Association Meeting, 2008.
84. Melmed GY, Frenck R, Barolet-Garcia C, Ibanez P, Simpson P, Papadakis KA, Ward J, Ippoliti A, Targan SR, Vasiliauskas EA. TNF blockers and immunomodulators impair antibody responses to pneumococcal polysaccharide vaccine (PPV) in patients with inflammatory bowel disease (IBD). **Gastroenterology 2008;134(4)Suppl(1):A-68 (#495)**. Oral presentation at American Gastroenterological Association Meeting, 2008.
85. Mahadevan U, Kane SV, Church JA, Vasiliauskas EA, Sandborn WJ, Dubinsky MC. The Effect of Maternal Peripartum Infliximab Use on Neonatal Immune Response. **Gastroenterology 2008;134(4)Suppl(1):A-69 (#499)**. Oral presentation at American Gastroenterological Association Meeting, 2008.
86. McGovern DP, Taylor KD, Landers CJ, Dutridge D, Derkowski CA, Mei L, Ippoliti A, Vasiliauskas EA, Dubinsky MC, Rotter JI, Targan SR, Fleshner P. Clinical, Serological and Genetic Predictors of Postoperative Recurrence in A Single-Center Prospectively Collected Cohort of Crohn's Disease Patients. **Gastroenterology 2008;134(4)Suppl(1):A-202 (#S1210)**. Poster presentation at American Gastroenterological Association Meeting, 2008.
87. Ibanez P, Pimentel M, Melmed GY, Ippoliti A, Targan SR, Vasiliauskas EA. Fatigue and Abdominal Bloating Predict Small Intestinal Bacterial Overgrowth (SIBO) in Patients with Ulcerative Colitis (UC). **Gastroenterology 2008;134(4)Suppl(1):A-350 (#M1154)**. Poster presentation at American Gastroenterological Association Meeting, 2008.
88. Low K, Hwang LJ, Sahakian A, Yang J, Lezcano S, Vasiliauskas EA, Ippoliti A, Ibanez P, Pimentel M. Making IBS a "Diagnosis of Inclusion": Development of a New Diagnostic Criteria for IBS. **Gastroenterology 2008;134(4)Suppl(1):A-423 (#M1808)**. Poster presentation at American Gastroenterological Association Meeting, 2008.
89. Melmed GY, Wang HL, Vasiliauskas EA, Dubinsky MC, Ippoliti A, McGovern DP, Targan SR, Fleshner P. What Is the Natural History of Inflammatory Bowel Disease-Unclassified (IBDU) After Ileal Pouch Anal Anastomosis (IPAA)? **Gastroenterology 2008;134(4)Suppl(1):A-500 (#T1174)**. Poster presentation at American Gastroenterological Association Meeting, 2008.
90. Melmed GY, Wang HL, Vasiliauskas EA, Dubinsky MC, Ippoliti A, McGovern DP, Targan SR, Fleshner P. Rigorous Histopathologic Assessment of the Colectomy Specimen for Features of Indeterminate Colitis (IC) Does Not Predict Outcome After Ileal Pouch-Anal Anastomosis (IPAA). **Gastroenterology 2008;134(4)Suppl(1):A-638 (#W1123)**. Poster presentation at American Gastroenterological Association Meeting, 2008.
91. Haritunians T, Taylor KD, Rotter JI, Ippoliti A, Dubinsky M, Vasiliauskas EA, Melmed GY, Psaty BM, Targan SR, Fleshner P, McGovern DP. Genetic Predictors of Medically Refractive Ulcerative Colitis (UC) Requiring Colectomy. **Gastroenterology 2009;136(5)Suppl(1CD):#857**. Oral presentation at American Gastroenterological Association Meeting, 2009.

92. White E, Dubinsky M, Melmed GY, Vasiliauskas EA, Ippoliti A, McGovern DP, Murrell ZA, Targan SR, Fleshner P. A Prospective Analysis of Clinical Variables, Serologic Factors and Outcome of Ileal Pouch-Anal Anastomosis in Patients with Backwash Ileitis. **Gastroenterology 2009;136(5)Suppl(1CD):#1104**. Oral presentation at American Gastroenterological Association Meeting, 2009.
93. Dai S-C, Fleshner P, Vasiliauskas EA, Ippoliti A, McGovern DP, Targan SR, Melmed GY. Adalimumab May Provide Short-Term Improvement in Bowel Movement Frequency for de novo Crohn's Disease After Ileal-Pouch Anal Anastomosis. **Gastroenterology 2009;136(5)Suppl(1CD):#W1133**. Poster presentation at American Gastroenterological Association Meeting, 2009.
94. Melmed GY, Ippoliti A, Vasiliauskas EA, McGovern DP, Dubinsky M, Simpson P, Targan SR, Spiegel BM. A Single-Item Numeric Rating Scale Shows Excellent Correlation with Measures of Crohn's Disease Activity and Health-Related Quality of Life. **Gastroenterology 2009;136(5)Suppl(1CD):#W1173**. Poster presentation at American Gastroenterological Association Meeting, 2009.
95. Shih DQ, Nguyen M, Ibañez P, Kwan LY, Targan SR, Vasiliauskas EA. Split-Dose Administration of 6-Mercaptopurine/Azathioprine: a Effective Novel Strategy for IBD Patients with Preferential 6mmp Metabolism. **Gastroenterology 2009;136(5)Suppl(1CD):#W1206**. Poster of Distinction presentation at American Gastroenterological Association Meeting, 2009.
96. Haritunians T, Jones MR, McGovern DP, Fleshner P, Ippoliti A, Dubinsky M, Vasiliauskas EA, Melmed GY, Shih DQ, Barrett R, Rotter JI, Targan SR, Taylor KD. Variants in Znf365 on 10q21 Are Associated With Crohn's Disease. #S30. Oral presentation at American Gastroenterological Association Meeting, 2010.
97. Cheng-Robles D, McGovern DP, Melmed GY, Berel D, Vasiliauskas EA, Dubinsky M, Ippoliti A, Shih D, Targan SR, Fleshner P. Genetic Markers Associated With the Development of Denovo Crohn's Disease After Ileal Pouch-Anal Anastomosis. #S1172. Poster of Distinction presentation at American Gastroenterological Association Meeting, 2010.
98. Brelian D, McGovern DP, Dubinsky D, Berel D, Shih DQ, Ippoliti A, Vasiliauskas EA, Targan SR, Fleshner P, Melmed GY. Unique Predictors of Chronic Pouch Inflammation Among Ulcerative Colitis Patients With Primary Sclerosing Cholangitis (PSC) Undergoing Ileal Pouch-Anal Anastomosis (IPAA). #S1187. Poster presentation at American Gastroenterological Association Meeting, 2010.
99. Cheng-Robles D, Melmed GY, Vasiliauskas EA, Dubinsky M, McGovern DP, Ippoliti A, Shih DQ, Targan SR, Fleshner P. Preoperative pANCA Expression Influences the Outcome of Ileal Pouch-Anastomosis in Inflammatory Bowel Disease-Unclassified (IBDU) #M489. Oral presentation at American Gastroenterological Association Meeting, 2010.
100. Basseri RJ, Basseri B, Ippoliti A, Vasiliauskas EA, Melmed GY, Targan SR, Papadakis KA. The Efficacy of Colorectal Cancer Surveillance in Crohn's Colitis. #M1937. Poster presentation at American Gastroenterological Association Meeting, 2010.
101. Nguyen M, Bradford K, Zhan X, Simpson P, Targan SR, Vasiliauskas EA, Shih DQ. Severity of Cytomegalovirus Infection on Pathology Specimens Is Associated With Colectomy Rates and Response to Antiviral Therapy in Inflammatory Bowel Disease Patients. #W1004. Oral presentation at American Gastroenterological Association Meeting, 2010.

102. Jones MR, Haritunians T, McGovern DP, Dubinsky M, Ippoliti A, Vasiliauskas EA, Melmed GY, Shih DQ, Fleshner P, Levine A, Leshinsky ES, Siscovick D, Marciante KD, Targan SR, Rotter JI, Taylor KD. Genome Wide Association Study in Ashkenazi Jewish Crohn's Disease Patients Reveals Novel Susceptibility Loci. #W1213. Poster of Distinction presentation at American Gastroenterological Association Meeting, 2010.
103. Farid M, Melmed GY, Targan SR, Ippoliti A, Vasiliauskas EA. The Economically Friendly Mutant: TPMT-Heterozygotes Achieve Therapeutic Levels on Low Doses of 6-MP. #W1263. Poster presentation at American Gastroenterological Association Meeting, 2010.
104. Kaneshiro M, Shih D, McGovern D, Ippoliti A, Targan S, Vasiliauskas E, Melmed G. Does Upper Endoscopy Impact the Diagnosis or Management of Adults with Colitis? Poster presentation at 2010 Advances in Inflammatory Bowel Diseases, Crohn's & colitis foundation's clinical & research Conference; Hollywood, FL, 2010
105. deFonseka AM, Haritunians T, Berel D, Targan SR, Landers CJ, Rotter JI, Vasiliauskas EA, Ippoliti A, Melmed GY, Shih DQ, Dubinsky M, Taylor KD, McGovern DP. Clinical, Serologic, and Genetic Associations With Low Bone Density in Patients With Inflammatory Bowel Disease. #21. Oral presentation at American Gastroenterological Association Meeting, 2011.
106. Basseri B, Vasiliauskas EA, Wang HL, Basseri RJ, Brelan D, Pimentel M, Soffer EE, Conklin JL. Lymphocytic Esophagitis is Uncommon in Adult Inflammatory Bowel Disease. #Sa1112. Poster presentation at American Gastroenterological Association Meeting, 2011.
107. Taylor KD, Haritunians T, McGovern DP, Landers CJ, Ippoliti A, Vasiliauskas EA, Guo X, Dubinsky M, Targan SR, Rotter JI. Genome-Wide Association Study of CD-Associated Anti-Microbial Antibodies. #Sa1277. Poster presentation at American Gastroenterological Association Meeting, 2011.
108. Nguyen M, Bradford K, Huang BL, Haritunians T, Fleshner P, Himmelfarb E, Landers CJ, Vasiliauskas EA, Ippoliti A, Melmed GY, Dubinsky M, Gonsky R, Rotter JI, Targan SR, McGovern DP, Taylor KD, Shih DQ. Genetic Predictors of Cytomegalovirus Infection in Patients With Inflammatory Bowel Disease. #Sa1284. Poster presentation at American Gastroenterological Association Meeting, 2011.
109. Chou JY, Vasiliauskas EA, Feldman EJ, Berel D, McGovern DP, Ippoliti A, Dubinsky M, Targan SR, Shih DQ, Nahm M, Ward J, Melmed GY. Immunosuppression Does Not Influence the Decay of Pneumococcal Antibodies 3 Years After Vaccination in Patients With Inflammatory Bowel Disease. #Su1194. Poster of Distinction presentation at American Gastroenterological Association Meeting, 2011.
110. Modiano N, Fleshner P, Taylor KD, Dubinsky M, Vasiliauskas EA, Ippoliti A, Shih DQ, Melmed GY, Targan SR, Berel D, Haritunians T, Rotter J, McGovern DP. Intestinal Granulomas in Crohn's Disease: Association With Patient Characteristics, Serologic Markers, and Genetics. #Su1734. Poster presentation at American Gastroenterological Association Meeting, 2011.
111. White E, Melmed GY, Vasiliauskas EA, Dubinsky M, Ippoliti A, McGovern DP, Shih DQ, Targan SR, Fleshner P. Does Preoperative Immunosuppression Influence Unplanned Hospital Readmission After Surgery in Patients With Crohn's Disease? #Tu1218. Poster presentation at American Gastroenterological Association Meeting, 2011.
112. Le Q, Melmed GY, Murrell ZA, Vasiliauskas EA, Shih DQ, Dubinsky M, Ippoliti A, Targan SR, Fleshner P. Factors Associated With Surgical Outcome of Ileal Pouch-Anal Anastomosis When Intentionally Used in Crohn's Disease. #Tu1276. Poster presentation at American Gastroenterological Association Meeting, 2011.

113. Siegel CA, Fleshner P, Siegel LS, Rotter JI, Dubinsky M, Vasiliauskas EA, Ippoliti A, Shih DQ, Melmed GY, Landers CJ, Haritunians T, Targan SR, Taylor KD, McGovern DP. Predicting Crohn's Disease Post-Operative Recurrence Using Clinical, Endoscopic, Serologic and Genetic Factors. #935 Oral presentation at American Gastroenterological Association Meeting, 2011.
114. Huang B, Melmed G, Wegge J, Shainsky K, Ippoliti A, McGovern D, Vasiliauskas E, Fleshner P, Dubinsky M, Targan S, Shih D. Facial Pyoderma Gangrenosum in Crohn's Disease: Treatment Options and Outcomes. **Am J Gastroenterol 2011, 106 (supp 2) S353 (#945)** ([www.nature.com/ajg/journal/v106/n2s/pdf/ajg2011336\\_7a.pdf](http://www.nature.com/ajg/journal/v106/n2s/pdf/ajg2011336_7a.pdf)). Poster presentation at American College of Gastroenterology Annual Scientific Meeting, 2011.
115. Karsan SS, Cohen ER, Targan SR, Ippoliti A, Shih DQ, Vasiliauskas EA, Dubinsky M, Berel D, McGovern DP. Analysis of Clinical and Serological Associations, and the Clinical Consequences of the Development of Human Anti-Chimeric Antibodies (HACAs), and Low Serum Infliximab (IFX) Levels in Inflammatory Bowel Disease (IBD). #Sa1289. Poster presentation at American Gastroenterological Association Meeting, 2012.
116. Kaur M, Berel D, Vasiliauskas EA, Ippoliti A, Dubinsky M, Melmed GY, Shih DQ, Feldman EJ, Fleshner P, Targan SR, McGovern DP. A Combination of Serum Albumin and Band Neutrophil Count Is Predictive of Short- Term Colectomy Following Infliximab Treatment for Severe Steroid Refractory Ulcerative Colitis. #Sa1916. Poster presentation at American Gastroenterological Association Meeting, 2012.
117. Weizman AV, Huang BL, Berel D, Targan SR, Dubinsky M, Fleshner P, Ippoliti A, Rotter JI, Vasiliauskas EA, Shih DQ, Li D, Melmed GY, McGovern DP. Serologic and Genetic Profiles Suggest Distinct Immune Pathways Among Patients With Pyoderma Gangrenosum and Inflammatory Bowel Disease. #Sa25 Oral presentation at American Gastroenterological Association Meeting, 2012.
118. Dezfoli S, Horton HA, Berel D, Targan SR, Vasiliauskas EA, Dubinsky M, Kaur M, McGovern DP, Ippoliti A, Feldman EJ, Melmed G. Immunomodulators, but Not Anti-TNF Monotherapy, Impair Pertussis and Tetanus Booster Vaccine Responses in Adults With Inflammatory Bowel Disease (IBD). #Su2081. Poster presentation at American Gastroenterological Association Meeting, 2012.
119. Williams CI, Karayev D, Learch T, Targan SR, Landers CJ, Rotter JI, Vasiliauskas EA, Ippoliti A, Kaur M, Melmed GY, Shih DQ, Dubinsky M, Taylor KD, Li D, Weisman MH, McGovern DP. Clinical, Serologic, and Genetic Associations Among Patients With Both Inflammatory Bowel Disease and Ankylosing Spondylitis. #Mo1695. Poster presentation at American Gastroenterological Association Meeting, 2012.
120. Horton HA, Dezfoli S, Berel D, Hirsch J, Targan SR, Ippoliti A, Vasiliauskas EA, McGovern DP, Kaur M, Shih DQ, Dubinsky M, Fleshner P, Grein J, Murthy R, Melmed G. Patients With Ulcerative Colitis Hospitalized With Clostridium difficile Infection (CDI) Should Be Treated With Vancomycin Regardless of Cdi Severity. #Mo626. Oral presentation at American Gastroenterological Association Meeting, 2012.
121. Gingold D, McGovern DP, Li D, Haritunians T, Melmed GY, Dubinsky M, Vasiliauskas EA, Ippoliti A, Kaur M, Shih DQ, Rotter JI, Taylor KD, Targan SR, Fleshner P. Prospective Evaluation of Genetic Determinants of Surgical Outcome After Ileal Pouch-Anal Anastomosis (IPAA). #Tu1910. Poster presentation at American Gastroenterological Association Meeting, 2012.



122. Zaghayan KN, Berel D, McGovern DP, Dubinsky M, Vasiliauskas EA, Melmed GY, Ippoliti A, Kaur M, Shih DQ, Murrell ZA, Targan SR, Fleshner P. Validated Nomogram for Preoperative Prediction of Chronic Pouchitis and Denovo Crohn's Disease After Ileal Pouch-Anal Anastomosis. #Tu1070. Oral presentation at American Gastroenterological Association Meeting, 2012.
123. Yoon J, Gerich M, Targan SR, Ippoliti AF, Vasiliauskas EA. Long-Term Outcomes of Thalidomide in Refractory Inflammatory Bowel Disease. #P945. Poster presentation at American College of Gastroenterology Annual Scientific Meeting, 2012.
124. Levy A, Melmed GY, Vasiliauskas EA. West Nile Virus Meningoencephalitis during Treatment of Crohn's Disease with Adalimumab. #P995. Poster presentation at American College of Gastroenterology Annual Scientific Meeting, 2012.
125. Vu M, Huang B, Ippoliti A, Feldman E, Fleshner P, Zakowski P, Vasiliauskas EA. Perineal Pyoderma Gangrenosum in a Patient with Inflammatory Bowel Disease. #P1000. Poster presentation at American College of Gastroenterology Annual Scientific Meeting, 2012.
126. Weizman A, Huang B, Berel D, Targan S, Dubinsky M, Fleshner P, Ippoliti A, Panikkath D, NIDDK IBD Genetics Consortium (NIDDK IBGDC), Rotter JI, Vasiliauskas E, Shih D, Li D, Melmed G, McGovern D. Clinical, Serologic, and Genetic Profiles Predict Pyoderma Gangrenosum Among Patients with Inflammatory Bowel Disease. Poster presentation at Canadian Association of Gastroenterology (CAG) Annual CASL Winter Meeting, 2013.
127. Halloran BP, Melmed GY, Jamil LH, Lo SK, Vasiliauskas EA, Mann NK. Double Balloon Enteroscopy-Assisted Stricture Dilation Delays Surgery in Patients with Small Bowel Crohn's Disease. #Sa1649. Poster presentation at American Gastroenterological Association Meeting, 2013.
128. Haas K, Wachsman A, Melmed GY, Azizyan A, Vasiliauskas EA, Rosentha CJ, Kaur M, Rabizadeh S, Mirocha JM, Fleshner P, Dubinsky M. Small Bowel Ultrasound Accurately Predicts Post-Operative Endoscopic Recurrence in Crohn's Disease. #Su1116. Poster presentation at American Gastroenterological Association Meeting, 2013.
129. Lau CC, Dubinsky M, Melmed GY, Vasiliauskas EA, McGovern DP, Berel D, Murrell Z, Ippoliti A, Shih DQ, Kaur M, Targan SR, Fleshner P. Influence of Biologic Agents on Short-Term Postoperative Complications in Patients with Crohn's Disease: A Prospective, Single-Surgeon Cohort Study. #Su1133. Poster presentation at American Gastroenterological Association Meeting, 2013.
130. Halloran BP, Melmed GY, Vasiliauskas EA, Jamil LH, Lo SK, Mann NK. Diagnostic and Therapeutic Double Balloon Enteroscopy in Crohn's Disease is Safe and Effective. #Su1164. Poster presentation at American Gastroenterological Association Meeting, 2013.
131. Kaur M, Panikkath D, Li D, Berel D, Vasiliauskas EA, Ippoliti A, Dubinsky M, Shih DQ, Melmed GY, Taylor KD, Fleshner P, Targan SR, McGovern DP. Perianal Crohn's Disease is Associated with Distal Colonic Disease, IBD-Related Serologies and Immune-Related Genetic Variation. #Mo562. Oral presentation at American Gastroenterological Association Meeting, 2013.
132. Levy AN, Anderson JM, Horton H, Sun E, Vasiliauskas EA, Dubinsky M, Fleshner P, Shih DQ, Kaur M, Ippoliti A, Targan SR, Drazin N, McGovern DP, Melmed GY. Thromboembolic Risk in Hospitalized IBD Patients is Compounded by Traditional Risk Factors and Hypercoagulable States. #Mo1242. Poster presentation at American Gastroenterological Association Meeting, 2013.

133. Al-Jiboury H, Weizman AV, Berel D, Berns M, Dubinsky M, Targan SR, Vasiliauskas EA, Shih DQ, Kaur M, Ippoliti A, McGovern DP, Melmed GY. Complications and Length of Stay after Cholecystectomy are Increased Among Men with IBD. #Mo1255. Poster presentation at American Gastroenterological Association Meeting, 2013.
134. Taleban S, Li D, Targan S, Ippoliti A, Vasiliauskas EA, Rotter JI, Shih DQ, Kaur M, Dubinsky M, Melmed GY, McGovern DP. Clinical, Serologic, and Genetic Associations in Patients with Ocular Manifestations in Inflammatory Bowel Disease. #Mo1304. Poster presentation at American Gastroenterological Association Meeting, 2013.
135. Yoon JL, Huang BL, Karsan SS, Melmed GY, Ippoliti A, Dubinsky M, Kaur M, Nguyen M, Vora P, Fleshner P, McGovern DP, Targan SR, Vasiliauskas EA, Shih DQ. Potential Synergism Between Anti-TNF and Thiopurine Therapy: Increased Thiopurine Metabolites by Anti-TNF. #Tu1139. Poster presentation at American Gastroenterological Association Meeting, 2013.
136. Karsan SS, Huang BL, Yoon JL, Dubinsky M, Berel D, Yan X, Melmed GY, Ippoliti A, Guo X, Taylor KD, Kaur M, Rotter JI, Targan SR, Vasiliauskas EA, McGovern DP, Shih DQ. Genetic and Serologic Associations with 6-MMP Preferential Metabolizers Reveal Novel Pathways that May be Involved in Thiopurine Metabolism. #Tu1166. May 21 Poster presentation at American Gastroenterological Association Meeting, 2013.
137. Lau CC, Dubinsky M, Melmed GY, Vasiliauskas EA, McGovern DP, Berel D, Murrell ZA, Ippoliti A, Shih DQ, Kaur M, Targan SR, Fleshner P. Preoperative Serum Biologic Levels Do Not Impact Postoperative Outcomes in Ulcerative Colitis. #Tu1010. Oral presentation at American Gastroenterological Association Meeting, 2013.
138. Lau CC, Dubinsky M, Melmed GY, Vasiliauskas EA, McGovern DP, Berel D, Ippoliti A, Murrell ZA, Shih DQ, Kaur M, Targan SR, Fleshner P. Higher Preoperative Serum Biologic Levels are Associated with Postoperative Complications in Crohn's Disease Patients. #M1011. Oral presentation at American Gastroenterological Association Meeting, 2013.
139. Taleban S, van Oijen MGH, Vasiliauskas EA, Shen B, Ippoliti AF, Targan SR, Fleshner PR, Melmed GY. Cost-Effectiveness of Colectomy with IPAA versus Colectomy with Permanent End-Ileostomy for Crohn's Colitis. Poster presentation at Advances in Inflammatory Bowel Diseases Crohn's & Colitis Foundation Clinical & Research Conference 2104.
140. Zaghiyan K, Barmparas G, Dubinsky M, Melmed G, Vasiliauskas E, McGovern D, Ippoliti I, Shih D, Targan S, Fleshner P. Preoperative anti-TNF $\alpha$  Therapy is Associated with Increased Incidence and Shorter Interval to Development of *denovo* Crohn's Disease After Ileal-Pouch Anal Anastomosis. Poster presentation at Advances in Inflammatory Bowel Diseases Crohn's & Colitis Foundation Clinical & Research Conference 2104.
141. Haritunians T, Li D, Liu Z, Yan X, Vasiliauskas EA, Ippoliti AF, Dubinsky M, Shih DQ, Melmed GY, Fleshner P, Targan SR, McGovern DPB. Exome Chip Analysis of Perianal Crohn's Disease Identifies Novel Loci Not Previously Described using Immunochip Platform. Poster presentation at Advances in Inflammatory Bowel Diseases Crohn's & Colitis Foundation Clinical & Research Conference 2104.
142. Yoon JL, Huang BL, Melmed GY, Amin J, Ippoliti A, Dubinsky M, Khanna P, Fleshner P, McGovern DP, Targan S, Vasiliauskas EA, Shih DQ. Modulation of Thiopurine Metabolism by Anti-TNF Therapy. #Sa1239. Poster presentation at American Gastroenterological Association Meeting, 2014.

143. Haritunians T, Li D, Yan X, Mengesha E, Rich SS, Onengut-Gumuscu S, Chen WM, Shih DQ, Li X, McGovern JF, Ippoliti A, Dubinsky M, Vasiliauskas EA, Melmed GY, Fleshner P, Targan S, McGovern DP. Genetic Variation Associated Medically Refractory Ulcerative Colitis Requiring Colectomy. #Sa127. Oral presentation at American Gastroenterological Association Meeting, 2014.
144. Huang BL, Amin J, Stewart MJ, Yan X, Yoon JL, Melmed GY, Ippoliti A, Vasiliauskas EA, Khanna P, Dubinsky M, Fleshner P, Alemayehu Y, Targan S, McGovern DP, Shih DQ. Genetic and Serological Predictors of H. pylori Infection in Patients With Inflammatory Bowel Disease. #Su1931. Poster presentation at American Gastroenterological Association Meeting, 2014.
145. Patel AV, Fleshner P, Melmed GY, Vasiliauskas EA. Systemic Therapy May Mask the Presence of Disease in Colitis Patients Undergoing Preoperative Small Bowel Evaluations. #Su1361. Poster presentation at American Gastroenterological Association Meeting, 2014.
146. Zaghiyan KN, Melmed GY, Dubinsky M, Vasiliauskas EA, McGovern DP, Ippoliti A, Shih DQ, Khanna P, Targan S, Fleshner P. Medical Prophylaxis After Ileocolic Resection for Crohn's Disease - No Need to Rush. #Su1384. Poster presentation at American Gastroenterological Association Meeting, 2014.
147. Fu N, Yan X, Haritunians T, Targan S, Melmed GY, Vasiliauskas EA, McGovern DP. Genetic, Serological and Clinical Associations in Inflammatory Bowel Disease (IBD) Patients With Clostridium difficile Infection (CDI). #Mo1242. Poster presentation at American Gastroenterological Association Meeting, 2014.
148. Robbins L, Zaghiyan KN, Melmed GY, Vasiliauskas EA, McGovern D, Ippoliti A, Shih DQ, Targan S, Fleshner P. Do Anti-TNF Agents Work in Ulcerative Colitis Patients with de novo Crohn's Disease Who Failed Anti-TNF Therapy Before Ileal Pouch-Anal Anastomosis? #Sa1152. Poster presentation at American Gastroenterological Association Meeting, 2015.
149. Morganstern B, Namita Singh<sup>3</sup>, Targan S, Carol J. Landers<sup>1</sup>, Nguyen M, Vasiliauskas EA, Shih D, Feldman EJ, Ippoliti A, McGovern D, Dubinsky M, Rabizadeh S, Melmed GY. Single-Center Experience of Vedolizumab in Patients with Inflammatory Bowel Disease: Does Age Matter? #Sa1182. Poster presentation at American Gastroenterological Association Meeting, 2015.
150. Manguso N, Zaghiyan KN, Barmparas G, Mann NK, Lo SK, Melmed GY, Vasiliauskas EA, Shih DQ, Ippoliti A, Targan S, Fleshner P. Long-Term Evaluation of Preoperative Wireless Capsule Endoscopy as a Predictor of Outcome After Ileal Pouch-Anal Anastomosis. #Sa1237. Poster presentation at American Gastroenterological Association Meeting, 2015.
151. Nguyen M, Pourmorady JS, Morganstern B, Yan X, Zhang A, Karsan SS, Fleshner P, Vasiliauskas EA, Melmed G, Ippoliti A, Targan S, McGovern D, Shih D. Genetic Associations with 6MMP Preferential Metabolizers by Elevated 6MMP:6TGN Ratios Reveal Novel Pathways Involved in Purine Metabolism. #Mo1750. Poster presentation at American Gastroenterological Association Meeting, 2015.
152. Mann NK, Jamil LH, Melmed GY, Vasiliauskas EA, Lo SK. Small Bowel Imaging in Crohn's Disease: Measuring the True Accuracy of Proximal and Distal Small Intestinal Disease Activity Using Total Enteroscopy in Patients with Established and Suspected Crohn's Disease. Su1184. Poster presentation at American Gastroenterological Association Meeting, 2015.
153. Gu P, Kapur A, Li D, Haritunians T, Vasiliauskas E, Shih DQ, Targan S, Spiegel B, McGovern D, Black J, Melmed GY. Biomarkers May Predict Higher Resource Utilization in IBD. #Sa1929. Poster presentation at American Gastroenterological Association Meeting, 2016.

154. Rezaie A, Pimentel M, Chang BW, Pan D, Chua KS, Lentz G, Sonesen M, Estiandan R, Vasiliauskas E, Targan S, Yan X, Li D, McGovern D. Breath Methane and Hydrogen Composition in Inflammatory Bowel Disease (IBD) Is Strikingly Different From Non-IBD Patients and Is Associated With IBD-Associated Genes: A Large-Scale Database Linkage Analysis. #Su1793. Poster presentation at American Gastroenterological Association Meeting, 2016.
155. Yoon SM, Haritunians T, Chhina S, Ye BD, Shih DQ, Vasiliauskas E, Ippoliti A, Targan S, Melmed GY, McGovern D. Factors Predicting Response to Anti-TNF Agents for Patients With Inflammatory Bowel Disease. #Sa188. Oral presentation at American Gastroenterological Association Meeting, 2016.
156. Stewart M, Dubinsky M, Morganstern B, Vasiliauskas E, Targan S, Ippoliti A, Shih DQ, Mould D, McGovern D, Melmed GY. The Steady-State Pharmacokinetics of Adalimumab: Do We Need to Drink From the 'Trough'? #Sa1965. Poster presentation at American Gastroenterological Association Meeting, 2016.
157. Gu P, Ko J, Yan X, Li D, Haritunians T, Vasiliauskas E, Targan S, Melmed G, McGovern, Shih D. Serologic and Genetic Markers May Help Predict Disease Behavior In Patients with Crohn's Disease (CD), #Sa1832. Poster presentation at American Gastroenterological Association Meeting, 2017.
158. Zhu L, Melmed G, Yan X, Haritunians T, Shih D, Vasiliauskas E, Ippoliti A, Rabizadeh S, Singh N, Targan S, Liu Z, Li D, McGovern D. UBE2L3, ANCA, ASCA, and CBIR1 are Associated with Mechanisms of Non-Response to Anti-TNF in IBD Patients with Adequate Drug Levels. #Sa1879. Poster presentation at American Gastroenterological Association Meeting, 2017.
159. Jacobs J, Tong M, Ruegger R, Li D, Haritunians T, Fleshner P, Vasiliauskas E, Ippoliti A, Melmed G, Shih D, Targan S, Borneman J, McGovern D, Braun J. Crohn's Disease, Obesity, and High Crohn's Disease Genetic Risk are Associated with Parallel Changes in the Microbiome of the Cecal & Sigmoid Mucosal Luminal Interface. #463. Oral presentation at American Gastroenterological Association Meeting, 2017.
160. Syal G, Bonthala N, Feldman E, Vasiliauskas EA, McGovern DPB, Melmed GY, Fleshner P, Targan SR, Shih DQ. Pharmacokinetic Effects of Anti-Tumor Necrosis Factor-alpha Agents On Thiopurine Drug Metabolism In Inflammatory Bowel Diseases. Poster presentation at American College of Gastroenterology Annual Scientific Meeting, 2017.
161. Gu P, Dube S, Ko J, Dalin Li, Haritunians T, Vasiliauskas E, Syal G, Bonthala N, Yang S, Fleshner P, Melmed G, Targan S, McGovern D. Clinical, Serologic, and Genetic Markers are Associated with Compiled Disease Behavior in Patients with Crohn's Disease (CD) #Sa1809. Poster presentation at American Gastroenterological Association Meeting, 2018.
162. Syal G, Robbins L, Kashani A, Bonthala N, Vasiliauskas E, Feldman E, Wishingrad M, McGovern D, Ha C, Targan S, Melmed G. Hypoalbuminemia and Bandemia Predict Failure of Infliximab Rescue Therapy in Acute Severe Colitis Independent of the Infliximab Dose. #Mo1891. Poster presentation at American Gastroenterological Association Meeting, 2018.

**Eric Vasiliauskas, MD****Director, Cedars-Sinai Nutrition & Integrative IBD Subspecialty Program**  
**Associate Clinical Director, Inflammatory Bowel Disease Center**

Dr. Eric Vasiliauskas is the Associate Clinical Director of the Inflammatory Bowel Disease Center at Cedars-Sinai & a member of the F. Widjaja Foundation Inflammatory Bowel and Immunobiology Research Institute.

Dr. Vasiliauskas is an internationally-recognized expert in in both Adult & Pediatric Inflammatory Bowel Disease who has long recognized the existence of subgroups within Crohn's disease & ulcerative colitis and how these important subtleties influence disease expression, disease course, responses to traditional medical and surgical interventions, as well as to dietary and other alternative approaches. He has thus been a longtime proponent of personalized medicine & individualized therapy in IBD.

Frequently referred to as "Dr. V", Dr. Vasiliauskas has been described as "a diet-friendly doctor" and is a strong advocate of living a healthy lifestyle that incorporates routine exercise, relaxation & stress management techniques (mindfulness practices, meditation, biofeedback, yoga, etc), getting adequate sleep, & eating a balanced healthy diet. He recognizes the significant potential benefits of both traditional and nontraditional approaches to IBD care, while at the same time also acknowledging the shortcomings of each approach practiced in isolation. Throughout his career, Dr. Vasiliauskas has been open to incorporating a broad spectrum of nontraditional options to help patients fine-tune their health to wellness. He is a firm believer that a complementary or integrative approach to IBD management optimizes desired outcomes, well-being and quality of life.

In his role as director of the Cedars-Sinai Nutrition & Integrative IBD Subspecialty Program, Dr. Vasiliauskas continues to explore the role of nutrition and a variety of dietary manipulations and other nontraditional interventions in the management of Crohn's disease, ulcerative colitis, IBD-associated small intestinal bacterial overgrowth, lymphocytic and collagenous colitis. In partnership with his patients & colleagues, he continues to examine the influences of diet and supplements, including herbal products & probiotics, on disease activity and specific symptoms, including the impact on extra-intestinal manifestations of IBD, such as joint involvement, mouth ulcerations, etc. In collaboration with his colleagues, Dr. Vasiliauskas is leading efforts to investigate the short-term and long-term effects of specific nutritional modifications on the gut microbiome and on epigenetic influences with the goal of augmenting our understanding of the complex interplay between diet, the gut microbiome, disease activity and expression.

Dr. Vasiliauskas was invited to cover the topic of Complementary & Alternative Therapies in IBD for the 2<sup>nd</sup> edition of the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN)'s IBD Book for Families entitled "Your Child with Inflammatory Bowel Disease: A Family Guide for Caregiving". His contribution focuses on the concept of "integrative medicine" in IBD which attempts to bring together the spectrum of conventional and complementary approaches in a coordinated way with an emphasizes on the importance nutrition, exercise, stress management, and a strong support network.

Dr. Vasiliauskas serves as the principal investigator or co-investigator on numerous research studies at Cedars-Sinai. He has been involved in pioneering the use of a variety of novel therapeutics in IBD, including biologic therapies (infliximab, adalimumab, certolizumab, natalizumab, vedolizumab, and ustekinumab), thalidomide, and placental stem cell therapy. His research has also included investigations of the potential applications of serum immune and genetic markers as well as other endoscopic and imaging techniques, including wireless capsule enteroscopy, double-balloon enteroscopy, ultrasound, and CT and MRI enterography in IBD.

Dr. Vasiliauskas has served on both the Professional Education Committee & the Patient Education Committee of the Crohn's and Colitis Foundation, as well as the Pediatric IBD Committee of the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN). He is also a member of the American Gastroenterological Association. He is principal- or co-investigator on over 130 research protocols and has author or co-authored over 200 articles, abstracts, chapters in medical textbooks and journals articles for such peer-reviewed publications as *Gastroenterology*, *Gut*, *Digestive Diseases and Sciences*, *Alimentary Pharmacology & Therapeutics*, *Inflammatory Bowel Diseases*, *Diseases of the Colon and Rectum*, *American Journal of Gastroenterology*, and others. He serves as a reviewer for numerous journals and is vice-chair of the Cedars-Sinai Medical Center Institutional Review Board & is also as a member of the CSMC emergency Rapid Activation IRB.

Dr. Vasiliauskas is an Associate Professor of Medicine & Pediatrics at the David Geffen School of Medicine at the University of California, Los Angeles (UCLA). He earned his bachelor's degree from the University of Illinois, Champaign-Urbana & his medical degree from the University of Illinois College of Medicine in Rockford. After a General Pediatrics internship and residency at Children's Hospital Los Angeles, Dr. Vasiliauskas completed a Pediatric Gastroenterology and Nutrition fellowship at Children's Hospital, Cedars-Sinai, Los Angeles County-University of Southern California Medical Center, Harbor-UCLA Medical Center and at Martin Luther King, Jr./Charles R. Drew Medical Center in Los Angeles. He also completed a 2-year clinical & clinical-research subspecialty fellowship specifically in Inflammatory Bowel Disease at Cedars-Sinai.

DrV has been recognized by his peers as one of the "best doctors" in Southern California in his field as listed in [www.superdoctors.com](http://www.superdoctors.com).

Dr. Vasiliauskas is a strong believer in community service & education. In his private life, he is the father of 2 mainstreamed adventurous deaf-blind braille-reading sons. DrV has been a longtime advocate of early braille immersion, braille fluency, childhood access to foreign language braille for dual immersion families, & childhood digital preparedness. He has been a strong proponent not only of equal expectations of blind and visually-impaired students, but of high expectations of blindness/VI educators as well. Dr. Vasiliauskas has written numerous articles and has given many presentations including workshops & KeyNote presentations at the local, state, and national level on topics related to raising and educating blind & visually-impaired children. He was instrumental in facilitating the inclusion of Lithuanian braille as an option in Duxbury's braille translation program.

DrV has served on the National Federation of the Blind (NFB)'s Educational Reform Task Force, as a parent mentor for the NFB's Teachers of Tomorrow Program, & was awarded a lifetime member of California Transcribers and Educators for the Blind & Visually Impaired (CTEBVI). He serves on the NFB Jernigan Institute Research Advisory Council, the NFB's Genetic Education Committee, & is a member of the NFB's Deaf-Blind Division, the National Organization of Parents of Blind Children (NOPBC), NFB of California, & the NFB Sports and Recreation Division.

In his local community, DrV is a founding member of the Manhattan Beach Unified School District (MBUSD) Medical Advisory Board, & has also served as a member of both MBUSD's Technology Committee & Technology Access Subcommittee. DrV is also a 4<sup>th</sup> degree member of the Knights of Columbus & participates in their charitable activities.

**Doximity Profile:** [www.doximity.com/pub/eric-vasiliauskas-md](http://www.doximity.com/pub/eric-vasiliauskas-md)

**LinkedIn Profile:** [www.linkedin.com/in/eric-vasiliauskas-b191ba104](http://www.linkedin.com/in/eric-vasiliauskas-b191ba104)